


The Journal of the American Diabetes Association

diabetes

Volume 21 • 1972

INDEX

By Subject and Author



Copyright 1973, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, DAVID M. KIPNIS, M.D., *St. Louis*

ASSOCIATE EDITORS: PAUL E. LACY, M.D., *St. Louis* • FRANZ M. MATSCHINSKY, M.D., *St. Louis*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1973

JOHN W. ENSINCK, M.D., *Seattle*

STEFAN S. FAJANS, M.D., *Ann Arbor*

GEROLD M. GRODSKY, PH.D., *San Francisco*

IRVING H. LEOPOLD, M.D., *New York*

ROGER H. UNGER, M.D., *Dallas*

PETER H. WRIGHT, M.D., *Indianapolis*

TERM EXPIRING DECEMBER 1974

MARGARET J. ALBRINK, M.D., *Morgantown, W. Va.*

RUBIN BRESSLER, M.D., *Tucson*

RONALD K. KALKHOFF, M.D., *Milwaukee*

CHRISTIAN R. KLIMT, M.D., DR. P.H., *Baltimore*

ARNOLD LAZAROW, M.D., PH.D., *Minneapolis*

ALEXANDER MARBLE, M.D., *Boston*

ARTHUR H. RUBENSTEIN, M.D., *Chicago*

TERM EXPIRING DECEMBER 1975

DAVID R. CHALLONER, M.D., *Indianapolis*

ALLAN L. DRASH, M.D., *Pittsburgh*

BRYCE L. MUNGER, M.D., *Hershey, Pa.*

HIROMICHI T. NARAHARA, M.D., *Albany*

DANIEL PORTE, JR., M.D., *Seattle*

LILLIAN RECANT, M.D., *Washington, D.C.*

DONALD F. STEINER, M.D., *Chicago*

ABSTRACTORS

TERM EXPIRING DECEMBER 1973

HUEY G. MCDANIEL, M.D., *Birmingham*

SUMER PEK, M.D., *Ann Arbor*

PAUL S. ROSENFELD, M.D., *Milwaukee*

PAUL H. SCHREIBMAN, M.D., *New York*

CHARLES R. SHUMAN, M.D., *Philadelphia*

TERM EXPIRING DECEMBER 1974

JOHN D. BAGDADE, M.D., *Seattle*

GUENTHER BODEN, M.D., *Philadelphia*

PAUL S. ENTMACHER, M.D., *New York*

JEROME M. FELDMAN, M.D., *Durham*

DINESH KUMAR, M.D., *Los Angeles*

THOMAS G. SKILLMAN, M.D., *Columbus, Ohio*

TERM EXPIRING DECEMBER 1975

R. PHILIP EATON, M.D., *Albuquerque*

N. KATSILAMBROS, M.D., *Athens, Greece*

ROGER L. LERNER, M.D., *New York*

THOMAS J. MERIMEE, M.D., *Boston*

JAMES E. VANCE, M.D., *Indianapolis*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and

not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications:* The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing, and if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas.

J. Lab. Clin. Med. 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

Subscription and Advertising Information

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 18 East 48th Street, New York, New York 10017. © American Diabetes Association, Inc., 1973. All rights reserved under International and Pan-American Copyright Convention.

Professional Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$23.00 for one year; \$40.00 for two years; \$57.00 for three years. Individual copies \$2.00. For sub-

scriptions outside the United States and U. S. Possessions, add \$2.00 per year for postage.

Subscriptions for medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: \$11.50 per year plus \$2.00 for foreign postage where applicable. Subscriptions in this category may be entered or renewed for only one-year terms.

Correspondence concerning subscriptions should be addressed to the Subscription Department.

DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.

SUBJECT INDEX 1972

This index covers all reading matter in Volume 21 of **DIABETES**. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index begins on page 44.

A

ABDOMEN

- insulin administration to, 204
- tumors
 - and lipid mobilization and food uptake, *774

ABETALIPOPROTEINEMIA, *60

ACETATE I-C-14

- utilization for fat synthesis
- rat strain differences in, *770

ACETIC THIOKINASE

- and lipogenesis, *982

ACETOACETATE

- brain utilization of, *247
- metabolism, *343
- palmitate oxidation to
 - and ketosis, 258, 259, 261

N-ACETYL-GLUCOSAMINE

- and insulin release, 540, 543

ACHLORHYDRIA, 646

ACID ETHANOL

- and serum nonsuppressible insulin-like activity, 271, 272-278

ACID MUCOPOLYSACCHARIDES

- skin assays, 735, 738-742

ACIDOSIS

- ammonium chloride induced
 - and glucose tolerance and insulin sensitivity in rats, 794-796

ACIDOSIS, LACTIC

- and phenformin, *1198

ACIDOSIS, METABOLIC

- and carbohydrate tolerance, 1109-1114

ACIDS

- alpha-ketomonocarboxylic, *359
- alpha-amino-isobutyric
 - and pancreas beta cell transport, *181
- blood lactic and pyruvic

- and diabetic coma, *350
- isovaleric and alpha-methylbutyric and hypoglycin A., *316
- lactic
 - and Tolinaase and phenformin therapy, *351
- nicotinic
 - and lipolysis, 427

ACROMEGALY

- and blood proinsulin-like components, 664
- and insulin secretion
 - and serotonin antagonists, *352
- and secretin
 - and insulin release, *1118

ACTH. See Adrenocorticotrophic hormone

ACTINOMYCIN D

- and hexokinase, *185
- and rat adipocyte fatty acid synthetase activity, *914

ADENOSINE 3', 5'-MONOPHOS-

- PHATE. See also Cyclic adenosine 3',5'-monophosphate; Dibutyladenosine 3',5'-monophosphate
- and isolated fat cells, 1027-1034
- and potassium flux and glucose output, *254

- rat liver and adipose tissue

- and glucagon, *54

- and synaptic activity

- and dopamine-sensitive adenylylase, *773

ADENYL CYCLASE, 440

- dopamine-sensitive
 - and nervous system, *773
- epinephrine-responsive
 - and insulin, *1117-1118
- glucagon-responsive
 - macromolecular inhibitor of, *180
- and glucagon and tolbutamide
- and islet cell adenoma, *912
- inhibition study, 289-293

- and insulin release, *328-329
- in islets of Langerhans
 - in obese and lean mice, *179
- localization in islets of Langerhans, *328
- response to glucagon, ACTH and epinephrine, *772

ADIPOSE TISSUE

- adenosine 3',5'-monophosphate and glucagon, *54
- cellularity
 - and growth hormone treatment in ateliotic dwarfs, *366
- epinephrine-stimulated lipolysis in siblings of diabetics, *361
- fat cell size
 - and obesity, *54
- fat cell size and number
 - assay, *247
 - and metabolism in middle-aged men and women, *180
- fatty acid synthetase
 - and glucose and insulin, *914
 - and insulin, 427
- free fatty acids release, *59-60
- glucose metabolism
 - and response to bovine insulin, 1151-1161
 - and ventromedial hypothalamic nuclei destruction, *1204-1205
- and insulin sensitivity
 - and obesity, 6-11
- isolated cells
 - and adenosine 3',5'-monophosphate and dibutyladenosine 3',5'-monophosphate, 1027-1034
- and lipotrophic diabetes, 827-830
- lipolysis and cellularity
 - and weight reduction in obese adolescents and adults, 754-760
- lipolysis and glycerol kinase
 - and body weight, *911-912
- lipoprotein lipase, *344
- metabolism
 - and glycerol kinase regulation by insulin, *122

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- monoglyceride hydrolase
and obese hyperglycemic mice, *186
noncollagen protein and cell number,
*1201
phosphofructokinase
and cyclic AMP and dibutyryl cyclic
AMP, *363
proinsulin activity, 485
rat
glucose transport in, *1042
and insulin, *60
resection
and diabetes and hyperinsulinism,
13-15
and sepharose-bound insulin, *335-336
- ADRENAL GLANDS**
and catecholamine release
and phenothiazine-induced hypergly-
cemia, *184
and glucagon secretion, *375
insufficiency
and hypoglycemia, *248
and insulin response to hemorrhagic
shock, *364
isolated cells
corticosterone production studies,
*983
and myocardial infarction, *119
tumors
and diabetes, *838
- ADRENALECTOMY**
and glucagon effect on adenosine 3'5'-
monophosphate levels, *54
and insulin response to hemorrhagic
shock, *364
and liver mitochondria structure, 259
and splanchnic nerve stimulation, *770
- ADRENALINE**
and adeny cyclase activity, *179
and amino acid metabolism, *56
and blood glucose and free fatty acid
responses to catecholamines,
*912
- ADRENOCORTICOTROPHIC
HORMONE**
action
and cyclic AMP, *251
adenyl cyclase response to, *772
and diabetic ketosis, 946-954
and growth hormone assays, *775-776
and insulin
and adipose tissue lipolysis, 427
in isolated adrenal cells, *983
and lipolysis
and mercury, *771
- and protein synthesis
and cyclic AMP, *119
unresponsiveness, *981
- AFRICAN PYGMIES**
metabolism studies in, *1045-1046
- AGE**
and blood glucose levels
and exercise, 89-99
and carbohydrate metabolism, *183-184
and insulin, glucagon and growth
hormone, *357
and carbohydrate tolerance, *347
and diabetes
and microangiopathy, *837
in Pima Indians, *180
in rural population in India, 1192
and diabetic mortality, *1044
and education of juvenile diabetics,
969
and fat cell size and number, *247
and glucose tolerance tests in children,
19
and motor nerve conduction velocity
in rats, 296-297
and muscle capillary basement mem-
brane changes
and diabetes, 881-896, 899-905
and proinsulin response to oral glu-
cose, *356
and retinal blood flow, *354
and retinopathy, *187
and serum glucose
in *Mystromys albicaudatus*, 718, 719,
720
and serum triglycerides response to
dietary fructose, *835
- ALANINE**
and glucagon secretion, *183
and gluconeogenesis
in diabetics and normal patients,
*341-342
and ethanol, *1202
-induced hyperglucagonemia
and alpha-adrenergic blockade,
*1043
and insulin activity, *1122-1123
and liver metabolism, 51
metabolism, *57
and glucose, *56
synthesis by muscle
and exercise, *770-771
uptake by pancreatic beta cells, *772
- L-ALANINE**
and pancreas a-amino isobutyric acid
transport, *181
- L-ALANINE-C-14**
metabolism
and tissue injury, *315
- ALBUMINURIA**
and bacteriuria, *118
- ALCOHOL**
and glucose tolerance, *247-248
and hypoglycemia
and basal insulin secretion, 65-69
-induced glucose intolerance, *184
and ketoacidosis, *56-57
sensitivity
ethnic differences in, *254
- ALCOHOLISM**
and fatty liver
and fatty acid metabolism, *835
and liver metabolism
and blood clearance rates, *983
- ALDOSE REDUCTASE**
and galactosemic cataracts, 295, 299-
300
in human placenta, *330
- ALDOSE REDUCTASE INHIBITORS**
and insulin release, *327
- ALKALINE PHOSPHATASE**
and diabetic pregnancy, 34-35
- ALLERGY**
to insulin
and purified pork insulin, 638-643
- ALLOXAN**
action
and diphenylhydantoin, 80-83
and beta cell membrane changes, *326
and glucose, *123
and insulin secretion, *326
and pancreatic beta cells, 77-78
- ALLOXAN DIABETES**
in arteriosclerotic and nonarterioscler-
otic rats, *1123
in female rats
and fetal pancreas transplants, 193-
201
and glucagon secretion, *183
glucose protection against, *123
and glycosaminoglycans metabolism,
1162-1166
and hypertriglyceridemia
and diet, *353-354
and jejunal mucosa enzymes, *188
and ketosis
and kidney function, *121
and lipid synthesis, *189

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- and lipoprotein lipase release, 149-155
- and liver mitochondria α -oxoglutarate carboxylation, *981
- and liver protein synthesis, *339
- and liver ribosomes, 84-88
- and pH of inflammatory exudates, *1201
- and pressor response to angiotensin and norepinephrine
- and insulin treatment, *354-355
- ALPHA-ADRENERGIC BLOCKADE**
 - and alanine-induced hyperglucagonemia, *1043
 - and insulin release, *181, 783-784, *1045
- ALPHA ADRENERGIC RECEPTORS**
 - and diazoxide-induced insulin secretion, *1045
 - and L-dopa
 - and growth hormone secretion, *911
 - and hypoinsulinemia, *348
- ALPHA-KETOMONOCARBOXYLIC ACIDS**
 - and insulin secretion, *359
- AMERICAN DIABETES ASSOCIATION**
 - Address of the President, 918-919
 - annual awards
 - Lilly, 920-921, 985, 1049, 1127-1128
 - Annual Banquet, 917
 - annual meetings
 - Central Council, 919
 - Thirty-second, 61-62, 124, 190, 255, 317-318, 840, 915-916, 1049
 - Thirty-third, 1128, 1208
 - Committee on Employment and Insurance
 - statement on employment of diabetics, 834-835
 - Committee on the Use of Therapeutic Agents, 832
 - Diabetes* index, 255
 - Diabetes* Week, 778, 841, 921, 986, 1049
 - and FDA labeling of oral hypoglycemic drugs, 833
 - FORECAST**
 - "Cholesterol and Other Blood Fats in Diabetes," 1208
 - "Diabetes in the Desert: The Pima Indians of Arizona," 841
 - "Health Foods: Are They Healthful for Diabetics?" 778
- "U100 Insulin: A New Era in Diabetes Therapy," 1128
- International Diabetes Federation Eighth Congress, 1050, 1128, 1208
- necrology, 63, 128, 192, 256, 320, 778, 842, 922, 986, 1050, 1130, 1210
- new members, 191-192, 256, 921-922, 1208-1209
- news of Affiliate Associations, 128, 192, 319-320, 778, 986, 1129, 1209
- news notes, 62-63, 128, 192, 256, 320, 778, 842, 922, 986, 1050, 1130, 1210
- obituaries
 - Beardwood, Joseph T., Jr., 839
 - Marks, Henry E., 178
- personals, 63, 256, 320, 922, 1050, 1130, 1210
- postgraduate courses, 62, 125-127, 190-191, 777, 840, 919-920, 984, 1048, 1124-1127, 1207, 1208, 1210
- Research and Development Awards, 127, 841, 920, 985, 1048-1049
- research grants program, 62, 1050
- research symposiums, 191, 255, 318-319, 777, 840, 919, 984, 1128-1129
- AMES REFLECTANCE METER, *1120**
- AMINES**
 - and insulin secretion, *248
 - uptake by brain, *315
- AMINO ACIDS**
 - and alloxan toxicity, *123
 - in fasted and fed rats
 - and exercise, *119
 - and glucagon metabolism, 848-855
 - and glucagon secretion, *183
 - and insulin, 447-451, *909
 - and insulin release, *56, 613, 617-618
 - insulin response to
 - and 2-deoxy-D-glucose and mannoheptulose, 1-5
 - and insulin secretion, 539, 570-571
 - liver transport
 - and proteins, *316
 - metabolic and hormonal responses to in malnourished infants, *182
 - metabolism
 - and exercise, *770-771
 - and glucose, *56
 - in perfused rat liver, *57
- and starvation during pregnancy, *1118-1119
- plasma and tissues
- and starvation, *179
- sequences of insulin, 457-459, 485
- sequences of proinsulins and intermediates, 461-466
- uptake
 - by brain, *315
 - by pancreatic beta cells, *772
- 6-AMINONICOTINAMIDE**
 - as diabetogenic agent in rats, 143-148
 - and insulin release
 - and glucose C-14 metabolism, *1198
- AMINOPHYLLINE**
 - and 6-aminonicotinamide, *1198
 - and glucagon and insulin secretion, 289-293
 - and insulin release, 689-690
 - and insulin-resistant hyperglycemia, *775
 - and insulin response to glucose, *770
- AMITRIPTYLINE**
 - and lipolysis and cyclic AMP in isolated fat cells, *1045
- AMMONIA**
 - intoxication
 - and mitochondrial swelling, *835-836
 - production
 - and ketone bodies, *251
 - in muscle, *1203
 - and renal gluconeogenesis, *57
- AMMONIUM CHLORIDE**
 - induced acidosis
 - and glucose tolerance and insulin sensitivity, 794-796
 - and insulin secretion, *248
- AMNIOTIC FLUID**
 - substrates
 - and maternal caloric deprivation, *1202
- AMPHETAMINES**
 - and insulin release, *252
- AMPHOTERICIN B**
 - and rhinocerebral phycomycosis, *185
- ANDROGENS**
 - and diabetic impotency, 23-28

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

ANEMIA
 hemolytic
 and pancreatic acinar atrophy and fibrosis, *773-774
 hypochromic microcytic
 and acetoacetate, *311
 and hypothyroidism
 and diabetes, *769

ANGINA PECTORIS
 and clofibrate therapy, *838, *910

ANGIOGRAPHY
 fluorescein
 and prediabetes diagnosis, *354

ANGIOPATHY, DIABETIC
 and hemochromatosis
 and cirrhosis, *123
 in juvenile diabetics, *913

ANGIOTENSIN
 pressor response to
 and insulin treatment in alloxan diabetic rats, *354-355

ANOXIA
 and lactic acid levels
 and phenformin and Tolinaise therapy, *351

ANTIBODIES
 to insulin, 649-656, 657-659, 660, 677
 assays, *769
 and diabetes, *57, *775
 in dogs adapted to bovine-porcine insulin, *182
 and insulin secretion, *914
 and insulinitis, 764-765
 polyethylene glycol screening test for, *379
 and serum-bound insulin neutralization, 930-934
 without previous immunization, 814-825
 to C-peptide, 1013-1025
 proinsulin
 in insulin-resistant patient, *368
 to smooth muscle tissue
 binding to fibroblasts, *314
 to thyroid antigen, *253

ANTICOAGULANT DRUGS
 hereditary resistance to
 and vitamin K, *183

ANTIMITOTIC AGENTS
 and insulin release, 987-997

ANTIMYCIN A
 and insulin release, *56

APES, See Macaca nigra

ARGAMINE
 and lipolysis, 427

ARGININE
 and blood glucose levels, 308-310
 derivatives
 and metabolism, *1122-1123
 and glucose
 and serum insulin and growth hormone, *316
 and glucose-induced insulin secretion, *1045
 and growth hormone secretion
 and sex, *774-775
 -induced glucagon and insulin secretion
 and aminophylline, 289-293
 -induced glucagon release
 and diabetes, *324
 -induced insulin release
 and cyclic AMP system in man, *312
 infusion
 and Huntington's chorea, *1121
 and insulin release, 1-2, *56, 570, 617
 insulin response to
 in *acomys cahirinus*, 1063
 and diethylstilbestrol and growth hormone, *378
 maternal and fetal, *251
 metabolism
 and glucose, *56
 and plasma glucagon, 218-223
 plasma growth hormone response to
 and diabetes, *312
 provocative tests
 plasma growth hormone unresponsiveness to, *981
 uptake by pancreatic beta cells, *772

ARGININE-U-C-14
 incorporation into blood glucose, 308-310

ARTERIES
 calcification
 and glucose tolerance, *252

ARTERIOGRAPHY
 and insulinoma diagnosis, *1206
 and islet cell adenomas, *185

ARTERIOSCLEROSIS
 and diabetes mortality, 634
 and hyperglycemia
 and tolbutamide therapy, *122-123
 in rats
 and alloxan diabetes, *1123

ARTERITIS
 and insulin response to glucose, *837

L-ASPARAGINASE
 and leukemia
 and transient diabetes, *1119

ASPARTATE
 metabolism, *57

ASPIRIN
 and hypoglycemia, 959

ATHEROSCLEROSIS
 and familial hypercholesterolemia, *1121
 and insulin, *186, 684
 and insulin response, *836
 and macroangiopathy, 679-680
 and plasma insulin, blood sugar, and serum lipid abnormalities, *253

ATROPINE
 and serum insulin response to glucose
 and konnyaku ingestion, *60

AUTOANALYZER, 308-310, 644
 and glucose tolerance tests in *Macaca nigra*, 1078-1088

AUTO-IMMUNE DISEASE, *914
 and insulinitis in late-onset diabetes, 764-766

AUTOTUTOR MARK II, 967-971

B

BABOONS
 and alpha-adrenergic blockade
 and insulin release, *181
 and diabetes
 and kidney glomerulosclerosis, *338
 and hemorrhagic shock
 insulin release during, *982

BACTERIA
 and jet insulin injection studies, 41

BACTERIURIA
 and diabetes, *118

BANTING, FREDERICK G., 385-395

BANTING MEMORIAL LECTURE, 1131-1150

BASEMENT MEMBRANE
 and diabetic glomerulosclerosis, 163-173
 and fluid secretion, *315
 thickening
 and aging and diabetes, 881-896, 899-905

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and glucose tolerance, *321
- and insulin and gamma globulin complexes, 872-879
- and juvenile diabetes, *913
- and pseudodiabetes of myopathy, *118
- width, *254
- BEARDWOOD, JOSEPH T., JR., 839
- BETA ADRENERGIC BLOCKING AGENTS
 - and glucagon secretion, *332-333
 - and insulin secretion, 783-784
 - and pancreatic glucagon and insulin secretion, *332
 - and tolbutamide response and diazoxide, *311
- BETA ADRENERGIC RECEPTORS
 - and carbohydrate metabolism, *1203
- BICARBONATE
 - and diabetic ketoacidosis, *323, *1203
 - and lactic acidosis, *1198
- BIGUANIDES
 - and sugar transport, *119
 - and unstable diabetes, *123
- BILE
 - lipids
 - and pregnancy, *912
- BLADDER
 - dysfunction
 - and diabetes, *364
 - function
 - and prediabetes, *359
 - neurogenic
 - and diabetic impotency, 24, 26-27
- BLOOD
 - acetoacetate, 3-hydroxybutyrate and glucose
 - diurnal variations in, *1205
 - and acetoacetate injections in rats, *311
 - and brain metabolism, *774
 - cholesterol
 - and diet, *1043
 - cholesterol, triglycerides and immunoreactive insulin
 - in normals and prediabetics, *383
 - circulation
 - and diabetes, *981
 - citrate
 - and exchange transfusion, *185
 - coagulation
 - and diabetes, 108-112
 - constituents
 - and diet, *1202
 - erythrocytes
 - glycolytic enzymes, in insulinoma, *773
 - ethanol and tolbutamide clearance
 - and alcoholism, *983
 - flow
 - and brain perfusion technic, *1123
 - and diabetes and prediabetes, *769
 - and glucose tolerance during bed-rest and exercise, 103-104
 - pancreatic, and exogenous insulin, *1204
 - and prostaglandins, *369
 - retinal, *354
 - ketone bodies
 - rapid estimation of, *1117
 - lactate and ketone bodies
 - and diabetic ketoacidosis, *186-187
 - lactic and pyruvic acids
 - and diabetic coma, *350
 - lipids
 - in monkeys, 1084-1086
 - lipoproteins
 - in combined hyperlipoproteinemia, *376
 - lymphocytes
 - response to phytohemagglutinin and *Candida albicans* antigen, 906-907
 - lymphocytes and fibroblasts
 - insulin binding to, 426-427
 - C-peptide, 661-670
 - platelet aggregation
 - and diabetes, 108-112, *355
 - and glucagon, *311-312
 - platelets
 - and diabetic retinopathy, *120-121
 - and fatty acid metabolism, *312
 - proinsulin, 661-670
 - prothrombin time
 - and vitamin K, *183
 - samples
 - and responses to amino acids in malnourished infants, *182
 - in study of diabetes in *Myodomys albicaudatus*, 716
 - and sulfonyleurea study, 217-223
 - transfusions
 - and glucose, *1120
 - viscosity
 - and juvenile diabetics, *254
- BLOOD GLUCOSE. *See also* Blood sugar
 - and alloxan
 - and diphenylhydantoin and glutathione, 80-83
 - and 6-aminocotinic acid, 144-148
 - and arginine, 308-310
 - assays
 - and surgery for islet cell adenomas, *185
 - and body weight, *362-363
 - capillary and venous, 1103-1105, 1107
 - control
 - and vascular diseases, 976-978
 - determination
 - and reflectance meter/enzyme test strip system, *1119
 - and diabetic instability, *836
 - and diet
 - in obese hyperglycemic mice, *119
 - diurnal
 - and unstable diabetes, *1203
 - and exercise
 - and diabetes, 89-99
 - and obesity, *909
 - in female diabetic rats
 - and fetal pancreatic transplants, 199-200
 - and glucose dosage, 1103-1104
 - and insulin
 - in diabetics and nondiabetics, *1047
 - and insulin administration to gastrointestinal tract, 203-207
 - and insulinoma, *250
 - and ketoacidosis, *181
 - and lipotrophic diabetics, 827-830
 - and metformin, *771
 - monitoring, 705-706
 - plasma immunoreactive insulin during, *324-325
 - and oral insulin, 644-647
 - and plasma growth hormone
 - and diabetic retinopathy, *322
 - production and oxidation
 - and insulin-dependent diabetes, *375
 - and propranolol, *122
 - response to catecholamines
 - and noradrenaline and adrenaline, *912
 - response to glucagon, glucose and tolbutamide
 - and liver cirrhosis and insulinemia, *121-122

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

BLOOD PRESSURE. *See also* Hypertension and kidney transplantation and diabetes, *322

BLOOD SUGAR

and atherosclerosis, *253
control, 834
and nerve tissue sorbitol and fructose, 1173-1178
determination
and Ames reflectance meter, *1120
and diabetic pregnancy outcome, *1201-1202
in diabetes survey, 1193-1196
formation
and lactate, *189
and glucagon infusion
in congestive heart failure patients, 940-944
and glycosuria
and insulin, *186
and insulin stability, 812
and nialamide, *363-364
in normals and prediabetics, *383
and pancreas extract injection in depancreatized dogs
and discovery of insulin, 386-395
and phenobarbitone, *1123
and sulfonyleureas, *1120
and kidney failure, *1120-1121
and uterine relaxants, *1045

BLOOD VESSELS. *See* Capillaries; Vascular disease; Vascular system

BODY

composition
and growth hormone administration to hypopituitary dwarfs, *982-983
and obesity and insulin secretion, *118
fat
and adipose tissue fat cell size and number, *180
forearm metabolism
and tolbutamide, *1206
growth
and adrenocorticotrophic hormone unresponsiveness, *981
and Cushing's syndrome, *1122
and metabolic response to growth hormone, *119-120
hands
and diabetic neuropathy, *314

height
and abetalipoproteinemia, *60
height and weight
in diabetes survey, 1193
and muscle capillary basement membrane changes, 883, 899-905
limbs
and gangrene surgery, *187
lower extremity ischemia
and femorotibial bypass, *322-323
organs
and insulin and proinsulin degradation, 1091-1100
weight
and adipose tissue glycerol kinase and lipolysis, *911-912
and diabetes, *362-363
and hypothalamic damage, *1206
and insulin sensitivity, 6-11
and spontaneous diabetes in monkeys, 1081
weight reduction
cardiovascular effects of, *980
and fat utilization and calorie restriction, *835
and insulin secretion, *1118

BONE

calcium, phosphorus, and magnesium
and intestinal microflora, *775
neonatal development
and maternal protein restriction, *1047

BOOK REVIEWS

Calories and Carbohydrates, by Barbara Kraus, 908
Current Topics on Glucagon, edited by M. Austoni, C. Scandellari, G. Federspil, and A. Trisotto, 311
Diabetic at Work and Play, The: A Modern Manual for Diabetics with the Latest Information on Oral Drugs, Diabetic Camps, Research and Many Other New Topics, by Buris R. Boshell, 908
Gourmet Recipes for Diabetics: The International Diabetic Diet Book, by Dorothy Tompkins Revell, 908
How to Live with Diabetes, by Henry Dolger, and Bernard Seeman, 1041

BRAIN

amino acid, amines and hexose uptake, *315
calcium
and feeding response in satiated rats, *1046
and extracellular markers for blood and cerebrospinal fluid transport, *774
and galactose toxicity, *315
glucose metabolism
in newborn rat, *775
hexokinase
localization on synaptosomal mitochondria, *1205
metabolism
and galactose toxicity, 202-208
and hepatic response to insulin-induced hypoglycemia, 802-803
and neonatal hypoglycemia, *910
perfused rat
glucose and D-3-hydroxybutyrate uptake, *1206
perfusion technic, *1123
utilization of ketone bodies
and ketoacidosis, *247

BRIJ 98

and oral insulin, 643-647, 648

BRUNNER'S GLAND

enterokinase secretion
and glucagon, *771

BUPHENIN

and hyperglycemia, *1045

BUTYLAMINE

and insulin secretion, *248

C

CAFFEINE

and cholesterol and triglyceride changes during glucose tolerance tests
in prediabetics, *365
and insulin secretion, 540, 543, 571

CALCIUM

absorption
and diabetes, *983
binding mechanisms
and hormones, *1121-1122
and feeding response in satiated rats, *1046

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

flux
and glucose ingestion in children,
*376
and insulin action, 696,697-698
and insulin release, 544-545, 570, *837
and insulin storage, 591-592
intestinal absorption, *775
in isolated adrenal cells, *982
and lipoprotein lipase, *188
and pancreatic beta cell amino acid
uptake, *772
and serum cholesterol and triglycerides
and hyperlipidemia patients, *980
uptake
and cytochalasin B, 602, 605

CALCIUM-45
efflux from perfused islets, *326-327

CALORIES
intake
and plasma insulin levels, 613, 617-
618
and weight loss in obese hypergly-
cemic mice, *835
and pregnancy
and amino acid metabolism, *1118-
1119
and maternal and amniotic fluid sub-
strate level, *1202

CANDIDA ALBICANS ANTIGEN
peripheral blood lymphocytes response
to
and diabetes, 906-907

CAPILLARIES
basement membrane thickening
and age and diabetes, *837
and pseudodiabetes of myopathy,
*118
muscle
basement membrane changes, *254,
881-896, 899-905
permeability and blood flow
and diabetes and prediabetes, *769
and polyol pathway activity, *330

CARBOHYDRATES
antinatriuretic effects of, *772
dietary
and childhood ketotic hypoglycemia,
*56
and glucagon and insulin secretion,
*912-913

and hypertriglyceridemia, *55
and liver glucose-6-phosphate dehy-
drogenase, 49, 53
and plasma tryptophan, *909
and regulation of pancreatic en-
zymes, *186
homeostasis
and insulin, glucagon and growth
hormone, *357
and insulin release, 559-561
metabolism
and adrenergic agents, *1203
and age, *183-184
and alcohol, *247-248
and catecholamines and methylpred-
nisolone, *772
and diabetic microangiopathy, 872
and glucagon, 939-944
and glucose tolerance and insulin
response to glucose, *1119
in infants of diabetic mothers, *1046
and menstrual cycle, *1204
and metformin, *914
in newborn infants of diabetic
mothers, *912
and psoriasis, *250
and streptozotocin, *59

CARBOHYDRATE INTOLERANCE
and acromegaly, *352
and chemical diabetes screening in
childhood, 46-47
severity of
and proinsulin response to oral glu-
cose, *356

CARBOHYDRATE TOLERANCE
and acute uremia and metabolic aci-
dosis, 1109-1114
and aging, *347
and progestin, *313
protein-bound
and diabetes, 863-870
and serotonin, *1200

CARBON DIOXIDE
production
and obesity, 6-11

CARCINOMA
and glucose metabolism
and insulin secretion, *1200

islet cell
circulating insulin in, *909-910
and streptozotocin therapy, *1204
and pancreatoduodenectomy, *188

CARDIOVASCULAR DISEASE
and disodium ethylenediaminetetra-
acetate and hypoglycemia, 960
etiology, 679-680
and oral hypoglycemic drug labeling,
832
and patient selection for UGDP, 1035-
1036
and pheochromocytoma
and insulin-dependent diabetes, *838

CARDIOVASCULAR SYSTEM
in chickens
and nonavian insulin, *59
and weight reduction, *980

CARNITINE
and liver palmitate metabolism, 259

CASE REPORTS
abetalipoproteinemia, *60
adipose tissue resection, 13-15
adrenocorticotrophic hormone unrespon-
siveness and excessive growth,
*981
alcoholic ketoacidosis, *56
ateliotic dwarfism and growth hor-
mone treatment, *366
concurrent bullous and atrophic skin
lesions, *251
congenital neuroblastoma and islet
hyperplasia, *1122
Cushing's syndrome and growth re-
tardation, *1122
diabetes
and defective pituitary reserve ca-
pacity, *981
and hypokalemic nephropathy,
*1042
and mumps in siblings, *182
in neonate, *249
and renal transplantation, *322
and rhinocerebral phycomycosis,
*185
secondary to L-asparaginase ther-
apy in acute leukemia, *1119
diabetic coma
and fibrinolysis and peritoneal dia-
lysis, *913
diabetic glomerulosclerosis without
diabetes, *769

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- diabetic microangiopathy in identical twins, *321-322
 drug-induced hypoglycemia, 956-962
 femorotibial bypass, *322-323
 generalized lipodystrophy with abnormal growth hormone homeostasis, *771
 hyperglycemia and hypoglycemia attacks
 and anti-insulin antibodies production without previous immunization, 814-825
 hyperparathyroidism
 and plasma insulin, *773
 hypoglycemia during pregnancy following pancreatoduodenectomy, *188
 hypophysectomy during diabetic pregnancy, 972-974
 idiopathic hypoglycemia and epinephrine excretion, *1200
 infant hypoglycemia
 and cataracts, *182
 infant ketoacidosis
 new syndrome in, *181
 insulinitis and late-onset diabetes, 762-763
 islet hypertrophy and beta-cell hyperplasia in juvenile diabetic, 114-116
 ketoacidosis and hemorrhaging, 108-110
 lipoatrophic diabetes without ketosis, 827-830
 lipoatrophy, *381-382
 lipoproteinemia, 745
 maternal blood sugar levels and fetal mortality and morbidity, *1201-1202
 pancreas transplantation, *355
 pheochromocytoma with insulin-dependent diabetes, *838
 temperate sprue, *773
- CATARACTS**
 and galactosemia, 202, 295-300
 and infant hypoglycemia, *182
 and polyol accumulation, *352
 in tuco-tuco, *1206
- CATECHOLAMINES**
 action
 and cyclic AMP, *251
 blood glucose and free fatty acid responses to
 and noradrenaline and adrenaline, *912
- and carbohydrate metabolism, *772
 and exercise-induced glucagon secretion, *334
 and insulin secretion, *119, *316
 and methysergide, 783-784
 release
 and glucagon, 944
 and phenothiazine-induced hyperglycemia, *184
 -secreting tumors
 and glucose intolerance, *838
- CATS**
 adrenalectomized
 and splanchnic nerve stimulation, *770
- CAUDAL DYSPLASIA**
 and diabetic pregnancy, *1042
- CEREBROSPINAL FLUID**
 and brain metabolism, *774
 and diabetic ketosis, *181
- CHICKS**
 galactose toxicity in, *315
 and nonavian insulin
 and cardiovascular response, *59
 and oral glucose loading
 and plasma insulin and glucose, *1046
 ornithine utilization in, *771
- CHILDREN. See also Diabetes, juvenile;**
Infants
 and chemical diabetes, 45-47
 and Cushing's syndrome
 and growth retardation, *1122
 diabetes control evaluation in, *361-362
 and diabetic ketoacidosis
 and coma, *60
 of diabetic parents
 retinal blood flow in, *354
 and effects of neonatal hypoglycemia, *910
 and glucose ingestion
 and calcium, magnesium and phosphorus flux, *376
 and glucose tolerance tests
 and diphenylhydantoin therapy, *355-356
 and growth hormone levels during sleep, *776
 and hypoglycemia, *248
 and epinephrine excretion, *1200
 and intravenous hyperalimentation, *837
- and ketotic hypoglycemia, *56
 obese
 and five-hour oral glucose tolerance test, *1042-1043
 and oral glucose tolerance tests, 16-20
 and salicylate-induced hypoglycemia, 959
 of short stature
 and metabolic response to growth hormone, *119-120
- CHINESE**
 and diabetes prevalence, *353
- CHINESE HAMSTER**
 prediabetic
 diabetes prevention in, *337-338
 pancreas structure in newborns, 1051-1059
- CHLORMADINONE ACETATE**
 and insulin release, *313
- CHLORPROMAZINE**
 -induced hypoglycemia, *184, 961
- CHLORPROPAMIDE**
 antidiuretic action of, *189
 and plasma glucagon, 216-223
- CHOLECYSTOKININ**
 release, *252
- CHOLESTEROL**
 and clofibrate, *838, *910
 levels
 and alloxan diabetes, 1163-1166
 and pediatric familial type II hyperlipoproteinemia, *1043
 metabolism
 and clofibrate, *1200-1201
 and insulin, *186
 and temperature, *314
 and metformin, *771
- CHOLESTEROL-C-14**
 production
 and liver tissue injury, *315
- CHOLINERGIC AGENTS**
 and pancreatic glucagon and insulin secretion, *332
- CHORIONIC GONADOTROPIN**
 and diabetic pregnancy, 33-34
- CHORIONIC SOMATOMAMMOTROPIN**
 and insulin and glucagon release, 1072-1075

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

CHROMATOGRAPHY

- column
 - and isolation of insulin-tryptophan complex, *1045
 - and mucopolysaccharides assays, 735
 - and glycoprotein study, 865-866
 - and insulin antibodies study, 822-823
 - and serum nonsuppressible insulin-like activity study, 271-278
- thin layer
 - and sodium acetate incorporation into rat aorta lipids, *186

CHROMIUM

- dietary
 - and diabetes in monkeys, 1079
 - in glucose tolerance factor, *1043
 - and glucose utilization
 - and marasmus, *313
- hepatic
 - and diabetes, *1046

CINANSERIN

- and insulin secretion, 784-786

CITRATE

- and amino acid metabolism, *56
- pancreatic
 - and insulin release, 999-1001

CITRIC ACID CYCLE

- and diabetic ketosis, 257
- and liver ketogenesis, 50-52

CLOFIBRATE

- and cholesterol metabolism
 - and hyperlipidemia, *1200-1201
- and fatty acid metabolism, *835
- and ischaemic heart disease, *838, *910
- and tumor-bearing mice, *837

COLCHICINE

- and insulin release, 991, 996-997

COLLAGEN

- in connective tissue study of diabetic rats, 736, 739

COMA, DIABETIC

- and blood ketone body estimation method, *1117
- and blood lactic and pyruvic acids, *350
- and diabetic ketoacidosis, *60
- and drug-induced hypoglycemia, 955-962
- and fibrinolysis and peritoneal dialysis, *913

- and insulin, 632-633
- and mortality, 633-634
- symposium on, *246

COMA, HYPOGLYCEMIC

- diagnosis, 961
- treatment, 961-962

CONCANAVALIN A

- binding to isolated white fat cells, *336-337
- and insulin, 1144

CONGENITAL DEFECTS

- dwarfism, *366, 633, 872-873, *982-983, *1046
- neuroblastoma and islet hyperplasia, *1122
- rubella
 - and diabetes incidence, *248-249

CORONARY DISEASE. *See* Arteriosclerosis; Cardiovascular disease; Heart disease; Myocardial infarction

CORTICOTROPHIN

- and lipolysis
 - and iodinated insulin, *55

CORTISONE ACETATE

- and fasting triglyceride and cholesterol in offspring of diabetic couples, *1044-1045

COXSACKIE B₁ VIRUS

- and diabetes, 766-767

CTENOMYS TALARUM. *See* Tuco-Tuco

CUSHING'S SYNDROME

- and growth retardation, *1122
- in infancy, *120

CYCLAMATES

- and blood constituents and hepatic lipids, *1202

CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE

- and adipose tissue metabolism
 - and insulin, 414-424
- and adrenalectomy, *340
- and amino acid metabolism, *56
- binding mechanisms, *1122
- formation
 - in islet cell adenoma, *912
- formation and degradation
 - in islet cell tumor, *185

- and glucagon
 - and pancreatectomy, 453
- and glucose, 571
- and glucose-induced insulin release, *1042
- and glucose release
 - and glucagon, *332
- and glucose repression in rat liver, *187
- and glycogen synthase, 429, 433-436
- and growth hormone secretion, *313
- and hormone action, *251
- and insulin
 - and lipolysis, 403
 - and liver metabolism, 439-445
- and insulin action, 454-455, 696-697, *772
- and insulin release, 1, 224-225, *312, *329, 545
- and prediabetes, 689-690
- in islet cell adenomas
 - and glucose, glucagon, tolbutamide and theophylline, *346-347
- in isolated adrenal cells, *983
- in isolated fat cells, 1027-1034
- and amitriptyline, *1045
- and kidney gluconeogenesis, *910
- and lipolysis
 - and mercury, *771
 - and tolbutamide, *836
- and liver protein synthesis, 453
- and phosphofructokinase, *363
- and plasma insulin, *180
- and plasma insulin response to tolbutamide, *311
- and protein synthesis
 - and hormones, *119
- in white fat cells
 - and tolbutamide, *835

CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE, 441, *838

- and insulin, 415-416
- localization in islets of Langerhans, *328

CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE

- and glycogen synthase, 435
- phosphodiesterase activity against, *838

CYCLIC NUCLEOTIDES

- receptor sites in fat cells, *336

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

CYCLOHEXAMIDE

- and gluconeogenesis
- and glucocorticoid, *349
- and hexokinase, *185
- and insulin secretion, *55
- and rat adipocyte fatty acid synthetase activity, *914

CYCLOHEXYLAMINE

- and insulin secretion, *248

CYCLOPHOSPHAMIDE

- and immune response to insulin, *58

CYPROHEPTADINE

- and acromegaly, *352
- and insulin release, 784-786
- and pancreatic beta-cell alterations, 71-78

CYTOCHALASIN B

- and insulin release, *327, 598, 600-602, 603

D

DECADRON

- and shock, *1201

2-DEOXYGLUCOSE

- and insulin release, 565
- in fetal rat pancreas, *121
- and insulin response to amino acids, 1-5

DEUTERIUM OXIDE

- and insulin release, 991-993, 996-997

DEXTRAN

- insulin complex
- and insulin action studies, *1122

DEXTROSTIX

- and blood glucose determination, *119

DIABETES MELLITUS

- and acute pancreatitis, *911
- and adipose tissue lipolysis, *361
- and adipose tissue resection, 13-15
- adult-onset
- and oral hypoglycemic agents and vascular complications, *57
- and 6-aminonicotinamide, 143-148
- and arterial calcification
- and glucose tolerance, *252
- in baboons, *338
- and bacteriuria, *118

- and beta-cell sensitivity to glucose, 224-233

- and bladder dysfunction, *364
- and blood glucose levels
- and walking, 89-99

- and blood lymphocytes response to phytohemagglutinin and *Can-dida albicans* antigen, 906-907

- and body weight constancy, *362-363
- and calcium absorption, *983

chemical

- in children, 45-47
- and hyperglycemia and hyperinsulinemia, *1121

- and circulating C-peptide immunoreactivity, 1013-1025

- and connective tissue changes, 733-743
- control

- and diabetic retinopathy, *382
- diagnosis

- and glucose tolerance during pregnancy, *186

- and scintiphotoscanning, *351

- and UGDP patient selection criteria, 1036

duration

- and platelet aggregation, *120-121
- and retinopathy, *187, *321-322

- and employment, 834-835

etiology

- and insulin action, 698-700
- and viruses, 713-714

- and fructose, *314

- and gangrene surgery study, *187

- and glibenclamide therapy, *55, *913

- and glomerular lesions

- and proteinuria, *1120

- and glucagon, *60, *332

- and glucagon secretion, *183

- and gluconeogenesis

- and alanine, *341-342

- and glucose tolerance

- and microangiopathy, *321

- and glycoprotein fucose elevation, 863-870

- and graded insulin infusions

- and plasma glucose, serum growth hormone and cortisol responses to, *379

- growth-hormone induced

- and Huntington's chorea, *374-375

- in guinea pigs, *338

- and hemochromatosis

- and angiopathy, *123

- hospital care for, *1120

- and Huntington's chorea, *1121
- and hyperphagia and polydipsia

- and adrenalectomy and hypophysectomy, *358-359

- and hypertriglyceridemia
- and postheparin lipolytic activity, *342

- and hypophysectomy during pregnancy, 972-974

- and hypothyroidism, *769

- and impotence

- and androgenic function, 23-28

- incidence

- and congenital rubella, *248-249

- and infection

- and plasma glucagon, *324

- and insulin

- and antigenicity, 649-656, 657-659, 660

- and insulin antibodies, *57, *775

- insulin-dependent

- and acute hypoglycemic insulin action, *182

- and blood glucose production and oxidation, *375

- and pheochromocytoma, *838

- and insulin disappearance rates, *1047

- and insulin and glucagon patterns, *359-360

- and insulin resistance

- and proinsulin antibodies, *368

- and insulin secretion, 608-613

- and alcohol hypoglycemia, 65-69

- and methysergide maleate, *315-316

- and xylitol and glucose, *187-188

- insulin-treated, 632-636

- and plasma insulin, glucose and free fatty acids, *325

- and intestinal absorption, *252-253

- and intestinal growth and hexose transport in rats, *59

- juvenile

- and blood viscosity, *254

- control evaluation, *361-362

- and fructose, *349-350

- and glomerular basement membrane thickening, *913

- and growth hormone, *312

- and growth hormone metabolism, 175-177

- and islet hypertrophy and beta-cell hyperplasia, 114-116

- and plasma lipid levels and diet, *366

- and programmed education, 967-971

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- and pseudo-dwarfism and Mauriac syndrome, 633
- "remission," *1205
- and self-management, *1204
- and sensory perception thresholds, *1199
- and ketone body metabolism, *246
- and kidney disease
 - in Pima Indians, *365-366
- late-onset
 - and insulinitis, 762-767
- like syndrome
 - and encephalomyocarditis virus infection, *247
- and lipemia
 - and insulin concentrations, *376-377
 - and liver cholesterol turnover, *314
 - and liver chromium content, *1046
 - and liver free fatty acid metabolism, 280-288
- and liver gluconeogenesis
 - and glucocorticoids, *339-340
- and liver 3-hydroxybutyrate dehydrogenase, *184-185
- and liver metabolism, 257-268
- and lower extremity ischemia
 - and femorotibial bypass, *322-323
- management, 683, 684
 - computer-delivered protocol for, *367
 - and diabetic neuropathy, 679
 - and diet, 681-682
 - and insulin, 678, 713
 - and macroangiopathy and atherosclerosis, 679-680
 - and microangiopathy, 680-681
 - and new insulins, 637-647
- maternal
 - and carbohydrate metabolism in newborn infants, *912
 - and diabetic fetopathy, 687
 - and infant erythroblastosis fetalis, *1199-2000
 - and infant hypocalcemia, *914
 - and infant hypoglycemia, *1202-1203
 - and neonatal carbohydrate metabolism, *1046
- maturity-onset
 - and diet, 1116-1117
 - and serotonin antagonists, *352
- and metabolic insulin clearance, 1003-1011
- and metformin, *771
- and microangiopathy
 - and age, *837
- mortality studies, *1044
- and mumps, *182
- and muscle capillary basement membrane changes, 881-896, 899-905
- and muscle capillary permeability and blood flow, *769
- in *Mystromys albicaudatus*, 715-721
- in neonate, *249
- and neuropathy of hands, *314
- new research on, *314
- and obesity, *246
 - and insulin resistance, *370
 - and insulin secretion, *1118
 - and low calorie diet with phentermine resin, *361
 - and phenformin, *362
- onset
 - and heredity and diet, *770
- and oral hypoglycemic drug labeling, 833
- and pancreatic alpha cell function
 - and insulin, 301-307
- and pancreatic beta cell function, 511
- and pancreas transplantation, *355
- and peripheral circulation
 - infrared thermography studies, *981
- and phenformin
 - and lactic acidosis, *1198
- and pituitary gland reserve capacity, *981
- and placental glycogen metabolism, 1185-1190
- and plasma amino acids, *340-341
- and plasma glucagon levels, *324
- and plasma immunoreactive insulin during continuous blood glucose monitoring, *324-325
- and platelet aggregation, *355
- and prediabetes transition to, 691-693
- prevalence
 - among Florida Seminoles, *776
 - and heredity and obesity, *250
- prevention, 693
 - and diet, *337-338
- and rat liver nuclear proteins, *377
- and renal transplantation, *322
- research
 - and beta-cell dysfunction, 703-704
 - and blood glucose analysis, 705-706
 - and glucose-insulin relationships, 704, 707-710
- and rhinocerebral phycomycosis, *185
- screening
 - errors in, *254
- and serum N-acetyl-beta-glucosaminidase, 1168-1171
- and serum phospholipids, *123
- and serum protein changes
 - and microangiopathy, *371
- and skin lesions, *251
- spontaneous
 - in *Macaca nigra*, 1077-1088
- and submaxillary gland extirpation, 722-731
- and sulfonylureas
 - and kidney insufficiency, *1120-1121
- surveys
 - among Chinese, *353
 - and Pima Indians, *180
 - of rural population of India, 1192-1195
- therapy
 - and U100 insulin, 832
 - and thyrotoxicosis, *370-371
- transient
 - and L-asparaginase therapy in acute leukemia, *1119
- treatment
 - and hemochromatosis, *1199
 - and jet insulin injection, 39-44
 - and sulfonylureas, *120
 - and UGDP, 1036-1037
- in tuco-tuco, *1205
- unstable
 - and biguanides, *123
 - and diurnal growth hormone and glucose abnormalities, *1203
 - and insulinogenic reserve, *836
 - and vascular disease, *314
 - and blood coagulation study, 108-112
 - in combined hyperlipoproteinemia, *376
 - and venous changes, *909

DIALYSIS

- and diabetes, *322
- peritoneal
 - and diabetic coma, *913

DIAMINE OXIDASE

- and diabetic pregnancy, 35

20, 25-DIAZACHOLESTEROL, *837

DIAZOXIDE

- and amino acid metabolism, *56
- and beta cell tumors, 535

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and hyperresponsiveness to tolbutamide, *360
and insulin secretion, *327, 856-861, *1045
and pancreatic beta cell uptake of amino acids, *772
and tolbutamide response, *311
- DIBUTEROL**
and amino acid metabolism, *56
- DIBUTYRYL CYCLIC 3',5'-ADENOSINE MONOPHOSPHATE**
and fat cell metabolism, *343
and insulin
and adipose tissue lipolysis, 427
and insulin release
in *acomys cahirinus*, 1065, 1067
and isolated fat cells, 1027-1034
and lipolysis
and insulin, 415-424
and phosphofructokinase, *363
and protein synthesis, *119
- DIET**
and adipose tissue glucose metabolism and insulin response, 1152
and alimentary lipemia, *58
and blood constituents and hepatic lipids, *1202
and blood glucose control
and tolbutamide and phenformin, 976-978
and blood glucose and serum insulin in obese hyperglycemic mice, *119
carbohydrate
and glucose metabolism, *179
and pancreatic alpha cell function, 301-307
and cerebral development in rat fetus, *189
and diabetes control, *361-362
and diabetes management, 681-682
and diabetes onset, *770
and diabetes prevention, *337-338
and diabetes survey of rural population in India, 1192
and diabetes treatment, 1116-1117
diabetic
and xylitol, *350-351
and differential feeder for parabiotic rats, *983
"elemental" liquids
and hemolytic anemia and pancreatic acinar atrophy and fibrosis, *773-774
- and exocrine pancreas development in neonatal rat, *186
food intake
and stomach tumors in obese mice, *774
galactose
and motor nerve conduction studies in rats, 295-300
and glucagon and insulin secretion, *912-913
and glucose tolerance tests, 1197
and growth hormone release during sleep, *913
high fat
and obese-hyperglycemic and non-obese mice, *182
high fructose
and juvenile diabetes, *349-350
high protein
and liver gluconeogenesis from fructose and glycerol, *358
and hyperlipemia
in gerbils, *60
and hypertriglyceridemia of streptozotocin diabetes, *353-354
-induced hypercholesterolemia, *1044
-induced jejunal lipodystrophy, *248
isocaloric
in lipoproteinemia study, 744
and konnyaku ingestion
and serum insulin response to glucose, *60
and lactose intolerance, 871
low calorie
and anorectic agents, obese diabetics and, *361
low casein and methionine
and rat fatty liver metabolism, *183
low cholesterol, high polyunsaturated fat
and insulin sensitivity, *361-362
and nutrient regulation of insulin secretion, 606-615, 617-618
and obesity
and hyperinsulinemia, *249
and pancreatic enzymes, *186
in weaned rats, *59
and pediatric familial type II hyperlipoproteinemia, *1043
and plasma glucagon, *331-332
and plasma lipid levels, *366
and proliferative diabetic retinopathy, *382
- protein-restricted
and neonatal growth hormone production and bone development, *1047
safflower oil
and insulin secretion, 923-928
sucrose
serum triglyceride response to, *835
and ventromedial hypothalamic nuclei destruction
and glucose metabolism, *1204-1205
vitamin K deficient
and resistance to oral anticoagulants, *183
- DIETHYLSTILBESTROL**
and insulin response to arginine and tolbutamide, *378
- DIHYDROXYACETONE**
and liver gluconeogenesis, *330-331
- DI-ISOPROPYLAMMONIUM DI-CHLORACETATE**, *358
- DILANTIN**. See Diphenylhydantoin
- DIMETHYLBIGUANIDE**. See Metformin
- DIPA**. See Di-isopropylammonium dichloracetate
- DIPHENYLHYDANTOIN**
and alloxan diabetogenic action, 80-83
and insulin secretion, *327, 856-861, *982
long-term therapy
and glucose and insulin responses to glucose tolerance tests, *355-356
- DISODIUM ETHYLENEDIAMINE-TETRA-ACETATE**
and insulin
and hypoglycemia, 960
- DIURESIS**
and secretin, *769
- DNA**
fetal, *315
kidney
in progeny of protein-deficient rats, *1041
in mouse diaphragm, *184
pancreatic
and diet in neonatal rats, *186

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

DOGS

- and acute uremia and metabolic acidosis
- and carbohydrate tolerance, 1109-1114
- adrenalectomized
- and splanchnic nerve stimulation, *770
- and ammonium chloride acidosis
- and glucose tolerance, 794, 796
- and antidiuretic action of chlorpropamide, *189
- arginine and tolbutamide infusion
- and diethylstilbestrol and growth hormone, *378
- Brunner's gland secretion in
- and glucagon, *771
- and carbohydrate metabolism
- and catecholamines and methylprednisolone, *772
- depancreatized
- and discovery of insulin, 385-394
- glucose turnover rates during running, *382-383
- and exercise
- and plasma glucagon, *1198-1199
- and glucagon secretion
- and growth hormone, *313
- glucagon studies in, *360-361
- and glucose feeding
- and insulin secretion, *911
- and glucose kinetics studies, *188
- hypophysectomized
- and tolbutamide and glybenclamide injections, *378-379
- and insulin antibodies, *182
- insulin distribution and binding in hindlimb of, *775
- and insulin-induced hypoglycemia, 802-803
- and insulin release
- and amino acids, *56
- and insulin secretion
- and oral glucose feedings, *909
- and thyroxine and hypophysectomy, *253
- and intestinal glucagon-like immunoreactivity
- and insulin secretion and glucose levels, *58
- liver free fatty acids metabolism
- and anti-insulin serum, 280-288
- mongrel and beagle
- and serum insulin response, *356

- and pancreas blood flow and insulin output
- and prostaglandins, *369
- partially depancreatized
- and glucose tolerance and insulin response, *339
- and pepsin secretion study, *250
- reticuloendothelial system
- and vascular clearance and lipid metabolism, *312
- and secretin
- and diuresis, *769
- and sodium linoleate infusion
- and plasma free fatty acids, glucose, insulin and ketones, 1179-1184
- submaxillary gland extirpation in
- and glucose and insulin tolerance, 722-731
- and tolbutamide response
- and diazoxide, *311

L-DOPA

- and plasma free fatty acids and glucose, *1121
- and plasma growth hormone, insulin, and thyroxine, *911

DOPAMINE

- and insulin secretion, *184
- sensitive adenylyl cyclase
- and synaptic transmission, *773

DOPAMINE BLOCKING AGENTS

- and insulin release, 783-784

D. PNEUMONIAE

- and liver cycloleucine, *316

DULCITOL

- and nerve conduction defect in galactose-fed rats, 295-300

DWARFISM

- ateliotic
- and growth hormone treatment effect on glucose tolerance and adipose tissue cellularity, *366
- and plasma insulin response to glucose, *1045-1046
- diabetic sexual ateliotic
- and microangiopathy, 872-873
- hypopituitary
- and growth hormone therapy, *982-983
- pseudo, 633
- pseudohypopituitary, *1046

E

EDEMA

- cerebral, *1203
- and diabetic ketosis, *180-181

ELECTROPHORESIS

- agar, 816
- of glycoproteins and collagen
- in connective tissue study of diabetic rats, 736, 738-739
- and neutral regular insulin study, 236, 241

ELIPTEN, *837

- EMBRYO, *See also* Fetus
- pancreas islets study, 511-533

EMIOCYTOSIS

- and insulin release, 535, 603

ENCEPHALOMYOCARDITIS VIRUS

- and diabetes-like syndrome, *247
- and mouse pancreas, *338-339

ENDOCRINE GLANDS

- adenomatosis
- and familial nesidioblastosis, *1122
- and diabetic microangiopathy, 872-873

ENDOPEPTIDASE

- trypsin-like
- and proinsulin conversion to insulin, 577-578

ENZYMES

- N-acetyl-beta-glucosaminidase
- and diabetes, 1168-1171
- adenyl cyclase
- and nervous system function, *773
- adenyl cyclase and cyclic AMP phosphodiesterase
- localization in rat islets of Langerhans, *328
- adenylate cyclase and phosphodiesterase
- and insulin release, *328-329
- aldose reductase
- and insulin release, *327
- assays
- and diabetic pregnancy, 34-35
- and cyclic AMP
- and insulin, 439-445
- cyclic AMP phosphodiesterase, *328
- and insulin, 415-416

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- enterokinase
 - and glucagon, *771
 - and galactose metabolism, 202, 208
 - glutathione-insulin transhydrogenase, *353
 - glycogen synthetase
 - and insulin, 428-437
 - glycogen synthetase and phosphorylase
 - and diabetes, 1185-1190
 - glycolytic
 - and insulinoma, *773
 - hexokinase, *1205
 - and insulin degradation, 468
 - by placenta, *374-375
 - and proinsulin assays, *122
 - and insulin and proinsulin degradation, 1093-1100
 - in jejunal mucosa
 - and alloxan diabetes and fasting in rats, *188
 - lipoprotein lipase
 - in rat heart and adipose tissue, *344
 - liver
 - and alcoholism, *983
 - liver acetic thiokinase
 - and lipogenesis, *982
 - liver adenylate cyclase
 - and glucagon, *981
 - liver threonine dehydratase, *980-981
 - pancreatic
 - and diet, *186
 - and serum anti-insulin, *911
 - phosphodiesterase
 - and cyclic AMP and cyclic GMP, *838
 - phosphofructokinase
 - and cyclic AMP and dibutyl cyclic AMP, *363
 - of placental polyol pathway, *330
 - and proinsulin conversion to insulin, 577-578, 581-583
 - proteolytic
 - and fat cell lipolysis, 423
 - and leucine incorporation into protein, *336
- EPINEPHRINE**
- adenyl cyclase response to, *772
 - and calcium transport, *327
 - and cyclic AMP, 441, 445
 - excretion
 - and idiopathic hypoglycemia, *1200
 - and glucagon secretion, *332-333
 - and glycogen synthase, 436
 - and insulin
 - and adipose tissue lipolysis, 427
 - and insulin release
 - and glucose administration, *348
 - and insulin response to glucose, *773
 - and insulin secretion, *770
 - and lipolysis
 - and mercury, *771
 - and protein synthesis
 - and cyclic AMP, *119
 - responsive adenyl cyclase
 - and insulin, *1117-1118
 - stimulated lipolysis
 - in siblings of diabetics, *361
- ERYTHROBLASTOSIS FETALIS**
- and fetal pancreas, *253-254
 - and glucose metabolism, plasma insulin and growth hormone secretion, *1199-2000
- 17B-ESTRADIOL**
- and tRNA methylases, *253
- ESTROGEN**
- and diabetic pregnancy, 31-32
 - and growth hormone secretion, *774-775
- ETHANOL**
- and alanine
 - and gluconeogenesis, *1202
 - blood clearance of
 - and alcoholism, *983
 - and diabetes, *1042
 - induced fatty liver
 - and pyrazole and glucose, *247
 - induced hypoglycemia, 958
 - and insulin release
 - in healthy subjects, 158-161
 - and intestinal triglyceride synthesis, *769-770
 - metabolism
 - and hypo-, hyper, and euthyroid rats, *181
 - and muscle damage, *838
 - and phenformin
 - in obesity and prediabetes, *363
 - and skeletal muscle lactate metabolism, *367
- ETHINONINE**
- and pancreas mitotic activity, 1055
- EXERCISE**
- and amino acid levels
 - in fasted and fed rats, *119
 - and amino acid metabolism, *770-771
 - and cardiovascular system
 - and weight reduction, *980
 - decreased
 - and glucose intolerance, 101-107
 - and glucagon secretion, *1198-1199
 - and glucose metabolism, *179, *776
 - and glucose turnover in depancreatized dogs
 - and insulin and glucagon infusion, *382-383
 - induced glucagon secretion
 - and catecholamines, *334
 - and insulin and glucose uptake, *980
 - and insulin secretion
 - and obesity, *909
 - and phentolamine, *119
 - and lactic acid levels
 - and phenformin and Tolinase therapy, *351
 - walking
 - and blood glucose levels in normals and diabetics, 89-99

F

FAMILY HISTORY

- and alcohol-induced glucose intolerance, *184
- and chemical diabetes in children, 45
- and diabetes following mumps in siblings, *182
- and diabetes prevention, *337-338
- and endocrine adenomatosis, *1122
- and epinephrine-stimulated lipolysis, *361
- and myotonic dystrophy
 - and insulin secretion, *378
- and prediabetes, *359
- and renal glycosuria, *248
- and sensory perception thresholds in relatives of diabetics, *1199

FASTING. *See* Starvation

FAT CELLS. *See also* Adipose tissue

- adenylate cyclase
 - and insulin, *772
- and antilipolytic action of tolbutamide, *836
- and insulin action study, 454
- insulin binding with membranes of, 398-401
- and insulin and lipolytic hormones
 - and mercury, *771
- insulin receptor of
 - and insulin resistance, *1042
- leucine incorporation into protein by, *336

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- lipolysis
and insulin, 414-424
lipolysis and cyclic AMP
and amitriptyline, *1045
and tolbutamide, *835
metabolism
and dibutyl cyclic AMP, *343
and insulin, *351-352, 403-411
purification of plasma membranes
and adenyl cyclase response to hormones, *772
and receptor sites for insulin and cyclic nucleotides, *336
size and number
assay method, *247
and enlargement of epididymal fat pads, *247
white
concanavalin A binding to, *336-337
- FATS**
and insulin release, 613-615, 617-618
tolerance
and oral contraceptives, *316
- FATTY ACIDS**
free
and anti-insulin serum, 280-288
and glucagon, *60
and glucose ingestion, 1104-1105
and β -hydroxybutyrate, *836
and hypertriglyceridemia and phenformin, *380
and phenformin, *1045
release from adipose tissue, *59-60
renal, *314
responses to catecholamines, adrenaline and noradrenaline and, *912
and streptozotocin, *59
and insulin release, 613-615, 617-618
metabolism
and pancreas alpha and beta cells, *909
by sheep liver and viscera, *118
and thrombin, *312
oxidation, oxidative phosphorylation
and diabetic rat liver mitochondria ultrastructure, 257-268
release by adipose tissue
and insulin, 414-424
synthetase activity
and glucose and insulin, *914
- FETUS**
cerebral development
and diet and growth hormone studies, *189
and diabetic fetopathy, 687
endocrine pancreas
cytological studies, *253-254
fibroblasts
glucose oxidation in, *360
growth
and maternal diabetes, *912
insulin response
and arginine, *251
lamb
and metabolism studies, *187
and maternal diabetes, 31, *315, 687, *912
mortality
and diabetic pregnancy, 31
mortality and morbidity
and maternal blood sugar levels, *1201-1202
pancreas, 620, 621, 623-624
insulin content, 193-201
insulin release studies, *345-346
islets study, 511-533, 536
and placental nitrogen conservation, *340
and streptozotocin therapy, *316
subhuman primate
and theophylline, *180
- FIBRINOLYSIS**
and diabetic coma, *613
- FIBROBLASTS**
cultured
glucose oxidation in, *360
of granulation tissue
and antismooth muscle serum, *314
- FLUID SECRETION STUDIES**, *315
- FLUPHENAZINE**
-induced hyperglycemia, *184
- FOOD AND DRUG ADMINISTRATION**
and labeling of oral hypoglycemic drugs, 833, 1116-1117
- FORMALDEHYDE**
-treated insulin, *55
- FREEZE ETCHING TECHNIC**, *326, 619-620
- FRUCTOSE**
and diabetes, *314
dietary
and diabetic children, *349-350
and fetal metabolism, *187
gluconeogenesis from, *358
and insulin secretion, 543, 561
and liver glucose production
and insulin-induced hypoglycemia, 797-803
metabolism
in fasted and streptozotocin diabetic rat, *122
in nervous tissues
and blood sugar control, 1173-1178
serum triglycerides response to
and age, *835
small intestine permeability for, *249
- D-FRUCTOSE**
and insulin response to glucose, 540
transport
and biguanides, *119
- FUCOSE**
protein-bound
and diabetes, 863-870

G

- GALACTOSE**
and insulin release, 543, 561
and nervous system defects, 295-300
toxicity, *315
and brain metabolism, 202, 208
- D-GALACTOSE**
and alloxan toxicity, *123
and insulin response to glucose, 540
intestinal uptake, *249
transport
and biguanides, *119
- GALACTOSEMIA**
and brain metabolism, 202, 208
and diabetic microangiopathy, *352
- GAMMA GLOBULIN**
and insulin complexes
and diabetic microangiopathy, 872-879
- GANGRENE**
and femorotibial bypass, *322-323
and insulin response, *836
and limb salvage arterial surgery, *187

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

CASTRECTOMY
and glucagon and insulin response, *1047

GASTRIN
and insulin secretion, 535

GASTROENTERITIS
and hypoglycemia, *248

GASTROINTESTINAL SYSTEM
absorption
and diabetes, *252-253
and cholecystokinin
and secretin, *252
and diet-induced jejunal lipodystrophy, *248
diseases
and "elemental liquid" diets, *773-774
and duodenal acidification
and pepsin secretion study, *250
enzyme activity
in rats, *59
gastric emptying rate
and oral glucose tolerance tests, *381
glucagon and insulin responses, *1047
glucagon-like immunoreactivity, *837-838
assays, *1206
and insulin and glucose, *58
glucose and galactose absorption, 1107
growth and hexose transport
in diabetic rats, *59
hormones
and insulin response to triglyceride, 928
and insulin administration
and plasma immunoreactive insulin, 203-207
jejunal mucosa
and glycolytic and pentose phosphate pathway enzymes, *188
lipodystrophy
diet-induced, *1044
lipoprotein production, *121
mechanical stimulation of
and serum insulin response to glucose, *60
microflora
and calcium and magnesium absorption, *775
and oral insulin, 643-647
permeability to glucose
and synthetic surfactants, *182-183
and portacaval shunting
and glucose tolerance and serum immunoreactive insulin response, *179

small bowel
and insulin response to glucose absorbed from, *54
small intestine
permeability for fructose, *249
sugar transport
and biguanides, *119
surgery
and glucose homeostasis, *1199
transport
and glucagon, *983
triglyceride synthesis
and ethanol, *769-770
xylitol absorption, *350-351

GEESE
and liver metabolism
and glucagon, *55

GENES
and autosomal recessive inheritance of renal glycosuria, *248
and familial hypercholesterolemia, *1121
and longevity in mice, *914

GERBILS
and diet-induced intestinal lipodystrophy, *1044
and hyperlipemia, *60
pancreas structure in newborns, 1051-1059

GIRAFFES
muscle capillaries basement membrane width in, *254

GLIBENCLAMIDE
and amino acid metabolism, *56
-glucose-response-test, *913
intrapancratic infusion
and insulin release, 209-215
and pancreatic beta cell uptake of amino acids, *772
pharmacodynamic aspects, *249, *249-250
studies, *55

GLIBORNURIDE
pharmacodynamic aspects, *249, *249-250

GLICLAZIDE
and microangiopathy, *357

GLISOXEPIDE
pharmacodynamic aspects, *249, *249-250, *912

GLOMERULOSCLEROSIS, DIABETIC
immunohistopathological study of, 163-173
without diabetes, *769

GLUCAGON
action
and cyclic AMP, *251
and adenosine 3'/5'-monophosphate levels, *54
and adenyl cyclase activation in islet cell adenoma, *912
adenyl cyclase response to, *772
biosynthesis, *58-59
and carbohydrate homeostasis, *357
and carbohydrate metabolism, insulin and growth hormone secretion
in congestive heart failure patients, 939-944
chronic administration of
and glucose tolerance and insulin hyperresponsiveness, *374
and cyclic AMP, 440
and pancreatotomy, 453
and diabetes
and infection, *324
and diuresis, *769
and enterokinase secretion, *771
gastrointestinal response to, *1047
and gastrointestinal transport, *983
and gluconeogenesis, *331
and hypoglycemic coma, 961-962
immunoreactive
in islet cell tumors, *333
and immunoreactive insulin
and blood glucose, *360-361
infusion
and glucose turnover in depancreatized dogs, *382-383
and insulin immunoreactivity, *313
-insulin ratio
and liver metabolism, *341
and insulin release
and arginine, *312
and insulin response, 1
in *acomys cahirinus*, 1064, 1069
and islet cell adenoma cyclic AMP content, *346-347
kidney sensitivity to
and starvation, *334
-like immunoreactivity
assays, *1206
and insulin secretion and glucose concentration, *58

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

and liver adenosine 3',5'-monophosphate and glucose, *187
 and liver cirrhosis, *121-122
 and liver gluconeogenesis
 and D-glyceraldehyde and dihydroxyacetone, *330-331
 -mediated plasma insulin responses
 and theophylline, *180
 metabolism, *333
 and diabetes, *332
 and myocardial oxygen consumption and potassium balance, *118-119
 physiology and pathophysiology, *60
 and plasma amino acids, *340-341
 and plasma lipids and blood platelets, *311-312
 and related synthetic peptides, 843-855
 release
 and human chorionic somatomammotropin, 1072-1075
 resistance
 and lipemia, *357
 -responsive adenyl cyclase
 macromolecular inhibitor of, *180
 secretion, *314
 adrenergic control of, *332-333
 and alanine, *183
 and aminophylline, 289-293
 and catecholamines, *334
 and diet, *912-913
 and exercise, *1198-1199
 during glucose infusions in starvation and diabetes, *359
 and growth hormone, *313
 and insulin deficiency, *183
 and pituitary and adrenal glands, *375
 selectively blocked
 and liver adenylate cyclase, *981
 serum insulin response to
 in mongrel and beagle dogs, *356

GLUCAGON I-131

and glucagon metabolism studies, *333

GLUCOCORTICOIDS

and ACTH, growth hormone or thyroxine and ketosis, 414
 and diabetic ketosis, 946-954
 and gluconeogenesis, *252
 and liver gluconeogenesis
 and diabetes, *339-340
 and liver mitochondrial structure, 258

GLUCONEOGENESIS

and alanine
 and diabetes, *341-342
 and ethanol, *1202
 from arginine, 308-310
 and cyclic AMP
 and insulin, 439-445
 from fructose and glycerol
 in liver of high-protein fed rats, *358
 and glucagon, *183
 and glucocorticoids, *252

GLUCORECEPTOR MECHANISMS, 555-568, 570, 611-613

GLUCOSAMINE

and insulin release, *328, 543, 544, 561, 570

D-GLUCOSAMINE

and insulin response to glucose, 540-541

GLUCOSE. See also Glucose intolerance; Glucose tolerance; Glucose tolerance tests

absorption
 and gut glucagon-like immunoreactivity, *837-838
 absorption from small bowel
 and insulin response, *54
 and adenyl cyclase activity, *179
 and alloxan
 and insulin secretion, *326
 and alloxan toxicity, *123
 and amino acid metabolism, *56
 and arginine
 and serum insulin and growth hormone, *316
 beta cell sensitivity to
 and prediabetes and diabetes, 224-233
 binding to intestinal epithelial brush borders
 and diabetes, *252-253
 brain metabolism
 in newborn rat, *775
 and calcium metabolism, *327
 disappearance rates
 in infants of diabetic mothers, *1046
 and methysergide maleate, *316
 disposal
 and myopathy, *118
 and ethanol-induced fatty liver, *247
 and fatty acid metabolism, *835
 and fatty acid synthetase activity, *914

and fetal metabolism, *187
 glibenclamide-response-test, *913
 and glucagon, *60
 and glucagon-like immunoreactivity, *58
 homeostasis
 and gastric surgery, *1199
 and glucagon, *314
 and hypoglycemia, 815
 and hypoglycemic coma, 961
 infusion
 insulin and glucagon patterns during, *359-360
 ingestion
 and metabolism, 1102-1108
 ingestion in children
 and calcium, magnesium and phosphorus flux, *376
 and insulin
 and hypoglycemia, *373
 and lipoatrophy, *381-382
 -insulin relationships, 704, 707-710
 and insulin secretion, *55, 143, 157-161, *370, 606-613, 617-618, 713, 989
 in *acomys cahirinus*, 1062
 and adenylate cyclase and phosphodiesterase, *328-329
 and ammonium ion, *248
 and arginine, *312, *1045
 and carbohydrate and lipid metabolism, *1119
 and chlormadinone acetate, *313
 and cyclic AMP, *1042
 and cytochalasin B., *327
 and diabetes and obesity, *187-188
 and diphenylhydantoin and diazoxide, 856-861
 and epinephrine, *770, *773
 and human chorionic somatomammotropin, 1072-1075
 and immunohistological detection of insulin in pancreatic tissue, *246
 and iodoacetate and antimycin A, *56
 and juvenile diabetes "remission," *1205
 and konnyaku ingestion, *60
 and kwashiorkor, *1119-1120
 and methysergide, 780-787
 and ouabain, *246
 and peripheral vascular disease, arteritis, and Raynaud's phenomenon, *836-837
 in rat islets, *1205

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

and serotonin and dopamine, *184
and small vessel disease, *836
stimulus-secretion coupling of, 594-603
and tolbutamide, 684
intestinal permeability to
and synthetic surfactants, *182-183
intestinal transport
and biguanides, *119
and islet cell adenoma cyclic AMP content, *346-347
kinetics
in dogs, *188
levels
and alcohol hypoglycemia, 65-69
and liver cirrhosis and insulinemia, *121-122
and liver gluconeogenesis, *371
loading
and diet and fasting, *1046
and iodinated insulin, *55
and obesity, *54
and maternal diabetes
and infant hypoglycemia, *1202-1203
metabolism
adipose tissue, 1151-1161
and carcinoid syndrome, *1200
and cyclic and dibutyl AMP, 1028-1030
and erythroblastosis fetalis, *1199-2000
and insulin, *184
in isolated pancreas islets, 538-545
in isoproterenol-stimulated rat salivary glands, *982
during leg exercise, *776
and methylene blue, *350
and obesity, 6-11
and pancreas alpha and beta cells, *909
in rat skin, *189
and shock, *1201
and ventromedial hypothalamic nuclei destruction, *1204-1205
oral
and alimentary lipemia, *58
and insulin secretion, *909, *911
output
and insulin and adenosine 3',5'-monophosphate, *254
oxidation
in cultured fibroblasts, *360
and exercise and dietary carbohydrate, *179
of isolated islets in tissue culture, 548, 550-551

and norepinephrine and theophylline, 416-417
pancreatic islet response to, *344-345
and plasma glucagon, growth hormone and insulin
during exchange transfusion, *1120
and plasma insulin
and diabetes, 1012
and theophylline, *180
and plasma and pancreatic insulin, *375-376
production
and mannose, fructose and hydroxybutyrate, 797-803
proinsulin response to
and age, obesity, and degree of carbohydrate intolerance, *356
prolonged infusion
and insulin secretion, *372
regulation
and hypertension, *776
renal, *314
repression in rat liver
cyclic 3',5'-AMP during, *187
responses
and diphenylhydantoin therapy, *355-356
and serum insulin levels
and trauma, *183
-stimulated insulin release
and glucoreceptor mechanisms in islets of Langerhans, 555-568
and insulin storage, 585-592
and sulfonylureas, *249-250
transport
in fat cells, 403
in rat adipose tissue, *1042
turnover
in depancreatized dogs, *382-383
uptake
and exercise, *980
by isolated perfused rat brain, *1206
uptake by brain
and perfusion techniques, *1123
uptake by fat tissue
and β -hydroxybutyrate, *836
utilization
and chromium, *313
and growth hormone, *342-343
and thyrotoxicosis, *370-371

GLUCOSE INTOLERANCE

alcohol-induced, *184
and catecholamine-secreting tumors, *838
and chromium deficiency, *313
and decreased physical activity, 101-107

and gastrectomy, *1047
and hypokalemia, *1043-1044
and myocardial infarction, *119
and obesity, *1118
and phenytoin, *187

GLUCOSE TOLERANCE

and acute uremia and metabolic acidosis, 1109-1114
and alcohol, *247-248
and ammonium chloride-induced acidosis, 794-796
and arterial calcification, *252
and carbohydrate and lipid metabolism, *1119
and chronic glucagon administration, *374
and encephalomyocarditis infection, *247
and glibenclamide, *55
and growth hormone treatment in ateliotic dwarfism, *366
and insulin response
in partially pancreatectomized dogs, *339
intravenous
and myocardial infarction, *184
and metformin, *771
and microangiopathy, *321
and myotonic dystrophy, *378
and nicotinic acid, *313
and obesity, 759, *1205
and portacaval shunt in rats, *179
and prediabetes, 686
and renal lesions, *769
seasonal variations in, *312-313
and submaxillary gland extirpation, 722-731
and temperate sprue, *773

GLUCOSE TOLERANCE FACTOR

and insulin, *1043

GLUCOSE TOLERANCE TESTS

and acute pancreatitis, *911
and bedrest and exercise, 102-106
and caffeine
and prediabetes, *365
and chemical diabetes in childhood, 46-47
and Chinese, *353
in diabetics and obese patients, 1012
and diphenylhydantoin therapy, *353-356
and ethanol and phenformin, *363
among Florida Seminoles, *776
and gastric emptying, *381
and glucose metabolism, 1102

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- in guinea pigs, *338
and Huntington's chorea, *1121
and hypertension, *776
and liver cirrhosis, *356
in *Macaca nigra*, 1078-1088
and myocardial infarction, *119
in neonates of diabetic mothers, *912
in obese children, *1042-1043
and obesity, *1205
oral
 and diabetes screening errors, *254
 discriminant analytical technic, *251
 and serum insulin and growth hormone levels in children, 16-20
 standardization of, 1197-1198
and peripheral vascular disease, arteritis, and Raynaud's phenomenon, *837
and phenformin
 and diabetic obesity, *362
and Pima Indians, *180
plasma catecholamines during, *348
and plasma insulin and uric acid and nicotinic acid, *313
and plasma lipids
 in normals and prediabetics, *383
and pregnancy, *186
and serum immunoreactive insulin levels and age, *183-184
- D-GLUCOSE**
and alloxan toxicity, *123
brain uptake of
 and phlorizin, *315
and insulin release, 559-561
transport
 and biguanides, *119
- GLUCOSE C-14**
metabolism
 and 6-aminonicotinamide, *1198
- GLUCOSE-6-PHOSPHATE DEHYDROGENASE**
in jejunal mucosa
 and alloxan diabetes, *188
- GLUCOSE U-C-14**
metabolism
 in fasted and streptozotocin diabetic rats, *122
utilization
 rat strain differences in, *770
- GLUCOSURIA**
and chemical diabetes screening, 47
and dietary fructose, *349
- GLUTAMATE**
metabolism, *57
- GLUTATHIONE**
and alloxan, 81-83
- GLUTATHIONE-INSULIN TRANSHYDROGENASE**, *353, 1095-1100
- GLYBENCLAMIDE**
and hypophysectomized dogs, *378-379
- GLYBURIDE**. See Glibenclamide
- D-GLYCERALDEHYDE**
and liver gluconeogenesis, *330-331
- GLYCERIDE-GLYCEROL SYNTHESIS**
of mammalian adipose tissue, 1154-1155
- GLYCEROL**
gluconeogenesis from, *358
and insulin secretion, 923-928
release
 and weight reduction, 758
- GLYCEROL KINASE**
in adipose tissue
 and body weight, *911-912
and insulin regulation, *122
- L-GLYCEROL 3-PHOSPHATE**
and lipid synthesis in rat skin, *189
- GLYCINE**
metabolism, *57
- GLYCOGEN**
placental metabolism
 and diabetes, 1185-1190
- GLYCOGEN STORAGE DISEASE**
and hypoglycemia, *248
- GLYCOGEN SYNTHASE**
and insulin, 428-437
- GLYCOGENOLYSIS**
and arginine infusion, 308-310
and cyclic AMP
 and insulin, 439-445
- GLYCOLATE**
urinary
 and streptozotocin diabetes, *372
- GLYCOLYSIS**
and insulin secretion, 4
- GLYCOPROTEIN**
in connective tissue study of diabetic rats, 736, 738-739, 740-741
- GLYCOPROTEIN FUCOSE**
and diabetes, 863-870
- GLYCOSAMINOGLYCANS**
metabolism
 and alloxan diabetes, 1162-1166
- GLYCOSURIA**
and diabetes prevalence among Chinese, *353
in diabetes survey of rural population in India, 1193-1196
and insulin, *186
and nicotinic acid, *313
- GOLGI APPARATUS**, 620
and insulin biosynthesis, 574-577, 582, 583
and insulin secretion, 510
- GROWTH HORMONE**
activity
 and lipoatrophy, *381-382
and body composition of hypopituitary dwarfs, *982-983
and carbohydrate homeostasis, *357
and cerebral development in rat fetus, *189
and diabetes, 699-700, *1203
and diabetic ketosis, 946-954
and diabetic retinopathy, *349
diurnal
 and unstable diabetes, *1203
and glucagon secretion, *313
and glucose tolerance and adipose tissue cellularity
 in ateliotic dwarfs, *366
homeostasis abnormalities
 and generalized lipodystrophy, *771
-induced diabetes
 and Huntington's chorea, *374-375
insufficiency
 beta-1-24 corticotropin tests of, *775-776
and insulin response to arginine and tolbutamide, *378
and juvenile diabetes, *312
levels
 in small normoglycemic and hypoglycemic infants, *250
and lipid and carbohydrate homeostasis, *342-343

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

and lipotrophic diabetes, 829, 830
and lipolysis
and iodinated insulin, *55
metabolic clearance rates
and juvenile diabetes, 175-177
metabolic response to
and short stature, *119-120
and metabolism of obese patients, *1046
neonatal
and maternal protein restriction,
*1047
and pancreas compartments of insulin,
*372
release
in sleep, *776, *913
secretion
and Cushing's syndrome, *1122
and L-dopa, *911
and erythroblastosis fetalis, *1199-
2000
and glucagon, in congestive heart fail-
ure patients, 939-944
and prostaglandins, *313
regulation by growth hormone, 22,
30
and serum secretin, *1118
sex-based variation of, *774-775
synthesis
and lipids, *187

GUINEA PIGS

adipose tissue
glucose metabolism and insulin re-
sponse, 1151-1161
and diabetes, *338
immune response to insulin, *58
perfused liver
and gluconeogenesis inhibition study,
*910

H

HALOPERIDOL

and hypoglycemia, 960
and insulin secretion, 783-784

HAMSTERS. *See also* Chinese hamsters; *Mystromys albicaudatus*

adipose tissue
glucose metabolism and insulin re-
sponse, 1151-1161
and insulin secretion
and glucose and tolbutamide, *370
and islet cell tumors
and cyclic 3'5' AMP, *185
and insulin studies, *313

HEART

myocardial oxygen consumption and
potassium balance
and glucagon, *118-119
perfused rat
and lipoprotein lipase release, 149-
155
rat
lipoprotein lipase, *344
rat aorta
and sodium acetate incorporation,
*186

HEART DISEASE. *See also* Arterioscler-
osis; Myocardial infarction
congestive heart failure
and glucagon infusion, 939-944
ischaemic
and clofibrate, *838, *910

HEMOCHROMATOSIS

and diabetes, *1199
and diabetic angiopathy, *123

HEMORRHAGE

and argon laser photocoagulation, *189
and diabetes, 108-112
and insulin release, *982
and shock
insulin response to, *364

HEPARIN

and lipolysis, *342
and lipoprotein lipase
and oral contraceptives, *316
release from alloxan diabetic rat
heart, 149-155

HEPATECTOMY

and angiotensinogen and renin levels,
*253

HEPATITIS

autoimmune, *314

HEREDITY

and autoimmune disorders, *914
and diabetes, *250
and fasting triglycerides and chole-
sterol in offspring of diabetic
couples, *1044-1045
and Huntington's chorea, *1121
and diabetes onset
and diet, *770
and diabetic-like microangiopathy, *373
and endocrine adenomatosis, *1122
and hypercholesterolemia, *1121
and lactose tolerance, 871
and lipodystrophy and growth hormone
abnormality, *771

and obesity

and insulin resistance and release,
*316
and renal glucosuria, *248
and resistance to oral anticoagulants,
*183

HEXOKINASE

and insulin release, 565
in rat prostate glands
and hormonal control, *185

HEXOSE

protein-bound
and diabetes, 867
transport
in diabetic rats, *59
uptake by brain, *315

HEXOSE MONOPHOSPHATE SHUNT
and dibutyl cyclic AMP, 1033-1034

HISTAMINE

and insulin secretion, *248

HISTONE PHOSPHORYLATION

and cyclic AMP
and insulin, 439-445

HORMONES

adenyl cyclase response to, *772
and amino acids
and infantile malnutrition, *182
androgen
and diabetic impotence, 23-28
and calcium and insulin binding mech-
anisms, *1121-1122
and cyclic AMP, *251
and diabetic pregnancy, 31-35
gastrointestinal
and insulin response to triglycerides,
928
and hexokinase control in rat prostate
glands, *185
human chorionic somatomammotropin
and insulin and glucagon release,
1072-1075
and insulin secretion, 539
lipolytic
fat cell response to, mercury and,
*771
lipolytic and glucocorticoid
and diabetic ketosis, 946-954
in pancreas, 536
parathyroid
and plasma insulin, *773
and protein synthesis
and cyclic AMP, *119
sex
and growth hormone secretion, *774-
775

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

sex steroids
and liver triglyceride biosynthesis, *365

HUNTINGTON'S CHOREA
and diabetes, *374, *1121

HYDROCORTISONE
and liver mitochondrial structure, 258
and rat fatty liver, *183

HYDROCORTISONE SODIUM SUC-
CINATE
and hypoglycemic coma, 961-962

β -HYDROXYBUTYRATE
and lipolysis, *836
and liver glucose production
and insulin-induced hypoglycemia,
797-803
metabolism, *343

3-HYDROXYBUTYRATE
brain utilization of, *247

D-3-HYDROXYBUTYRATE
uptake
by isolated perfused rat brain, *1206

3-HYDROXYBUTYRATE DEHYDROG-
ENASE
in diabetic liver mitochondria, *184-185

5-HYDROXYTRYPTAMINE
and insulin secretion, *251-252

HYPERALIMENTATION
intravenous
in children, *837

HYPERAMMONEMIA
and glucose metabolism
and insulin, *184

HYPERBILIRUBINEMIA
neonatal
and phenobarbitone therapy, *1123

HYPERCALCEMIA
and hyperparathyroidism, *773

HYPERCHOLESTEROLEMIA
and diabetes
and diet, *366
diet-induced, *1044
familial, *1121

HYPERCOAGULABILITY
and diabetes, 108-112

HYPERGLUCAGONEMIA
alanine-induced
and alpha-adrenergic blockade, *1043
and insulin, 301-307

HYPERGLYCEMIA
and alcohol ingestion, *247-248
and L-asparaginase therapy, *1119
and chemical diabetes, *1121
compared with ketosis, 257
and diabetes
in tuco-tuco, *1206
and diet, *770
in obese mice, *119
and glucagon, *360-361
and glucagon secretion
and alanine, *183
and growth hormone metabolic clear-
ance rates, 176
and hemorrhagic shock, *364
and hyperglucagonemia, 301-307
and hypoglycemia
and anti-insulin antibodies produc-
tion, 814-825
and hypothalamic stimulation, *771
insulin-resistant
and aminophylline, *775
and intravenous alimentation, *837
and islet of Langerhans structure, *1043
and liver cirrhosis, *356
and metabolic acidosis and acute ure-
mia, 1109-1114
and myocardial infarction
and tolbutamide therapy, *122-123
in *Mystromys albicaudatus*, 716-721
neonatal
and insulin studies, *181
and obesity
and high-fat diet in mice, *182
and pentobarbital, *836
phenothiazine-induced, *184
and phenytoin toxicity, *187
and postheparin lipolytic activity, *342
and splanchnic nerve stimulation
and andralectomy, *770
and streptozotocin, *59
and synthetic glucagon peptides, 845-
846
and uterine relaxants, *1045
and vascular disease, 679-680

HYPERINSULINISM
and adipose tissue resection, 13-15
and chemical diabetes, *1121
and diabetes
and connective tissue changes, 733-
743
and diabetic pregnancy, *912
and insulin insensitivity, 6
and insulin resistance
in genetically obese rats, *838
and liver cirrhosis, *356
and liver glucose production, *380-381

and obesity, *314, *380, 613, 617-618
and blood proinsulin, 663-664
and diet, *249
and obesity and hyperlipidemia
induced in monkeys, *1201

HYPERLIPEMIA
alcoholic, *770
and diabetes, *123
in gerbils, *70

HYPERLIPIDEMIA
and calcium, *980
and cholesterol metabolism
and clofibrate, *1200-1201
and metformin, *771
and obesity and hyperinsulinemia
induced in monkeys, *1201

HYPERLIPOPROTEINEMIA, 744-752
combined
and diabetes and vascular disease,
*376
and cortisone acetate, *1044
pediatric familial type II
and diet, *1043
type II, *1121
and diet, *366

HYPEROSMOLALITY
and diabetes
and ketogenesis, *369-370
in galactose-fed chicks, *315

HYPERPARATHYROIDISM
and infant hypocalcemia, *914
and plasma insulin, *773

HYPERPHAGIA
dietary prevention of, *337-338
and polydipsia
and adrenalectomy and hypophys-
ectomy, *358-359

HYPERTENSION
and glomerulonephritis
without diabetes, *769
and glucose regulation, *776

HYPERTHYROIDISM
and thyroid function tests, 1012

HYPERTRIGLYCERIDEMIA
endogenous
and plasma triglycerides synthesis,
*55
and insulin deficiency, *366-367
and phenformin
and insulin and free fatty acids, *380
and plasma free fatty acid metabolism,
*835

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

and postheparin lipolytic activity, *342
and pregnancy, *365
and streptozotocin diabetes
and diet, *353-354

HYPOCALCEMIA

in infants of diabetic mothers, *914

HYPOCHOLESTEREMIC DRUGS

and tumor-bearing mice, *857

HYPOGLYCEMIA

and alcohol
and basal insulin secretion, 65-69
and arginine-induced insulin release,
*312
and biguanides
and insulin, *123
and cataracts
in infants, *182
and diabetes
and kidney insufficiency, *1120-1121
drug-induced, 955-962
and exchange transfusions of citrated
blood, *185
factitious, *980
and glixoxepid, *912
and hyperglycemia
and anti-insulin antibodies produc-
tion, 814-825
and hyperparathyroidism, *773
idiopathic
and epinephrine excretion, *1200
and infants, *248
and beta cell nesidioblastosis, *189
and glucose administration in diabetic
mother, *1202-1203
and growth hormone levels, *250
and insulin
and central nervous system, *337
and growth hormone, 22, 30
and intravenous glucose, 610
and iodinated insulin, *55
ketotic
diagnosis in children, *56
and lactic acidosis, *1198
liver response to
and mannose, fructose and hydroxy-
butyrate, 797-803
and metformin, *771
and monamine oxidase inhibitor, *251-
252
neonatal, *179-180, *910
nondiabetic reactive and asymptomatic
biochemical
and insulin-glucose dynamics, *373
and oral insulin, 644, 645
and pancreatoduodenectomy
and pregnancy, *188

and phenobarbitone, *1123

reactive

and phenformin therapy, *367-368
and tolbutamide, *1123

HYPOGLYCIN A

and Jamaican vomiting sickness, *316

HYPOGONADISM

hypogonadotropic
and diabetic impotency, 23, 26

HYPOINSULINEMIA

and alpha-adrenergic activity, *348

HYPOKALEMIA

and glucose intolerance, *1043-1044

HYPOLIPEMIA

in pregnant rhesus monkeys, *912

HYPOLIPIDEMIA

in "acatalase nic" mice *56

HYPOPHYSECTOMY

and aminophylline
and hyperglycemia, *775
and diabetic pregnancy, 972-974
and diabetic retinopathy, *349
and glucagon secretion, *375
and insulin secretion, *253
and pancreatectomy
and diabetic ketosis in rats, 946-954
and tolbutamide and glybenclamide,
*378-379

HYPOPITUITARISM

and dwarfism
and growth hormone, *982-983
and growth hormone levels, *776
and hypoglycemia, *248

HYPOTHALAMIC-HYPOPHYSEAL SYSTEM

and insulin, *1200

HYPOTHALAMUS

damage
and obesity, *1206
lesions
and insulin resistance and hyperinsu-
linemia, *838
and lipolysis, *55
stimulation
and plasma glucose, insulin and glu-
cagon, *771
ventromedial destruction
in diabetic rats, *1043
and glucose metabolism, *1204-1205

HYPOTHYROIDISM

and diabetes, *769

I

IMMUNE COMPLEX DISEASE

and diabetic microangiopathy, *352

IMMUNOELECTROPHORESIS

and diabetic glomerulosclerosis, 163-173
and insulin antibodies assays, 816, 819

IMPOTENCE

and diabetes
and androgenic function studies, 23-
28

IMURAN

and immune response to insulin, *58

INDIA

diabetes survey of rural population of,
1192-1195

INFANTS

big
and glucose tolerance during preg-
nancy, *186
congenital neuroblastoma and islet hy-
perplasia, *1122
and Cushing's syndrome, *120
of diabetic mothers
and carbohydrate metabolism, *912,
*1046
and caudal dysplasia, *1042
and drug-induced hypoglycemia, 955
and hypocalcemia, *914
and erythroblastosis fetalis
and glucose metabolism, plasma in-
sulin and growth hormone se-
cretion, *1199-2000
and exchange transfusion
of citrated blood, *185
and glucose, *1120
and hyperbilirubinemia
and phenobarbitone therapy, *1123
and hypoglycemia, *248
and cataract, *182
and glucose administration in dia-
betic mother, *1202-1203
hypoglycemic and normoglycemic
and growth hormone levels, *250
and ketoacidosis, *181
and malnutrition
and metabolic and hormonal re-
sponses to amino acids, *182
and marasmus
and chromium and glucose utiliza-
tion, *313
mortality
and glucose tolerance during preg-
nancy, *186
and neonatal hypoglycemia, *179-180,
*910

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- temporary, *181
- newborn
 - and permanent diabetes, *249
- premature
 - and intravenous hyperalimentation, *837
 - and serum insulin and growth hormone response to arginine and glucose, *316
- and severe idiopathic hypoglycemia and beta cell nesidioblastosis, *189
- and type II hyperlipoproteinemia and plasma and blood cholesterol, *1043
- INFECTION**
 - and diabetes
 - and plasma glucagon levels, *324
 - rhinocerebral phycomycosis, *195
- INFRARED THERMOGRAPHY**
 - and circulation studies in diabetics, *981
- INSULIN**
 - action, 454-455, 485
 - and amino acid sequences, 457-459
 - and atomic structure, 509
 - computer studies of, *347
 - and insulin-dextran complex studies, *1122
 - and insulin receptor, 396-401
 - and lead intoxication, *381
 - molecular basis of, 468-474, 695-700
 - related to atomic structure, 492-505
 - acute hypoglycemic action
 - and insulin-dependent diabetes, *182
 - acute response to glucose
 - and epinephrine, *773
 - and adipose tissue lipolysis, 427
 - administration
 - to gastrointestinal tract in rabbit, 203-207
 - amino acid sequences, 485
 - analogs synthesis, *772-773
 - antibodies, *57, *182, *379, 649-656, 657-659, 660, 677, *775, 764-765, *769, 814-825, 914, 930-934
 - antisera
 - proinsulin cross-reactivity with, 465-466
 - assays
 - in monkeys, 1078-1089
 - in obese rats, *1123
 - and atherosclerosis, 684
 - "big"
 - and streptozotocin therapy for islet cell carcinoma, *1204
 - "big" and "little", 677
 - binding
 - to lymphocytes and fibroblasts, 426-427
 - binding activity
 - in diabetics and nondiabetics, *775
 - and hormones, *1121-1122
 - binding proteins, 426
 - bioassays
 - and insulin stability determinations, 805-812
 - biosynthesis
 - and amino acids, *772
 - and cytochalasin B, 602-603
 - monolayer newborn rat pancreas for study of, 627-630
 - and blood glucose levels
 - and exercise, 98-99
 - and carbohydrate homeostasis, *357
 - circulating antibodies to
 - polyethylene glycol screening test for, *379
 - concentrations
 - and diabetic lipemia, *376-377
 - content
 - of beta cell tumors, 535
 - of fetal rat pancreas, 193-201
 - and cyclic AMP and dibutyryl cyclic AMP activity, 1028
 - and cyclic AMP levels, 453
 - deamino-A¹ sheep
 - synthesis, *981
 - deficiency
 - and glucagon secretion, *183
 - and hypertriglyceridemia, *366-367
 - and ketosis, 257-258
 - and liver glucose production, *380-381
 - and liver ribosomal aggregation, 84-88
 - degradation
 - and chemicals and hormones, 468-469
 - and fat cells, 403-411
 - by human placenta, *374-375
 - in rat liver, *382
 - in rats, 1091-1100
 - degrading enzymes
 - and proinsulin assay, *122
 - dependent diabetes
 - and blood glucose production and oxidation, *375
 - and pheochromocytoma, *838
 - derivatives, 427-473
 - and diabetes control
 - and retinopathy, *382
 - and diabetes management, 632-636, 678
 - and diabetes mortality, 633-636
 - and diabetic pregnancy, *315
 - dimer, 494, 496-497
 - macromolecular modeling system for, 506-508
 - disappearance rates
 - in nondiabetics and diabetics, *1047
 - discovery of, 385-395
 - distribution and binding
 - in dog hindlimb, *775
 - dosage
 - and diabetes in neonate, *249
 - and drug-induced hypoglycemia, 959-960
 - exogenous
 - and insulin secretion in normal and obese hyperglycemic mice, *344
 - and fat cells
 - and lipolysis, 414-424
 - and mercury, *771
 - and fatty acid synthetase, *914
 - fish
 - amino acid sequences, 459
 - and fructose metabolism, *314
 - and gamma globulin
 - and diabetic microangiopathy, 872-879
 - and glucagon, *60
 - glucagon ratio
 - and liver metabolism, *341
 - and glucose
 - and hypoglycemia, *373
 - and glucose metabolism
 - in hyperammonemic rats, *184
 - in rat diaphragm and epididymal fat pads, 935-938
 - in rat skin, *189
 - glucose relationships, 704, 707-710
 - and glucose tolerance factor, *1043
 - and glycogen synthase, 428-437
 - and glycolytic enzymes, *773
 - and glycosuria, *186
 - graded infusions of
 - and plasma glucose, serum growth hormone and cortisol responses, *379
 - guinea pig and coypu
 - amino acid sequences, 457-458
 - hexamer structure, 497-499
 - hyperresponsiveness
 - and chronic glucagon administration, *374
 - and hypertriglyceridemia
 - and phenformin, *380
 - immune response to, *58
 - immunoassays
 - and antibodies study, 814-825

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- immunohistological detection in pancreatic tissue, *246
- immunoreactive
 - circulating components of, 673-676
 - and glucose dosage, 1105-1106
 - and intravenous glucagon, *360-361
 - and neonatal hyperglycemia, *181
 - and obesity, 13-15
 - and serum nonsuppressible insulin-like activity, 278
 - during thyrotoxic periodic paralysis attacks, *1047
- induced hypoglycemia
 - and mannose, fructose and hydroxybutyrate, 797-803
 - and plasma growth hormone, *312
- infusion
 - and glucose kinetics in dogs, *188
 - and glucose turnover in depancreatized dogs, *382-383
- and insulin antibodies
 - in dogs, *182
- interaction with liver membranes, *334-335
- intestinal response to, *1047
- in islet cell carcinoma, *909-910
- jet injections of, 39-44
- and late-onset diabetes, 763
- levels
 - and obesity, *380
- like activity
 - of arginyl compounds, *1122-1123
 - in fibrosarcoma, *352-353
 - nonsuppressible, 271-278
 - and lipid synthesis, *189
 - and liver adenylate cyclase, *772
 - and liver enzymes, 713
 - and liver epinephrine-responsive adenyl cyclase, *1117-1118
 - and liver gluconeogenesis, *371
 - and liver glucose-6-phosphate dehydrogenase, 49, 53
 - and liver metabolism, 453, *1200
 - and intracellular cyclic AMP level, 439-445
 - and liver plasma membranes, *335
 - and liver protein synthesis, 453
 - liver response to
 - and prediabetes, *323-324
 - metabolic clearance of, 1003-1011
 - modified
 - activity of, 502-504
 - monomer structure, 493-494
 - neutral Regular, 235-245, 637-638
 - new forms of, 637-647, 648
- nonavian
 - and cardiovascular response in chickens, *59
- nonhypoglycemic, *55
- oral, 643-647, 648
- and oxytetracycline
 - and hypoglycemia, 960
- pancreas compartments of,
 - and growth hormone, *372
- and pancreatic alpha-cell function
 - and diabetes, 301-307
- and pancreatic blood flow and insulin output, *1204
- and placental glycogenesis, *1199
- and plasma amino acids, *340-341
- plasma growth hormone unresponsiveness to, *981
- and plasma insulin, glucose and free fatty acids, *325
- and plasma tryptophan in rats, *909
- polyalanyl derivatives of, *835
- and potassium flux and glucose output, *254
- and pressor response to angiotensin and norepinephrine
 - and alloxan diabetes, *354-355
- and proinsulin, *57, *314
- conformational studies, 486-491
- proinsulin conversion to, 572-579, 581
- proinsulin-like component of, *313
- proinsulin ratio
 - and diabetes, 664
- and propranolol
 - and hypoglycemic coma, 960
- and protein synthesis, 447-451
- in anterior pituitary gland, *1200
- and cyclic AMP, *119
- and protein turnover in skeletal muscle, *341
- purified pork
 - and insulin allergy, 638-643
- and pyruvic dehydrogenase, 427
- rat
 - amino acid sequences, 458-459
 - and rat adipocytes, *60
 - and rat fatty liver, *183
 - and rat mammary cell metabolism, *315
- reactions
 - and pituitary reserve capacity, *981
- receptor sites in fat cells, *336
- receptors
 - in central nervous system, *337
 - of liver plasma membranes, *335
- and regulation of glycerol kinase, *122
- release
 - and acromegaly, *1118
 - "acute phase," 157-161
- and adenylate cyclase and phosphodiesterase, *328-329
- and age, *184
- and aldose reductase inhibitors, *327
- and alpha adrenergic receptors, *348
- and alpha-adrenergic receptor blockade, *181
- and amino acids, *56
- and 6-aminonicotinamide, *1198
- and antimitotic agents, 987-997
- arginine-induced, *312
- and autonomic nervous system, 624-627
- and cyclic 3'5' AMP, *185
- and diazoxide, *360
- and diphenylhydantoin and diazoxide, *327
- and encephalomyocarditis infection, *247
- and fats and fatty acids, 613, 615, 617-618
- in fetal pancreas, *345-346
- and glucoreceptor mechanisms, 570
- glucosamine-induced, *328
- and glucose, 143, 713, *1042
- and glyburide infusion, 209-215
- and human chorionic somatomatomotropin, 1072-1075
- and intracellular pH of pancreatic beta cells, *911
- and iodoacetate and antimycin A, *56
- in islet cell adenomas, *346-347
- and islet glucoreceptor mechanisms, 555-568
- L-leucine and L-phenylalanine induced, *369
- methamphetamine induced, *252
- by monoamineoxidase inhibitor, *363-364
- and ouabain, *246
- and packet storage, 585-592
- and pancreatic calcium uptake, *837
- and pancreatic islet citrate levels, 999-1001
- perfusion studies, 987-997
- and phenformin, *1045
- and phenytoin, *187
- and prostaglandins, *329, *369
- and protein and amino acids, 613, 617-618
- and pyridine nucleotide, *983
- stimulus-secretion coupling of, 594-603, 605
- and uremia, *910-911
- release and content
 - in rat islets, *1205
- release and inhibition
 - in fetal rat pancreas, *121

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- requirements
 - and infection, *324
 - reserves
 - and diabetic instability, *836
 - resistance
 - and alcohol, *247-248
 - and fat cell insulin receptors, *1042
 - in genetically obese rats, *838
 - and hemochromatosis, *1199
 - in obese mice, *314-315
 - and obesity, *249, *314
 - and proinsulin antibodies, *368
 - and steroid-induced ketoacidosis, *54
 - resistance factor
 - secretion by hyperfunctioning pancreatic islets, *370
 - resistance and release
 - and obesity, *316
 - resistant hyperglycemia
 - and aminophylline, *775
 - response
 - by adipose tissue, 1151-1161
 - to amino acids, 2-deoxy-D-glucose, mannoheptulose and, 1-5
 - to arginine and tolbutamide, *378
 - and diphenylhydantoin, therapy, *355-356
 - to hemorrhagic shock, *364
 - in partially depancreatized dogs, *339
 - and prediabetes, 685-687
 - of pregnant women and their fetuses, *251
 - and small-vessel disease, *836
 - to sucrose and glucose, *58
 - to tolbutamide and propranolol, *122
 - response to glucose
 - and carbohydrate and lipid metabolism, *1119
 - and chlormadinone acetate, *313
 - and myocardial infarction, *119
 - and peripheral vascular disease, arteritis and Raynaud's phenomenon, *836-837
 - and prediabetes and diabetes, 224-233
 - from small bowel, *54
 - and tolbutamide, 684
 - secreting tumors, *1120
 - secretion, *188, 510, 535
 - in *acomys cahirinus*, 1060-1070
 - and alcohol hypoglycemia, 65-69
 - and alpha-ketomonocarboxylic acids, *359
 - and amines and pancreatic beta cells, *248
 - and amino acids, 570-571
 - and aminophylline, 289-293
 - and ammonium ion, *248
 - and arginine, *1045
 - and beta adrenergic and cholinergic agents, *332
 - and body composition in obese patients, *1118
 - and carcinoid syndrome, *1200
 - and chemical diabetes, *1121
 - and diazoxide, *1045
 - and diet, *912-913
 - and diphenylhydantoin, *982
 - and diphenylhydantoin and diazoxide, 856-861
 - and epinephrine, *770
 - and glibenclamide, *913
 - and Glisoxepid, *912
 - and glucagon, in congestive heart failure patients, 939-944
 - and glucagon-like immunoreactivity, *58
 - and glucose, 606-613, 617-618
 - and glucose and alloxan, *326
 - glucose-induced, and juvenile diabetes "remission," *1205
 - during glucose infusions in starvation and diabetes, *359-360
 - and glucose and tolbutamide, *370
 - and isolated insulin antibodies, *914
 - in isolated pancreas islets, 538-545
 - and kwashiorkor, *1119-1120
 - and lipotrophy, *381-382
 - and long-chain triglycerides, 923-928
 - and metal ions, 570
 - and metformin, *914
 - and methylene blue, *350
 - and methysergide maleate, *315-316
 - and monoamines, *251-252
 - and myotonic dystrophy, *378
 - nutrient regulation of, 606-615, 617-618
 - and obesity after exercise, *909
 - and oral glucose administration, *909, *911
 - and ouabain, *913
 - and pancreatic beta-cell webs, *838
 - and pancreatic monoamines, *345
 - and phenolamine, *119
 - and prediabetes, 688-691
 - and prolonged glucose infusion, *372
 - seasonal variations in, *312-313
 - and serotonin antagonists, *352, 779-787
 - and serotonin and dopamine, *184
 - and slow-rise and square wave stimuli, *55
 - and sodium beta-hydroxybutyrate, *373-374
 - and sulfonylureas, *1120
 - and synthetic glucagon, 845-846
 - and thyrotoxicosis, *370-371
 - and thyroxine and hypophysectomy, *253
 - and tolbutamide, *1123
 - and xylitol and glucose, *187-188
 - secretion and content
 - of isolated islets in tissue culture, 548-549, 551-553
 - sensitivity
 - and ammonium chloride-induced acidosis, 794-796
 - scoring system for clinical evaluation of, *361-362
 - sensitivity of adipose tissue
 - and obesity, 6-11
 - sepharose-bound
 - and muscle, adipose tissue and cultured liver cells, *335-336
 - serum-bound
 - and insulin antibodies, 930-934
 - and sodium acetate incorporation into lipids of rat aorta, *186
 - storage
 - threshold distribution hypothesis for, 585-592
 - structure, 1131-1149
 - synthesis, 469-471
 - therapy
 - and antigenicity, 649-656, 657-659, 660, 677
 - and tissue cyclic AMP levels, 426
 - tolerance
 - and dosage, *121
 - and submaxillary gland extirpation, 722-731
 - tolerance tests
 - during bedrest, 104-105
 - and triglyceride synthesis, *351-352
 - tryptophan complex
 - isolation of, *1045
 - U100 Lente, 832, 954
 - and unstable diabetes
 - and biguanides, *123
 - and zinc, 487-489
- INSULIN RECEPTOR, 396-401
- I-131 INSULIN
- and fat cell metabolism, 403-411
 - metabolic clearance studies of, 1003-1011
- uptake
- and exercise, *980
- INSULINASE, 1095-1100
- INSULINEMIA
- and liver cirrhosis

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and glucose, tolbutamide and glucagon administration, *121-122
- INSULINOMAS**
 - and blood proinsulin-like components, 665
 - and glycolytic enzymes, *773
- INSULITIS**
 - and late-onset diabetes, 762-767
- IODINE**
 - treated insulin, *55
- ODOACETAMIDE**
 - and amino acid metabolism, *56
- ODOACETATE**
 - and insulin release, *56
 - in fetal rat pancreas, *121
- IONOGRAMS**
 - and tissue glycogen synthase study, 429, 431
- IRON**
 - deficiency
 - and acetoacetate-induced anemia, *311
- ISLETS OF LANGERHANS.** *See also* Pancreas, islets
 - adenyl cyclase, *179
 - alpha and beta cells
 - and glucose and fatty acid oxidation, *909
 - of fetal pancreas, *253-254
 - glucoreceptor mechanisms, 555-568
 - hyperplasia
 - and congenital neuroblastoma, *1122
 - immunohistological detection of insulin in, *246
 - and insulin biosynthesis, 572-579, 581-583
 - insulin secretion
 - and insulin antibodies, *914
 - isolated in tissue culture
 - metabolism studies, 546-553
 - localization of adenylyl cyclase and cyclic AMP phosphodiesterase, *328
 - structure, *1043
- L-ISO PROPYLNORADRENALINE**
 - and insulin secretion, *252
- ISOPRENALINE**
 - insulin response to
 - in *acomys cahirinus*, 1065, 1069

- ISOPROTERENOL**
 - stimulated rat salivary glands and glucose metabolism, *982
- ISOXSUPRINE**
 - and hyperglycemia, *1045
- J**
- JAMAICAN VOMITING SICKNESS,** *316
- K**
- KETOACIDOSIS**
 - alcoholic, *56-57
 - in infancy, *181
- KETOACIDOSIS, DIABETIC, 794,** *1203
 - and L-asparaginase, *1119
 - and bicarbonate therapy, *323
 - and blood coagulation, 108-110
 - and blood ketone body estimation method, *1117
 - and blood lactate and ketone bodies, *186-187
 - and blood lactic and pyruvic acids, *350
 - and brain utilization of ketone bodies, *247
 - and coma, *60
 - and insulin, 632-633
 - steroid-induced, *54

- KETOGENESIS**
 - and hyperosmolar diabetic syndrome, *369-370
 - regulation, *1203
- KETONE BODIES**
 - in amniotic fluid
 - and maternal caloric deprivation, *1202
 - brain utilization of
 - in normal and ketoacidotic rats, *247
 - formation, *1203
 - and diabetes, 257-268
 - and lipolysis suppression, *377
 - metabolism
 - in fasted and diabetic rats, *246
 - in perfused skeletal muscle, *343
 - and renal ammoniogenesis, *251
 - and renal metabolism, *314
 - and unstable diabetes, *836
 - uptake by dog kidney, *251
- KETONURIA**
 - and dietary fructose, *349-350
 - and ketoacidosis in infancy, *181
 - and lipotrophic diabetes, 827-830

- and nicotinic acid, *313
- KETOSIS**
 - and cerebrospinal fluid pressure, *180-181
 - and hypoglycemia
 - diagnosis of, *56
 - and insulin deficiency, 414
 - and ketogenesis regulation, *1203
 - and kidney function, *121
 - lipotrophic diabetes without, 827-830
 - and lipolytic and glucocorticoid hormones, 946-954
 - and liver mitochondria, 257-268
- KETOSTIX**
 - and blood ketone body estimation, *1117
- KIDNEY**
 - amino acids
 - and exercise, *119
 - ammoniogenesis
 - and ketone bodies, *251
 - and antidiuretic action of chlorpropamide, *189
 - and bladder dysfunction, *364
 - and diabetic glomerulosclerosis, 163-173
 - in diabetic guinea pigs, *338
 - diabetic-like microangiopathy, *373
 - disease
 - and diabetes, in Pima Indians, *365-366
 - dog
 - and ketone bodies uptake, *251
 - failure
 - and sulfonylurea blood-sugar-reducing action, *1120-1121
 - function
 - and bacteriuria, *118
 - and diabetic ketosis, *121
 - glomerular lesions
 - and proteinuria, *1120
 - glomerulonephritis
 - without diabetes, *769
 - glomerulosclerosis
 - in diabetic baboons, *338
 - diabetic-like, *373
 - gluconeogenesis
 - and ammonia production, *57
 - and cyclic AMP, *910
 - glycosaminoglycans
 - and alloxan diabetes, 1163-1166
 - glycosuria
 - and heredity, *248
 - hypokalemic nephropathy, *1042
 - and insulin and proinsulin degradation, 1091-1100

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and liver cholesterol synthesis in rat, *1047
metabolism, *314
microangiopathy, *357
polyalanyl insulin, *835
of progeny of protein-deficient rats, *1041
and starvation
and mineralcorticoid and glucagon sensitivity, *334
transplantation
and diabetes, *322
and pancreas transplantation, *355
uric acid excretion
and nicotinic acid, *313
- KIMMELSTIEL-WILSON DISEASE**
and glomerulosclerosis without diabetes, *769
- KWASHIORKOR**
and insulin secretion, *1119-1120
- L**
- LACTASE**
and race, 871
- LACTATE**
and blood sugar and liver glycogen formation, *189
and liver gluconeogenesis and phenyl-ethylbiguanide, *910
metabolism
and ethanol, *367
- LACTIC ACID**
and serum and plasma osmolality, *838
- LACTOSE TOLERANCE TESTS**
in Nigeria, 871
- LACTOSURIA**
in diabetes survey, 1193
- LEAD**
intoxication
and insulin action, *381
- LESIONS**
arterial
and diabetes, *187
beta-cell
and encephalomyocarditis infection, *247
glomerular
and proteinuria, *1120
microangiopathic, *357
neurologic
and impotency, 23-28
- skin
and diabetes, *251
testicular
and diabetic impotence, 25-28
- LEUCINE**
incorporation into protein, *336
and insulin release, 3-4, *56
and insulin secretion, 539
metabolism
and glucose, *56
pancreatic islet cell electrical activity in response to, *345
uptake by pancreatic beta cells, *772
- L-LEUCINE**
-induced insulin release, *369
- LEUCINE-C-14**
incorporation into growth hormone and lipids, *187
- LEUKEMIA**
and L-asparaginase therapy
and transient diabetes, *1119
- LEYDIG CELLS**
and diabetic impotence, 25-26
- LIPEMIA**
alimentary
and sucrose and glucose, *58
and diabetes
and insulin concentrations, *376-377
and glucagon resistance, *357
- LIPIDS**
biliary
and pregnancy, *912
and growth hormone synthesis, *187
metabolism
in dogs, *312
and glucose tolerance and insulin response to glucose, *1119
and menstrual cycle, *1204
and prediabetes, 687
and streptozotocin, *59
mobilization
and tumors in obese mice, *774
rat aorta
and sodium acetate incorporation, *186
synthesis
and starvation, alloxan diabetes and insulin, *189
- LIPOATROPHIC DIABETES**
and urine polypeptides, *837
without ketosis, 827-830
- LIPOATROPHY**
and growth hormone activity
and glucose and insulin abnormalities, *381-382
- LIPODYSTROPHY**
and growth hormone abnormalities, *771
intestinal
diet-induced, *1044
- LIPOGENESIS**
and high-fat diet, *182
and liver acetic thiokinase, *982
- LIPOLYSIS**
adipose tissue
and body weight, 754-760, *911-912
and cyclic AMP, 1034
epinephrine-stimulated
in siblings of diabetics, *361
and growth hormone, *342-343
and β -hydroxybutyrate, *836
in hypophysectomized rats, 950-951
inhibition, *55
and insulin, 414-424
and cyclic AMP, 403
in isolated fat cells
and amitriptyline, *1045
ketone suppression of, *377
and mercury, *771
and phenformin, *362
postheparin, *54, *342
in white fat cells
and tolbutamide, *835
- LIPOMATOSIS**
and adipose tissue resection, 13-15
- LIPOPROTEIN LIPASE**, *188
and insulin, *377
and plasma triglyceride removal, *342
post heparin
and oral contraceptives, *316
in rat heart and adipose tissue, *344
release
from alloxan diabetic rat heart, 149-155
- LIPOPROTEINS**
release
and cyclic AMP and insulin, 439-445
- LIPOTROPHIN**
and lipolysis
and iodinated insulin, *55
- LIVER**
acetic thiokinase
and lipogenesis, *982

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

adenylate cyclase
and insulin, *772
and selectively blocked glucagon,
*981
and alcoholic ketoacidosis, *56-57
amino acids
and exercise, *119
cells
and sepharose-bound insulin, *335-
336
cholesterol
and temperature, *314
cholesterol synthesis
and kidney inhibitory factor, *1047
chromium
and diabetes, *1046
cirrhosis
and angiopathy, *123
and diabetes and hemochromatosis,
*1199
and hyperinsulinemia, *356
and insulinemia, *121-122
cycloleucine
and D. pneumoniae, *316
cytosol
and ethanol and sorbitol metabolism,
*181
enzymes
and alloxan diabetes, *188
and cold exposure, *58
and insulin, 713
epinephrine-responsive adenylyl cyclase
activity
and insulin, *1117-1118
ethanol-oxidizing and drug metabolizing
enzymes
and alcoholism, *983
fatty
alcohol-induced, *770
and pyrazole and glucose, *247
free fatty acid metabolism
and anti-insulin serum, 280-288
and diabetic ketosis, 947-948, 950-
954
glucagon-responsive adenylyl cyclase
macromolecular inhibitor of, *180
gluconeogenesis
from fructose and glycerol, *358
and glucagon, *331
and glucocorticoids, *339-340
and D-glyceraldehyde and dihy-
droxyacetone, *330-331
and insulin and glucose, *371
and phenylethylbiguanide, *910
and glucose homeostasis, 686-687
glucose output
and acute hypoglycemic action of
insulin, *182

glucose production
and insulin deficiency and hyperin-
sulinemia, *380-381
and mannose, fructose and hydroxy-
butyrate, 797-803
glucose-6-phosphate dehydrogenase and
carbohydrate and insulin, 49,
53
and glycerol kinase
and regulation by insulin, *122
glycogen formation
and lactate, *189
and glycoprotein synthesis, 868-870
and growth hormone metabolism, 177
homeostasis
and L-asparagine, *254
3-hydroxybutyrate dehydrogenase
and diabetes, *184-185
and hyperglycemic response to splan-
chic nerve stimulation, *770
injury
and pancreatic mitosis, 1054-1055
and insulin and proinsulin degradation,
1091-1100
ketogenesis
and gluconeogenesis, 50-52
lipids
and diet, *1202
lipogenesis
and diet, *60
and free fatty acid conversion to
triglyceride fatty acid, *835
membranes
insulin interaction with, *334-335
metabolism
and glucagon:insulin ratio, *341
and insulin, 453, *1200
and insulin and cyclic AMP levels,
439-445
and rapid indicator-dilution technic
studies, *180
and streptozotocin, *59
and tissue injury, *315
mitochondria
and diabetic ketosis, 257-268
mitochondrial swelling
and ammonia toxicity, *835-836
 α -oxoglutarate carboxylation and dia-
betes, *981
perfused rat
and amino acid metabolism, *57
and glucocorticoids and glucone-
genesis, *252
potassium flux and glucose output
studies, *254
perfused sheep, *57-58
and plasma angiotensinogen and renin
levels, *253

plasma membrane
and calcium and insulin binding
mechanisms, *1122
and insulin receptors of, *335
protein synthesis
and alloxan diabetes, *339
and insulin and cyclic AMP, 453
rat
and carbohydrate metabolism and
adrenergic agents, *1203
and cyclic 3'5'-AMP during glucose
repression, *187
and diabetic ketosis, 257-268
and diet, *183
and glucagon and adenosine 3'5'-
monophosphate levels, *54
and insulin degradation, *382
nuclear proteins and diabetes, *377
ribosomes
and insulin deficiency, 84-88
and protein synthesis, *339
sensitivity to endogenous insulin
and prediabetes, *323-324
splanchnic nerve stimulation and adren-
alectomy, *770
threonine dehydratase
and tris aminmethane and orthophos-
phate, *980-981
triglycerides
biosynthesis, and pregnancy and sex
steroids, *365
and ethanol, *247
and glucagon, *55
and oral contraceptives, *316

M

MACROANGIOPATHY
and atherosclerosis, 679-680
MAGNESIUM
flux
and glucose ingestion in children,
*376
and insulin action, 696, 697-698
and insulin secretion, 570
intestinal absorption, *775
loss
and ammonia toxicity, *836
MALATE
labeled
and gluconeogenesis study, *252
MALNUTRITION
infantile
and amino acid responses, *182
kwashiorkor
and insulin secretion, *1119-1120

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- marasmus
and glucose utilization and chromium, *313
- maternal
and lactosuria, 1195
- MAMMARY GLAND
metabolism
and insulin, *315
- MANGANESE
-induced hypoglycemia, 960
- MANNOHEPTULOSE
and amino acid metabolism, *56
and glucose protection from alloxan toxicity, *123
and insulin release, 544, 570-571
in fetal rat pancreas, *121
and insulin response to amino acids, 1-5
and insulin synthesis, 570
and pancreas metabolism, 562-564
- D-MANNOHEPTULOSE
and insulin response to glucose, 541
- MANNOSE
and insulin secretion, 539, 543
and liver glucose production
and insulin-induced hypoglycemia, 797-803
- D-MANNOSE
and alloxan toxicity, *123
- MARASMUS
and glucose utilization
and chromium, *313
- MARIHUANA
and hypoglycemia, 961
- MARKS, HENRY E., 178
- MARMOSETS
and diet-induced jejunal lipodystrophy, *248
- MAURIAC SYNDROME, 633
- MEBANAZINE
and insulin
and hypoglycemia, 960
- MENSTRUATION
and carbohydrate and lipid metabolism, *1204
and growth hormone secretion, *774-775
- MENTAL ILLNESS
and sulfonyleureas, 959
- MENTAL RETARDATION
and galactosemia, 202, 208
- 6-MERCAPTOPYRINE
and immune response to insulin, *58
- MERCURY
and fat cell response to insulin and lipolytic hormones, *771
- METABOLISM
adipose tissue
and glycerol kinase regulation by insulin, *122
and insulin, 414-424
and obesity, 6-11, *54
and adipose tissue fat cell size and number, *180
in African pygmies, *1045-1046
amino acids
and exercise, *770-771
and glucagon and insulin, *340-341
and glucose, *56
and infantile malnutrition, *182
in perfused rat liver, *57
and starvation during pregnancy, *1118-1119
and arginine derivatives, *1122-1123
and blood proinsulin and C-peptides, 669
brain, *315
and galactose toxicity, 202, 208
and hepatic response to insulin-induced hypoglycemia, 802-803
and ketoacidosis, *247
brain glucose
in newborn rat, *775
calcium, *326-327
carbohydrate
and adrenergic agents, *1203
and age, *183-184
and alcohol, *247-248
and catecholamines and methylprednisolone, *772
and diabetic microangiopathy, 872
in infants of diabetic mothers, *1046
and metformin, *914
in newborn infants of diabetic mothers, *912
and pancreatic enzymes, *186
and psoriasis, *250
carbohydrate and lipid
and glucose tolerance and insulin response to glucose, *1119
and menstrual cycle, *1204
and streptozotocin, *59
cholesterol
and clofibrate, *1200-1201
and insulin, *186
- ethanol and sorbitol
in hypo-, hyper-, and euthyroid rats, *181
- fat cell
and dibutyl cyclic 3', 5' AMP, *343
and insulin, *351-352
- fat and lactate
and phenformin, *1045
- fatty acids
by sheep liver and viscera, *118
and thrombin, *312
- fetal
and starvation, *187
- forearm
and tolbutamide, *1206
- free fatty acids, *835
- fructose
and insulin, *314
- gastrin
and secretin, *249
- and glomerular basement membrane thickening, *913
- glucagon, *333
- glucose
of adipose tissue, 1151-1161
and carcinoid syndrome, *1200
and dosage, 1102-1108
and erythroblastosis fetalis, *1199-1200
and exercise and dietary carbohydrate, *179
in hyperammonemic rats, *184
and insulin and proinsulin, 935-938
in isolated pancreas islets, 538-545
in isoproterenol-stimulated rat salivary glands, *982
and leg exercise, *776
and methylene blue, *350
in rat skin, *189
and shock, *1201
and ventromedial hypothalamus nuclei destruction, *1204-1205
- glucose and fatty acids
and pancreas alpha and beta cells, *909
- glucose C-14
and 6-aminocotinamide, *1198
- U-C-14-glucose, xylitol, fructose, and sorbitol
in fasted and streptozotocin diabetic rats, *122
- glycosaminoglycans
and alloxan diabetes, 1162-1166
- growth hormone
and juvenile diabetes, 175-177
and short stature, *119-120
and insulin clearance, 1003-1011

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- of isolated pancreas islets in tissue culture, 546-553
- isolated perfused sheep liver, *58
- ketone bodies
 - in fasted and diabetic rats, *246
 - in perfused skeletal muscle, *343
- kidney, *910
- lactate
 - and ethanol, *367
- lipid
 - in dogs, *312
- and lipotrophy, *381-382
- liver, 50-52
 - and anti-insulin serum, 280-288
 - and diabetic ketosis, 257-268
 - and glucagon, *55
 - and glucagon:insulin ratio, *341
 - and insulin, 453, *1200
 - and insulin and cyclic AMP levels, 439-445
 - and rapid indicator-dilution technic studies, *180
 - and tissue injury, *315
- mammary cell
 - and insulin, *315
- and obesity
 - and exogenous growth hormone, *1046
- ornithine, *771
- pancreatic beta cell
 - and phlorizin, *910-911
- pancreatic islet
 - and glucose, *344-345
- placental glycogen
 - and diabetes, 1185-1190
- and prediabetes, 685-693
- proinsulin, *347
- protein
 - and insulin, 447-451
- renal, *314
- triglyceride and insulin, 923-928
- METABOLITES**
 - and glucose
 - in perfused pancreas, 564-565
 - islet cell, 571
 - and insulin secretion, *344-345
- METAFORMIN**
 - and carbohydrate metabolism
 - in obese, nondiabetic women, *914
 - and hyperlipidemia, *771
 - and hypoglycemia, *771
- METHAMPHETAMINE**
 - induced insulin release, *252
- METHIONINE**
 - and pancreas mitotic activity, 1055
- and pancreatic beta cell uptake of amino acids, *772
- and rat fatty liver metabolism, *183
- L-METHIONINE**
 - and pancreas α -amino-isobutyric acid transport, *181
- METHOTREXATE**
 - and immune response to insulin, *58
- 3-O-METHYL-D-GLUCOSE**
 - excretion
 - and metformin, *771
 - intestinal uptake, *249
 - transport
 - and biguanides, *119
- N-METHYLBENZYLAMINE**,
 - and insulin secretion, *248
- METHYLCHOLANTHRENE**
 - induced thyroiditis
 - and autoimmunity, *253
- METHYLENE BLUE**
 - and glucose metabolism and insulin secretion, *350
- METHYLPHENIDATE**
 - and tumor-bearing mice, *837
- METHYLPREDNISOLONE**
 - and carbohydrate metabolism, *772
- METHYSERGIDE MALEATE**
 - and insulin secretion, *315-316, 779-787
- MICROANGIOPATHY**
 - and bacteriuria, *118
 - and diabetes, 680-681
 - and age, *837
 - diabetic
 - and concurrent bullous and atrophic skin lesions, *251
 - in humans and animals, *357
 - and insulin and gamma globulin interactions, 872-879
 - and muscle capillary basement membrane changes, 881-896, 899-905
 - and polyol metabolism, galactosemia, and immune complex disease, *352
 - and serum protein changes, *371
 - diabetic-like, *373
 - and glucose tolerance, *321
- MICROSCOPY**
 - electron
 - and abetalipoproteinemia, *60
- of beta cell tumors, 535
- capillary basement membrane, *118
- of depancreatized baboon kidney, *338
- of diabetic rat liver, 259-260, 264-268
- of endocrine pancreas in newborn rodents, 1051-1059
- of glomerular basement membrane of juvenile diabetics, *913
- and intestinal lipoprotein production, *121
- and islets of Langerhans, *1043
- of mouse pancreatic beta cells, 1068-1070
- and muscle capillary basement membrane changes, 882, 884-896
- of pancreas of diabetic monkeys, 1086, 1087
- and pancreatic islets, 595-603
- of testicular tissue, 25-28
- light
 - of isolated islets in tissue culture, 547-553
- light and electron
 - of human embryonic and fetal pancreatic islets, 511-533
 - and islet cell changes in streptozotocin diabetic rabbits, 129-137
- pancreas
 - and long-term juvenile diabetes, 115-116
- of pancreatic islets
 - from cyproheptadine-treated rats, 71-78
 - in late-onset diabetes, 763-767
- MINERALOCORTICOID**
 - kidney sensitivity to
 - and starvation, *334
- MINERALS**
 - calcium, magnesium and phosphorus flux
 - and glucose ingestion in children, *376
 - and insulin secretion, 570
 - lead intoxication
 - and insulin action, *381
 - zinc
 - and insulin, 497-498, 509
- MONKEYS**
 - and glucose tolerance tests
 - and bedrest and exercise, 105
 - and induced obesity, hyperinsulinemia and hyperlipidemia, *1201

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- Macaca nemestrina*
and streptozotocin diabetes induced
by direct pancreatic infusion,
138-141
- Macaca nigra*
spontaneous diabetes in, 1077-1089
- rhesus
and insulin response to hemorrhagic
shock, *364
and jet insulin injections, 39-44
- MONOAMINE OXIDASE
in mouse pancreas, *120
- MONOAMINE OXIDASE INHIBITORS
and hypoglycemia, *251-252
and insulin release, *363-364
- MONOAMINES
and insulin secretion, 779-787
- MONOGLYCERIDASE
postheparin, *54
- MONOGLYCERIDE HYDROLASE
in obese hyperglycemic mice, *186
- MORTALITY
and Cushing's syndrome in infancy,
*120
and diabetes, *1044
and arteriosclerosis, *1123
and insulin, 633-636
- fetal
and maternal blood sugar levels,
*1201-1202
and galactose toxicity in chicks, 208
and heart disease
and clofibrate therapy, *838
and lactic acidosis, *1198
and renal transplantation
and diabetes, *322
and sulfonylurea treatment, *120
and tolbutamide
in UGDP study, 1036-1037
and x-irradiation in mice, *914
- MOUSE
acomys cahirinus
and defective immunoreactive insulin
secretion, 1060-1070
and alloxan
and diphenylhydantoin, 80-83
and anti-insulin serum
and pancreatic islet studies, *911
diabetic
and glomerular lesions and protein-
uria, *1120
and diabetic-like microangiopathy, *373
and encephalomyocarditis virus infec-
tion
and diabetes-like syndrome, *247
hyperglycemic
and pancreas α -amino isobutyric acid
transport, *181
and insulin release
and methamphetamine, *252
- islets
and insulin release, *328-329, *914
longevity and mortality distribution
studies, *914
and microangiopathy, *357
mutant "acatalasemic",
and hypolipidemia, *56
- obese, *1044
and adipose tissue glycerol kinase
and lipolysis, *911-912
and glycerol kinase regulation, *122
and insulin resistance, *314-315
and plasma growth hormone, *122
with transplanted tumors, *774
- obese hyperglycemic
and adipose tissue monoglyceride hy-
drolase, *186
and caloric restriction studies, *835
and diet, *119
and exogenous insulin, *344
and high-fat diet, *182
and insulin release and citrate studies,
999-1001
- obese and lean
and islets of Langerhans adenyl cy-
clase and phosphodiesterase,
*179
- pancreas
and encephalomyocarditis virus in-
fection, *338-339
tumor-bearing
and hypocholesteremic drugs, *837
- MUCOPOLYSACCHARIDES
metabolism
and psoriasis, *250
- MUMPS
and diabetes, *182, 766
- MUSCLE
alanine synthesis
and exercise, *770-771
amino acids
and exercise, *119
ammonia production, *1203
antibody to
binding to fibroblasts, *314
capillaries basement membrane changes,
*254
and aging and diabetes, 881-896,
899-905
- capillary permeability and blood flow
and diabetes and prediabetes, *769
and ethanol, *838
and insulin and proinsulin degradation,
1091-1100
- myopathy
and capillary basement membrane
thickening, *118
- phosphofructokinase
and cyclic AMP and dibutyryl cyclic
AMP, *363
- and sepharose-bound insulin, *335-336
- skeletal
ketone-body metabolism in, *343
lactate metabolism and ethanol, *367
protein turnover in, *341
- MYOCARDIAL INFARCTION, 763
and clofibrate therapy, *838, *910
and glucose tolerance, *184
and glucose tolerance tests, *312-313
and hormone and metabolic disturb-
ances, *119
and hyperglycemia
and tolbutamide therapy, *122-123
- MYOTONIC DYSTROPHY
and insulin secretion, *378
- MYSTROMYS ALBICAUDATUS
pancreatic islet structure studies, *1043
spontaneous diabetes mellitus in, 715-
721

N

- NAUSEA
and oral insulin, 645
- NEPHRECTOMY
and uremia
and insulin release, *910-911
- NERVOUS SYSTEM
and adenyl cyclase, *773
autonomic
and insulin release, 624-627
central
insulin-sensitive receptor in, *337
conduction
in galactose-fed rats, 295-300
and diabetic impotence, 23
disease
and hypoglycemia, *248
and growth hormone release, *913
and impotence
and diabetes, 23-28
and lipolysis
and β -hydroxybutyrate, *836
and phenothiazine-induced hypergly-
cemia, *184

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

sensory perception thresholds
and diabetes, *1199
splanchnic nerve stimulation, *770
tissue
and insulin binding proteins, 427
sorbitol and fructose, blood sugar
control and, 1173-1178

NEUROBLASTOMA
congenital
and islet hyperplasia, *1122

NEUROPATHY, DIABETIC
and diabetes management, 679
galactosemic, 295-300
of hands, *314
and impotence, 23-28
and prediabetes, *359

NIALAMIDE
and insulin release, *363-364

NICOTINAMIDE
and streptozotocin-induced beta-cell
toxicity, *325-326

**NICOTINAMIDE ADENINE NUCLEO-
TIDES**
and insulin, *315

NICOTINIC ACID
and glucose tolerance, plasma insulin,
and uric acid excretion, *313

NIGERIA
lactase activity levels in, 871

NITROGEN
conservation
placental, *340

NITROGEN MUSTARD
and steroid-induced ketoacidosis, *54

NORADRENALINE
and blood glucose and free fatty acid
responses to catecholamines,
*912

NOREPINEPHRINE
and fat cell metabolism, 420
and glucose tolerance tests, *348
and insulin release
and prostaglandins, *329
pressor response to
and insulin treatment in alloxan dia-
betic rats, *354-355
and theophylline
and cyclic AMP, 417

NUCLEOTIDES
and glucagon, 440

**NUTRITION, *59. See also Diet; Malnu-
trition; Starvation**
and insulin secretion, 606-615, 617-618
postnatal
and kidney cellular development in
progeny of protein-deficient
rats, *1041

O

OBESITY
and adipose tissue
fat cell size and metabolism, *54
glycerol kinase and lipolysis, *911-
912
monoglyceride hydrolase, *186
and caloric restriction, *835
and cardiovascular disease, *980
in children
and glucose tolerance tests, *1042-
1043
and diabetes, *246, *250
and low calorie diet with phenter-
mine resin, *361
and phenformin, *362
and diabetes prevalence, *776
and ethanol
and phenformin, *363
and exercise
and insulin secretion, *909
and food intake
and plasma glucagon, *331-332
and glucose tolerance, 1012, *1205
and growth hormone administration,
*1046
and hyperglycemia
and high-fat diet in mice, *182
and hyperinsulinemia, *380, 613, 617-
618
and adipose tissue resection, 13-15
and beta cell hyperplasia and in-
sulin resistance, *314
and blood proinsulin, 663-664
and diet, *249
and hyperinsulinemia and hyperlipi-
demia
induced in monkeys, *1201
and hypothalamic damage, *1206
and insulin assays, *1123
and insulin resistance, *314-315, *370
and insulin resistance and release, *316
and insulin secretion
and alcohol hypoglycemia, 65-69
and body composition, *1118
and xylitol and glucose, *187-188
and insulin sensitivity of adipose tissue,
6-11

and metformin
and carbohydrate metabolism, *914
in new strain of mouse, *1044
and plasma growth hormone response
to hypoglycemia and arginine,
*312
and proinsulin response to oral glucose,
*356
and weight reduction
and adipose tissue lipolysis and cellu-
larity, 754-760

OBITUARIES
Beardwood, Joseph T., Jr., 839
Marks, Henry E., 178

OCTANOATE
and fat cell lipolysis, 418, 419, 421
and growth hormone synthesis, *187

OLEATE
and fat cell lipolysis, 418, 419

OLIGOMYCIN
and insulin release
in fetal rat pancreas, *121

ORAL CONTRACEPTIVES
and plasma lipids, lipoproteins, and in-
travenous fat tolerance, and
post-heparin lipoprotein lip-
ase activity, *316

ORAL HYPOGLYCEMIC AGENTS
and diabetic mortality, *1044
di-isopropylammonium dichloracetate,
*358
labeling laws, 833, 1116-1117
and vascular disease, *57

ORNITHINE
utilization
by chick, *771

ORPHENADRINE
-induced hypoglycemia, 961

ORTHOPHOSPHATE
and liver threonine dehydratase, *980-
981

OUABAIN
and glucose-induced biphasic insulin
release, *246
and insulin secretion, *913

OXYGEN
consumption by splanchnic bed, 50-51
myocardial consumption of
and glucagon, *118-119
uptake
in diabetic rat liver, 257-268
of isolated islets in tissue culture,
547-548, 550

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

OXYTETRACYCLINE

- and insulin
- and hypoglycemia, 960

P

PALMITATE

- and glucose metabolism, 419
- and growth hormone synthesis, *187
- metabolism
- and ketosis, 258, 259, 261, 267

PANCREAS

- acinar atrophy and fibrosis
- and hemolytic anemia, *773-774
- of *acomys cahirinus*, 1068-1070
- and alloxan
- and diphenylhydantoin, 81-83
- alpha and beta cells
- and glucose and fatty acid oxidation, *909
- alpha cell function
- and diabetes, 301-307
- amino acid metabolism
- and glucose, *56
- anglerfish islets
- and glucagon biosynthesis, *58-59
- beta cell dysfunction
- and diabetes, 703-704
- beta cell metabolism
- and phlorizin, *910-911
- beta cell nesidioblastosis
- in idiopathic hypoglycemia of infancy, *189
- beta cell C-peptide
- immunoreactivity studies, 1013-1025
- beta cell responses, 619-630
- beta cell structure, 536
- beta cell tumors, 535
- beta cell webs
- and insulin secretion, *838
- beta cells
- alanine, arginine and leucine uptake by, *772
- and alloxan and streptozotocin, *326
- and amines, *248
- and α -amino-isobutyric acid transport, *181
- and arginine, *312
- calcium uptake assays, *837
- and cyclic AMP, *329
- of cyproheptadine-treated rats, 71-78
- embryonic, 523, 528, 531-533
- and encephalomyocarditis infection, *247
- and glucose-induced insulin release, 594-603, 605
- and glucose protection from alloxan toxicity, *123

- insulin detection study, *246
- and insulin secretion, *914
- intracellular pH, *911
- and obesity, *314
- replication, *346
- and sensitivity to glucose in prediabetes and diabetes, 224-233
- and sulfonylurea-induced insulin response, *122
- vital damage, 713-714
- blood flow and insulin output
- and exogenous insulin, *1204
- citrate levels
- and insulin release and inhibition, 999-1001
- cultured fetal human, *345-346
- of diabetic monkeys, 1086, 1087
- duct-ligated
- response to glucose, *344-345
- early research, 385-395
- endocrine
- structure in newborn rodents, 1051-1059
- endocrine cells
- in embryos, 519-523
- enzyme activity
- in rats, *59
- enzymes
- and dietary regulation, *186
- exocrine
- and diet, *186
- fetal, 620, 621, 623-624
- fetal and embryonic, 536
- fetal endocrine
- cytological studies, *253-254
- fetal rat
- insulin content study, 193-201
- insulin release and inhibition studies, *121
- glucagon
- and sulfonylureas, 216
- glucagon and insulin secretion
- and beta adrenergic and cholinergic agents, *332
- golden hamster cell cultures
- and insulin secretion study, *370
- insulin
- and glucose, *375-376
- insulin output and blood flow
- and prostaglandins, *369
- insulin release
- and calcium, 591-592
- and hemorrhagic shock, *982
- and insulin secretion, 510
- and diphenylhydantoin and diazoxide, 856-861
- and species variation, *184
- and sulfonylureas, *1120

- islet cell adenoma
- and adenyl cyclase activation by glucagon and tolbutamide, *912
- cyclic AMP content, glucose, glucagon, tolbutamide and theophylline and, *346-347
- and factitious hypoglycemia, *980
- islet cell carcinoma
- circulating insulin in, *909-910
- and streptozotocin, *1204
- islet cell tumors
- and immunoreactive glucagon, *333
- and plasma proinsulin, *1204
- proinsulin content, 675-676
- and proinsulin-like component of insulin, *313
- islet hyperplasia, 536
- congenital, *1122
- islet insulin secretion
- and exogenous insulin, *344
- islets
- and 6-aminonicotinamide, *1198
- and anti-insulin serum, *911
- calcium efflux from, *326-327
- cyclic AMP levels, starvation and, *329
- in diabetic guinea pigs, *338
- and electrical activity in response to leucine and tolbutamide, *345
- embryogenesis, 511-533
- hypertrophy and beta cell hyperplasia in long-term juvenile diabetics, 114-116
- and insulin release, 571
- and insulin release and content, *1205
- and insulin resistance factor secretion, *370
- insulin secretion and glucose metabolism, 538-545
- and late-onset diabetes, 762-767
- metabolism, 546-553
- monoamines, *120
- pyridine nucleotide depletion, 789-792
- response to glucose, *344-345
- and streptozotocin diabetes, 129-137
- structure, 536-537, *1043
- ultrastructure studies, *120
- isolated perfused rat
- and human chorionic somatomammotropin effects on insulin and glucagon release, 1072-1075
- isolated rat islets
- perfusion, 987-997
- monoamines
- and insulin secretion, *345, 779-787

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- monolayer cultures
 - and insulin biosynthesis studies, 627-630
- mouse
 - and monoamines, *251-252
- perfused canine
 - and glucagon secretion studies, *314
- perfused rat
 - and insulin release studies, *55, *56, *369
- rat
 - endocrine function in monolayer cultures of, *368
 - and ouabain and insulin release, *246
- rat islets
 - and alloxan and glucose interactions, *326
 - and methylene blue, *350
- scintiphotoscanning, *351
- and streptozotocin-induced beta cell toxicity
 - and nicotinamide and pyridine nucleotides, *325-326
- streptozotocin infusion
 - in *Macaca nemestrina*, 138-141
- transplantation
 - in diabetic subject, *355
- tumors
 - insulin secreting, *1120
- PANCREATECTOMY**
 - and discovery of insulin, 385-394
 - and glucagon
 - and cyclic AMP, 453
 - and glucose turnover
 - and insulin and glucagon infusion, *382-383
 - and hypophysectomy
 - and diabetic ketosis in rats, 946-954
 - and liver free fatty acid metabolism, 280
 - and liver 3-hydroxybutyrate dehydrogenase, *184
- subtotal
 - and chlormadinone acetate, *313
- PANCREATITIS**
 - acute
 - diabetes incidence after, *911
 - and oral insulin, 646-647
- PANCREOZYMIN**
 - and insulin release, 928
- PARAPLEGIA**
 - and impotence
 - and androgenic function, 23-28
- PARATHORMONE**
 - action
 - and cyclic AMP, *251
- PARATHYROIDECTOMY**
 - and plasma insulin levels, *773
- PARKINSON'S DISEASE**
 - and L-dopa
 - and plasma growth hormone, insulin, and thyroxine, *911
- PENTOSE PHOSPHATE PATHWAY**
 - and insulin, *315
 - and insulin release, 143
 - overactivity
 - and psoriasis, *250
 - and xylitol absorption, *352
- PEPSIN**
 - secretion
 - and secretin and duodenal acidification, *250
- C-PEPTIDE**
 - in blood, 661-670
 - circulating immunoreactivity studies
 - and diabetes, 1013-1025
 - proinsulin conversion to, 572-579
- PEPTIDES**
 - diabetogenic, 714
 - synthetic
 - and glucagon, 843-855
 - C-terminal, 714
- PEROXIDASE**
 - and hypolipidemia, *56
- pH
 - arterial
 - and acidosis diagnosis, 1110
 - of inflammatory exudates
 - in acidotic diabetic rabbits, *1201
 - intracellular
 - of pancreatic beta cells, *911
- PHENFORMIN**
 - and ethanol
 - and obesity and prediabetes, *363
 - and fat and lactate metabolism and insulin production
 - and starvation, *1045
 - and glibenclamide, *55
 - and lactic acid levels
 - and anoxia and exercise, *351
 - and lactic acidosis, *1198
 - lipid-lowering effect of, *380
 - and lipomatosis, 15
 - and obese diabetics, *362
 - and reactive hypoglycemia, *367-368
 - UGDP study of, 976-978
 - and vascular disease, *57
- PHENOBARBITONE**
 - and blood sugar, *1123
- PHENOTHIAZINE**
 - induced hyperglycemia, *184
- PHENOXYBENZAMINE**
 - and diazoxide-induced insulin secretion, *1045
 - and insulin secretion, 783-784
- PHENTERMINE RESIN**
 - and low-calorie diet
 - and obese diabetics, *361
- PHENTOLAMINE**
 - induced alpha-adrenergic blockade
 - and insulin release, *181
 - and insulin secretion, *248
 - and exercise, *119
- L-PHENYLALANINE**
 - and cholecystokinin release, *252
 - induced insulin release, *369
- β -**PHENYLETHYLAMINE**
 - and insulin secretion, *248
- PHENYLETHYLBIGUANIDE**
 - and liver gluconeogenesis, *910
- PHENYLISOTHIOCYANATE**
 - degradation studies, *835
- PHENYTOIN**
 - and hyperglycemia, *187
- PHEOCHROMOCYTOMA**
 - and insulin-dependent diabetes, *838
- PHLORIZIN**
 - and brain uptake of D-glucose, *315
 - and intestinal fructose uptake, *249
 - and pancreatic beta cell metabolism, *910-911
- PHOSPHATE**
 - induced hypoglycemia, 961
- PHOSPHENOLPYRUVATE**
 - formation, *189
- PHOSPHODIESTERASE**
 - and cyclic AMP and cyclic GMP, *838
 - and insulin release, *328-329
 - in islets of Langerhans
 - of obese and lean mice, *179
- PHOSPHENOLPYRUVATE CARBOXYKINASE**
 - and cyclic AMP
 - and insulin, 439-445
- PHOSPHOFRUCTOKINASE**
 - and cyclic AMP and dibutyl cyclic AMP, *363

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

6-PHOSPHOGLUCONATE DEHYDROGENASE

in jejunal mucosa
and alloxan diabetes, *188

PHOSPHOLIPIDS

levels
and alloxan diabetes, 1163-1166

PHOSPHORUS

flux
and glucose ingestion in children,
*376

PHOSPHORYLASE

and synthase, 430

PHOSPHORYLATION

fatty acid
and diabetes, 257-268

PHOTOCOAGULATION

argon laser
and diabetic retinopathy, *189

PHYTOHEMAGGLUTININ

peripheral blood lymphocyte response
to
and diabetes, 906-907

PIMA INDIANS

and diabetes, *180
and kidney disease, *365-366
and viral hypothesis, 766

PITUITARY GLAND

ablation
during diabetic pregnancy, 972-974
diabetogenic polypeptide from, *837
and glucagon secretion, *375
growth hormone synthesis
and lipids, *187
protein synthesis
and insulin, *1200
reserve capacity
and diabetes, *981

PLACENTA

glycogen metabolism
and diabetes, 1185-1190
glycogenesis
and insulin, *1199
insulin degradation by, *374-375
lactogen
and diabetic pregnancy, 32-33
and insulin and glucagon release,
1072-1075
and maternal diabetes, *315
and nitrogen conservation during pregnancy, *340
polyol pathway, *329-330

enzymes of, *330
and streptozotocin, *316

PLASMA

amino acids
and exercise, *119
glucagon and insulin control of, *340-341
and starvation, *179
angiotensinogen and renin
regulation by liver, *253
L-asparagine
and hepatic homeostasis, *254
catecholamine
during oral glucose tolerance test,
*348
cholesterol
and diet, *1043
cholesterol and triglycerides
and clofibrate, *1200-1201
fasting growth hormone levels
and diabetic retinopathy, *322
free fatty acids
conversion to plasma triglyceride
fatty acid, *835
and glucagon infusion in congestive
heart failure patients, 942,
944
and menstrual cycle, *1204
uptake by liver, 947-948, 950-954
free fatty acids and glucose
and L-dopa, *1121
free fatty acids, glucose, insulin, and
ketones
and sodium linoleate infusion, 1179-
1184
free fatty acids and insulin
in malnourished infants, *182
free fatty acids and ketone
and insulin secretion, 923
free fatty acids metabolism
and anti-insulin serum, 280-288
glucagon
and diabetes, *324
and exercise, *1198-1199
and food intake, *331-332
and infection, *324
and sulfonyleureas, 216-223
glucagon, growth hormone and insulin
and glucose during exchange trans-
fusions, *1120
glucose
and graded insulin infusions, *379
and growth hormone secretion, *774-
775
glucose and free fatty acids
and pentobarbital, *836

glucose, free fatty acids, cortisol and
growth hormone
and growth hormone administration,
22, 30
glucose and immunoreactive insulin
and adipose tissue resection, 13-15
glucose, insulin and glucagon
and hypothalamic stimulation, *771
growth hormone
clearance, 175-177
and juvenile diabetes, *312
in obese mice, *122
during sleep, *776
growth hormone, insulin and thyroxine
and L-dopa, *911
growth hormone responses
and Cushing's syndrome, *1122
growth hormone and sulfation factor
in African pygmies, *1045-1046
hyperosmolality
and hyperglycemia, *837
immunoreactive insulin
in *acomys cahirinus*, 1060-1070
during continuous blood glucose
monitoring in diabetics, *324-
325
and insulin administration to gas-
trointestinal tract, 203-207
and surgery for islet cell adenomas,
*185
and weight reduction, *1118
insulin
and adipose tissue fat cell size and
number, *180
and atherosclerosis, *253
and diet, *249
and erythroblastosis fetalis, *1199-
1200
and glucose, *375-376
and hyperparathyroidism, *773
and hypokalemia, *1043-1044
in kwashiorkor, *1119-1120
and metabolic insulin clearance,
1003-1011
and metformin, *771
and methamphetamine, *252
and nicotinic acid, *313
and obesity and exercise, *909
and pancreatic alpha cell response
to hyperglycemia, 301-307
response to glucose, 226-233
and theophylline, *180
insulin and blood glucose
and obesity, *54
insulin, glucose and free fatty acids
and insulin-treated diabetes, *325
insulin and glucose response to glucose
loading

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

and diet and fasting, *1046
 insulin and triglycerides
 seasonal variations in, *312-313
 insulin and uric acid
 and nicotinic acid, *313
 isovaleric acid and α -methylbutyric acid
 and hypoglycin A, *316
 lipase activity
 and heparin, 152-153
 lipids
 and diet, *366
 and glucagon, *311-312
 and glucose tolerance tests, *383
 and pregnancy in rhesus monkeys,
 *774
 lipids and lipoproteins
 and oral contraceptives, *316
 membrane vesicles
 and glucose transport, *1042
 membranes of fat cells
 and insulin, 403-411
 osmolality
 and serum osmolality, lactic acid
 values and, *838
 and platelet aggregation, *355
 proinsulin
 assay, *122
 and islet cell tumors, *1204
 proinsulin-like components of, 673-676
 testosterone
 and diabetic impotence, 23-24
 triglyceride removal
 and hyperglycemia, *342
 triglycerides
 and adipose tissue fat cell size and
 number, *180
 and exercise, *909
 and fasting, *54
 and glucagon, *55
 synthesis, *55
 triglycerides and cholesterol
 and cortisone acetate, *1044-1045
 tryptophan
 and insulin, *909
 very-low-density lipoprotein study, 744-
 752

POLYDIPSIA
 and hyperphagia
 and adrenalectomy and hypophysec-
 tomy, *358-359

POLYETHYLENE GLYCOL
 and insulin antibodies screening test,
 *379

POLYOL
 metabolism
 and diabetic microangiopathy, *352

POLYOL PATHWAY
 activity
 in isolated capillary preparation, *330
 placental, *329-330
 enzymes, *330

POLYPEPTIDES
 diabetogenic
 from pituitaries, *837
 synthesis, 476-484

POSTHEPARIN LIPOLYTIC ACTIVITY
 deficiency in
 and hyperglycemia, *342

POTASSIUM
 and antinatriuretic effects of carbohy-
 drate, *772
 flux
 and insulin and adenosine 3', 5'-
 monophosphate, *254
 and insulin action, 697-698
 and insulin secretion, 570
 myocardial
 and glucagon, *118-119
 and prostaglandins
 and growth hormone secretion, *313
 uptake and loss
 and cyclic AMP and insulin, 439-445

POTASSIUM PARA-AMINOBENZOATE
 and hypoglycemia, 960

FREDIABETES
 and beta cell sensitivity to glucose, 224-
 233
 and caffeine
 and glucose tolerance tests, *365
 in children, 45-47
 in Chinese hamster
 and prevention of diabetes, *337-338
 and diabetes prevention, *337-338, 693
 and diabetic neuropathy, *359
 and ethanol
 and phenformin, *363
 and glucose tolerance, *321
 and hypoglycemia
 and insulin-glucose dynamics, *373
 and insulin secretion, *314, 688-691
 and liver sensitivity to endogenous in-
 sulin, *323-324
 and low insulin response, 685-687
 and plasma lipids during glucose tol-
 erance tests, *383
 and retinal blood flow, *354
 and transition to diabetes, 691-693

PREDNISOLONE
 and immune response to insulin, *58

PREGNANCY
 and amino acid metabolism
 and starvation, *1118-1119
 and biliary lipids, *912
 and caloric deprivation
 and maternal and amniotic fluid sub-
 strate level, *1202
 and glucose tolerance test indications,
 *186
 and human chorionic somatomammo-
 tropin
 and insulin and glucagon release,
 1074-1075
 and hypoglycemia following pancreato-
 duodenectomy, *188
 and insulin response
 and arginine, *251
 and liver triglyceride biosynthesis, *365
 and maternal protein restriction
 and postnatal growth hormone pro-
 duction and bone develop-
 ment, *1047
 and placental nitrogen conservation,
 *340
 in rhesus monkeys
 and plasma lipid levels, *774
 and uterine relaxants
 and hyperglycemia, *1045

PREGNANCY, DIABETIC
 and blood sugar levels
 and perinatal mortality and morbid-
 ity, *1201-1202
 and fetal and placental composition,
 *315
 and glucose tolerance tests in neonates,
 *912
 and hypophysectomy for diabetic ret-
 inopathy, 972-974
 and insulin deficiency
 and endogenous hypertriglyceride-
 mia, *366-367
 and laboratory studies, 31-35
 and lactosuria, 1195
 and phocomelic diabetic embryopathy
 syndrome, *1042
 and pituitary reserve loss, *981
 and placental glycogen metabolism,
 1185-1190
 and streptozotocin, *316

PROGESTERONE
 and diabetic pregnancy, 34

PROGESTIN
 and carbohydrate tolerance, *313

PROINSULIN
 action, *57

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- in adipose tissue, 485
- and structure, 505
- amino acid sequences, 461-463, 465-466
- antibodies
 - and insulin resistance, *368
 - and antibodies to insulin, 656-657
- assay, *122
- biosynthesis
 - and glucose, 538
- biosynthesis, intracellular transport, and conversion to insulin and C-peptide, 572-579, 581-583
- in blood, 661-670
- content of beta cell tumors, 535
- conversion to insulin, *314
- degradation
 - in rats, 1091-1100
- and glucose metabolism
 - in rat diaphragm and epididymal fat pads, 935-938
- and insulin
 - conformational studies, 486-491
 - like component of insulin, *313
 - and hypokalemia, *1043-1044
 - like plasma components, 673-676
- metabolism, *347
- and C-peptide immunoreactivity, 1013-1025
- porcine
 - synthesis of related polypeptides, 476-484, 485
- response to oral glucose
 - and age, obesity, and degree of carbohydrate intolerance, *356
- structure
 - and action, 509
- synthesis, 509
- transport, 510
- PROLINE**
 - and ornithine utilization studies in chick, *771
- PROPOXYPHENE**
 - and hypoglycemia, 960-961
- PROPRANOLOL**
 - and insulin
 - and hypoglycemic coma, 960
 - and insulin secretion, 783-784
 - and blood sugar, *1120
 - and liver carbohydrate metabolism, *1203
 - and tolbutamide-induced insulin response, *122
- PROSTAGLANDINS**
 - and blood flow and insulin output, *369
 - and growth hormone secretion, *313
- and insulin release, *329
- PROSTATE GLAND**
 - hexokinase
 - and testosterone, *185
- PROTEIN KINASE**
 - and cyclic AMP, 571
- PROTEINS**
 - adipose tissue noncollagen
 - as index of cell number, *1201
 - and amino acid flux into liver tissue, *316
 - bound carbohydrates
 - and diabetes, 863-870
 - deficiency
 - in pregnant rats, *1041
 - dietary
 - and glucagon and insulin secretion, *912-913
 - and glucagon biosynthesis, *58-59
 - hepatic synthesis
 - and tissue injury, *315
 - insulin binding, 426
 - and insulin release, 613, 617-618
 - leucine incorporation of, *336
 - of plasma very-low-density lipoprotein
 - selenomethionine incorporation into, 744-752
 - rat liver nuclear
 - and diabetes, *377
 - restriction in pregnant rats
 - and postnatal growth hormone production and bone development, *1047
 - synthesis
 - and alloxan diabetes, *339
 - and cyclic AMP and hormones, *119
 - and fatty acid synthetase activity, *914
 - and insulin, 447-451
 - and insulin and cyclic AMP, 453
 - synthesis in anterior pituitary
 - and insulin, *1200
 - turnover in skeletal muscle
 - and insulin, *341
- PROTEINURIA**
 - and glomerular lesions, *1120
 - in Pima Indians, *365-366
- PROTEOLYSIS**
 - and cyclic AMP
 - and insulin, 439-445
- PSEUDODIABETES**
 - and myopathy
 - and capillary basement membrane thickening, *118
- PSORIASIS**
 - and carbohydrate metabolism, *250
- PURINE NUCLEOTIDE CYCLE**
 - and ammonia production, *1203
- PYRAZOLE**
 - and ethanol-induced fatty liver, *247
- PYRIDINE NUCLEOTIDES**
 - depletion
 - and streptozotocin-induced diabetes, 789-792
 - and insulin release
 - from toadfish insulin secretion granules, *983
 - and streptozotocin-induced beta cell toxicity, *325-326
- PYRUVATE**
 - metabolism
 - and glucose, *56
- PYRUVIC DEHYDROGENASE**
 - and insulin, 427
- R**
- RABBIT**
 - acidotic diabetic
 - and pH of inflammatory exudates, *1201
 - and antibodies to insulin, 651-656, 657-659, 660
 - and blood sugar
 - and insulin storage times, 812
 - and insulin administration to gastrointestinal tract, 203-207
 - and insulin response to amino acids
 - and 2-deoxy-D-glucose and mannoheptulose, 1-5
 - and iodinated insulin, *55
 - and neutral Regular insulin, 242-245
 - renal gluconeogenesis and ammonia
 - production in, *57
 - and serum insulin levels
 - and trauma, *183
 - and streptozotocin diabetes
 - and islet cell changes, 129-137
 - and thyrotoxicosis
 - and glucose utilization and insulin secretion, *370-371
- RACE**
 - and alcohol sensitivity, *254
 - and lactose tolerance tests, 871
- RADIOIMMUNOLOGY**
 - in synthetic glucagon studies, 844-845, 846-848, 855

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- RAT. See also *Mystromys albicaudatus*
 and acetoacetate
 and anemia, *311
 adipocytes
 fatty acid synthetase activity, *914
 adipose tissue
 glucose metabolism and insulin response, 1151-1161
 and alloxan diabetes
 and arteriosclerosis, *1123
 and glycosaminoglycans metabolism, 1162-1166
 and jejunal mucosa enzymes, *188
 and liver ribosomal aggregation, 84-88
 and pressor response to angiotensin and norepinephrine, *354-355
 and 6-aminonicotinamide as diabotogenic agent, 143-148
 and ammonium chloride-induced acidosis
 and glucose tolerance and insulin sensitivity, 794-796
 and blood sugar
 and nervous system sorbitol and fructose, 1173-1178
 brain
 glucose and D-3-hydroxybutyrate uptake, *1206
 brain hexokinase, *1205
 brain utilization of ketone bodies, *247
 and carbohydrate and lipid metabolism and streptozotocin, *59
 cyproheptadine-treated
 and pancreatic beta cell alterations, 71-78
 diabetic
 and calcium absorption, *983
 and connective tissue changes, 733-743
 and insulin resistance, *1042
 and intestinal growth and hexose transport, *59
 and ketosis, 946-954
 and liver metabolism, 257-268
 and α -oxoglutarate carboxylation in liver mitochondria, *981
 and ventromedial hypothalamic destruction, *1043
 diabetic pregnancy in, *315
 and streptozotocin therapy, *316
 diaphragm and epididymal fat pads
 and insulin and proinsulin studies, 935-938
 and diet
 and blood constituents and hepatic lipids, *1202
 and hypertriglyceridemia, *353-354
 and effects of maternal protein restriction, *1047
 and ethanol-induced fatty liver
 and pyrazole and glucose, *247
 fasted and fed
 and amino acid levels, *119
 feeding response
 and brain calcium, *1046
 fetal development
 and diet and growth hormone, *189
 galactose-fed
 and nerve conduction defects, 295-300
 gastrointestinal transport
 and glucagon, *983
 genetically obese
 and hyperinsulinemia and insulin resistance, *838
 and glibenclamide, *55
 and glucose oxidation
 and diet and exercise, *179
 and glucose-U-C-14 and acetate 1-C-14 utilization for fat synthesis, *770
 heart
 lipoprotein lipase, *344
 high protein fed
 and liver gluconeogenesis, *358
 hyperammonemic
 and glucose metabolism, *184
 and hyperglycemia
 and aminophylline, *775
 hypo-, hyper-, and euthyroid
 and ethanol and sorbitol metabolism, *181
 and hypothalamic stimulation
 and plasma glucose, insulin, and glucagon, *771
 and insulin and proinsulin degradation, 1091-1100
 and insulin secretion
 and phenolamine, *119
 islets of Langerhans
 adenyl cyclase and cyclic AMP phosphodiesterase, *328
 and alloxan and glucose, *326
 and ketone body metabolism, *246
 and kidney function
 and diabetes, *121
 and liver gluconeogenesis
 and glucose and insulin, *371
 and liver triglyceride biosynthesis
 and pregnancy and sex steroids, *365
 mammary cell metabolism
 and insulin, *315
 and microangiopathy, *357
 neonatal
 and diet and exocrine pancreas development, *186
 newborn
 brain glucose metabolism in, *775
 and noradrenaline or adrenaline
 and blood glucose and free fatty acid responses to catecholamines, *912
 obese
 and insulin resistance and release, *316
 obese hyperglycemic
 and pancreatic beta cell uptake of amino acids, *772
 pancreas islet structure, 536-537
 and pancreatic hydrolases
 from birth to weaning, *59
 parabiotic
 differential feeder for, *983
 plasma glucose and free fatty acids
 and sodium pentobarbital, *836
 and plasma tryptophan
 and insulin, *909
 and portacaval shunting
 and glucose tolerance and serum immunoreactive insulin response, *179
 protein-deficient
 and kidney cellular development in progeny of, *1041
 salivary glands
 isoproterenol-stimulated, *982
 and serum triglycerides response to sucrose and age, *835
 streptozotocin diabetic
 and U-C-14 glucose, xylitol, fructose, and sorbitol metabolism, *122
 and hyperphagia and polydipsia, *358-359
 and liver nuclear proteins, *377
 and urine glucolate, *372
 and tolbutamide
 and insulin secretion and hypoglycemia, *1125
 and uremia
 and insulin release, *910-911
 and ventromedial hypothalamic nuclei destruction
 and glucose metabolism, *1204-1205
 and obesity, *1206
 Zucker "fatty"
 and insulin and obesity studies, *1123
 RAYNAUD'S PHENOMENON
 and insulin response to glucose, *837
 RESPIRATION
 and ketotic diabetes, 264-267

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

RETICULOENDOTHELIAL SYSTEM
lipid metabolism and vascular clearance in dogs, *312

RETINA

blood flow
in children of diabetics and prediabetics, *354
of diabetic monkeys, 1086
glycosaminoglycans
and alloxan diabetes, 1163-1166
and microangiopathy, *357

RETINOPATHY, DIABETIC

and argon laser photocoagulation, *189
and bacteriuria, *118
and blood platelet adhesiveness and aggregation, *120-121
and diabetes control program, *382
factors in progression of, *187
and hypophysectomy, *349
and pregnancy, 972-974
in identical twins, *321-322
and plasma growth hormone levels, *322
and platelet aggregation, *355

REYE'S SYNDROME

and hypoglycemia, *248

RHESUS MONKEYS

and pregnancy
and biliary lipids, *912
and plasma lipid levels, *774

RHINOCEREBRAL PHYCOMYCOSIS

and diabetes, *185

RNA

binding to hepatic ribosomes
and insulin deficiency, 84-88
and insulin action, 455
-messenger
and insulin and liver metabolism, 453
pancreatic
and diet in neonatal rats, *186
synthesis
and fatty acid synthetase activity, *914
transfer-
and insulin and protein synthesis, 449
viruses, 714

tRNA METHYLASES

regulation, *253

RP 22410. See Glisoxepid

RUBELLA

congenital
and diabetes incidence, *248-249

S

SALICYLATES

and hypoglycemia, 959-960

SALIVARY GLANDS

isoproterenol-stimulated
and glucose metabolism, *982

SCHWANN CELL

and aldose reductase, 299

SCINTIPHOTOSCANS OF PANCREAS,

*351

SECRETIN

and diuresis, *769
and insulin release
and acromegaly, *1118
and pepsin secretion, *250
release, *252
and serum gastrin immunoassays, *249

SELENIUM SCAN

and insulinoma diagnosis, *1206

SELENOMETHIONINE

incorporation into apoprotein of plasma
very-low-density lipoprotein,
744-752

SEMINIFEROUS TUBULES

and diabetic impotence, 26

SEMINOLES

diabetes survey among, *776

SEPHAROSE

-bound insulin
and muscle, adipose tissue and cultured liver cells, *335-336

SEROTONIN

antagonists
and insulin secretion, 779-787
and insulin secretion in acromegaly, *352
and carbohydrate tolerance
and insulin secretion, *1200
and insulin secretion, *184, *316

SERUM

N-acetyl-beta-glucosaminidase
and diabetes, 1168-1171
antiglucagon
in synthetic glucagon study, 844-855
anti-insulin
assays, *769

and enzyme histochemical studies of
pancreatic islets, *911
and hyperglucagonemia, *183
and liver free fatty acid metabolism
in dogs, 280-288

betalipoproteins

and abetalipoproteinemia, *60
-bound insulin
and insulin antisera, 930-934
cholesterol
and atherosclerotic disease, *253
cholesterol and triglycerides
and caffeine, *365
and calcium, *980
creatine, sodium and potassium
and acidosis diagnosis, 1110
creatinine
in Pima Indians, *365-366
free fatty acids
and weight reduction, 758
free fatty acids and glucose
and L-dopa, *1121
free fatty acids, insulin, and growth
hormone
and myocardial infarction, *119
gastrin immunoassays
and secretin, *249
glucose
in *Mystromys albicaudatus*, 715-721
glucose, ketones, immunoreactive insulin and free fatty acids
and sodium beta-hydroxybutyrate,
*373-374

glycoproteins

and diabetes, 863-870
growth hormone and cortisol responses
to graded insulin infusions, *379
immunoreactive insulin
and age, *183-184
and exercise, 104
in genetically obese rats, *838
in monkeys, 1078-1079, 1081
in obese rats, *1123
and portacaval shunt, *179
response to glucagon, glucose and tolbutamide, *121-122

insulin

and arginine, 308-310
and insulinoma, *250
in obese hyperglycemic mice, *119
and trauma, *183
insulin, cholesterol and triglyceride
levels
in obese diabetics, *361
insulin and growth hormone
and arginine and glucose, *316
during oral glucose tolerance tests
in children, 16-20

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- insulin responses
 differences between mongrel and beagle dogs, *356
 and small-vessel disease, *836
 insulin response to glucose
 and konnyaku ingestion, *60
 lipids
 in "acatalasemic" mice, *56
 and atherosclerosis, *253
 and metformin, *771
 in monkeys, 1078-1079
 nonsuppressible insulin-like activity, 271-278
 osmolality
 and galactose toxicity syndrome, *315
 and plasma osmolality, lactic acid values and, *838
 C-peptide and proinsulin, 1013-1025
 phospholipids
 and diabetes, *123
 proinsulin and insulin, *347
 protein
 and diabetic microangiopathy, *371
 triglycerides
 response to fructose, age and, *835
 and sucrose and glucose, *58
- SEX
 and adipose tissue fat cell size and number, *180
 and blood glucose levels
 and exercise, 89-99
 and diabetic mortality, *1044
 and glucose tolerance tests in children, 19
 and growth hormone secretion, *774-775
 and muscle capillary basement membrane changes, 883-896, 899-905
 and serum glucose
 in *Mystromys albicaudatus*, 718, 719, 720
- SEXUAL FUNCTION
 and diabetes, 23-28
- SHEEP
 renal glucose, free fatty acid and ketone body metabolism in, *314
- SHOCK
 and fibrinolysis and peritoneal dialysis, *913
 hemorrhagic
 and insulin release, *364, *982
 traumatic
 and glucose metabolism, *1201
- SKIN
 bullous and atrophic lesions
 and diabetes, *251
 and diabetes
 and hyperinsulinism, 733-743
 fibroblasts
 glucose oxidation in, *360
 and glucose metabolism
 and insulin, *189
 glycosaminoglycans
 and alloxan diabetes, 1163-1166
 and lipid synthesis
 and starvation, alloxan diabetes and insulin, *189
 psoriasis
 and carbohydrate metabolism, *250
 toad
 and proinsulin action study, *57
- SLEEP
 growth hormone release during, *913
- SMOKING
 and hypoglycemia, 961
- SODIUM
 extracellular
 and glucose metabolism, 543
 and insulin secretion, 570, 861
 and pancreatic α -amino isobutyric acid transport, *181
 transport
 and proinsulin action, *57
- SODIUM ACETATE
 incorporation into lipids of rat aorta and insulin, *186
- SODIUM ACETATE I-C-14
 incorporation into rat aorta and insulin, *186
- SODIUM BETA-HYDROXYBUTYRATE
 and insulin secretion, *373-374
- SODIUM LINOLEATE
 and plasma free fatty acids, glucose, insulin and ketones, 1179-1184
- SODIUM PENTOBARBITAL
 and plasma glucose and free fatty acids, *836
- SORBITOL
 brain synthesis
 and cerebral edema during diabetic ketosis, *180-181
 and insulin release, 565
 metabolism
 in fasted and streptozotocin diabetic rat, *122
 and hypo-, hyper-, and euthyroid rats, *181
 in nervous tissues
 and blood sugar control, 1173-1178
- SORBITOL DEHYDROGENASE
 in human placenta, *330
- L-SORBOSE
 intestinal uptake, *249
- SPASMOLYTIC DRUGS
 and vein reactivity in diabetes, *909
- SPLANCHNIC NERVE
 stimulation
 and adrenalectomy, *770
- SPRUE
 temperate, *773
- STARVATION
 and amino acid metabolism
 during pregnancy, *1118-1119
 and carbohydrate, *772
 and diabetes treatment, 634
 and fat and lactate metabolism
 and insulin production, *1045
 and fetal metabolism, *187
 and glucagon secretion, *331-332
 and insulin and glucagon patterns, *359-360
 and insulin-induced hypoglycemia, 797-803
 and jejunal mucosa enzymes, *188
 and ketone body metabolism, *246
 and kidney gluconeogenesis, *910
 and kidney sensitivity to mineralocorticoid and glucagon, *334
 and lipid synthesis in rat skin, *189
 and lipolysis
 and iodinated insulin, *55
 and liver ketogenesis, 50-52
 and liver metabolism
 and glucagon:insulin ratio, *341
 and metabolism
 in streptozotocin diabetic rats, *122
 and plasma and tissue amino acids, *179
 and postheparin lipolytic and monoglyceridase activities, *54
 and tissue and islet cyclic AMP levels, *329
- STEROIDOGENESIS
 in isolated adrenal cells, *983
- STEROIDS
 -induced diabetic ketoacidosis, *54
- STREPTOZOTOCIN
 and beta cell membrane changes, *326

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

SUBJECT INDEX 1972

- and carbohydrate and lipid metabolism, *59
- and diabetic pregnant rats, *316
- and glucose metabolism
 - and insulin secretion, *1200
- induced beta cell toxicity
 - and nicotinamide and pyridine nucleotides, *325-326
- induced diabetes
 - and fetal and placental composition, *315
- and islet cell carcinoma
 - and "big" insulin, *1204
- and islet cell tumors
 - and plasma proinsulin, *1204
- and pancreatic beta cells, 77-78
- STREPTOZOTOCIN DIABETES**
 - and connective tissue changes in rats, 733-743
 - and glucose and fatty acid metabolism, *909
 - and hyperosmolar diabetic syndrome and ketogenesis, *369-370
 - and hyperphagia and polydipsia and adrenalectomy and hypophysectomy, *358-359
 - and hypertriglyceridemia and diet, *353-354
 - and islet cell changes, 129-137
 - and kidney function, *121
 - and liver mitochondria α -oxoglutarate carboxylation, *981
 - and liver nuclear proteins, *377
 - in *Macaca nemestrina*
 - induced by pancreatic infusion, 138-141
 - and metabolism, *122
 - and pyridine nucleotide depletion in pancreatic islets, 789-792
 - and urine glycolate, *372
 - and ventromedial hypothalamic destruction, *1043
- STRESS**
 - and glucose tolerance, *184
- SUBMAXILLARY GLAND**
 - extirpation
 - and glucose and insulin tolerance, 722-731
- SUCCINATE**
 - and amino acid metabolism, *56
- SUCROSE**
 - and diabetes, *770
 - dietary
 - and blood constituents and hepatic lipids, *1202
- oral
 - and alimentary lipemia, *58
- SUGAR**
 - and alloxan toxicity, *123
 - and insulin release, 559-561, 570
 - transport
 - and biguanides, *119
- SUGAR ALCOHOL**
 - formation
 - and nerve conduction defects, 295-300
- SULFATION FACTOR**
 - and dwarfism, *1046
- SULFONYLUREAS**
 - and blood sugar
 - and kidney failure, *1120-1121
 - and chemical diabetes in children, 47
 - and diabetes treatment, *120
 - glibenclamide, *55
 - and hypoglycemic coma, 955-962
 - and insulin release, 160-161
 - and blood sugar, *1120
 - and labeling laws, 833
 - pharmacodynamic aspects, *249, *249-250
 - and plasma glucagon suppression, 216-223
 - response test, *913
- SURGERY**
 - adipose tissue resection
 - and diabetes and hyperinsulinism of symmetric lipomatosis, 13-15
 - adrenalectomy
 - and insulin response to hemorrhagic shock, *364
 - and splanchnic nerve stimulation, *770
 - and adrenalectomy and hypophysectomy
 - and diabetic hyperphagia and polydipsia, *358-359
 - and bladder dysfunction, *364
 - femorotibial bypass
 - and diabetes, *322-323
 - for gangrene, *187
 - gastrectomy
 - and intestinal glucagon and insulin responses, *1047
 - gastric
 - and glucose homeostasis, *1199
 - and glucagon secretion, *313
 - hypophysectomy
 - during diabetic pregnancy, 972-974
 - and diabetic retinopathy, *349
 - and glucagon secretion, *375
- and tolbutamide and glybenclamide injections, *378-379
- and islet cell adenomas
 - and blood glucose and plasma immunoreactive insulin assays during, *185
- pancreatectomy
 - in baboons, *338
 - and glucose turnover, *382-383
- pancreatectomy and hypophysectomy
 - and diabetic ketosis in rats, 946-954
 - and liver 3-hydroxybutyrate dehydrogenase, *184-185
- pancreatoduodenectomy
 - and hypoglycemia following pregnancy, *188
- parathyroidectomy, *773
- partial pancreatectomy
 - and glucose tolerance and insulin response, *339
- portacaval shunt, *179
- and serum insulin levels, *183
- submaxillary gland extirpation
 - and glucose and insulin tolerance, 722-731
- ventromedial hypothalamic destruction, *1043
 - and glucose metabolism, *1204-1205
 - and obesity, *1206
- SYNALBUMIN**, 714
- T**
- TEMPERATURE**
 - and cholesterol turnover, *314
 - and insulin secretion, *312-313
 - and liver enzymes activities, *58
- TESTES**
 - and diabetic impotence, 25-26
- TESTOSTERONE**
 - and rat prostate hexokinase, *185
- α -THALASSEMIA**
 - and fetal pancreas, *253-254
- THEOPHYLLINE**
 - and calcium metabolism, *327
 - and glucose stimulated insulin release, 559-560, 561
 - and insulin response, 1
 - in *acomys cahirinus*, 1065, 1069-1070
 - and islet cell adenoma cyclic AMP content, *346-347
 - and norepinephrine
 - and cyclic AMP, 416-417

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

SUBJECT INDEX 1972

- and plasma insulin responses
in subhuman primate fetus and neonate, *180
- THROMBIN**
and fatty acid metabolism, *312
- THYROID FUNCTION TESTS, 1012**
- THYROID GLAND**
and ethanol and sorbitol metabolism, *181
and glibenclamide, *55
and thyrotoxicosis
and insulin secretion and glucose utilization, *370-371
- THYROIDITIS**
methyl-cholanthrene-induced and spontaneous
and autoimmunity studies, *253
- THYROTOXIC PERIODIC PARALYSIS**
and immunoreactive insulin, *1047
- THYROXINE**
and insulin secretion, *253
and rat fatty liver, *183
- TISSUE**
adipose. *See* Adipose tissue
amino acids
and starvation, *179
and ammonia production, *1203
connective
and diabetes and hyperinsulinism, 733-743
cyclic AMP levels
and insulin, 426
and starvation, *329
epididymal fat pads
enlargement modes, *247
glycosaminoglycans
and alloxan diabetes, 1162-1166
and jet insulin injections, 41-42
liver
metabolic response to injury, *315
liver plasma membranes
and insulin, *334-335, *1200
mouse diaphragm
DNA content, *184
nervous system
and blood sugar control, 1173-1178
rat adipose tissue and muscle
phosphofructokinase, *363
rat diaphragm
insulin-like activity bioassays, 272-273
rat diaphragm and epididymal fat pads
and insulin and proinsulin, 935-938
- rat epididymal fat pads
protein synthesis studies, *1119
testicular
and diabetic impotence, 24-28
- TISSUE CULTURES**
of isolated islets, 546-553
- TOADFISH**
islets
and pyridine nucleotide, *983
- TOLBUTAMIDE**
and adenyl cyclase activation in islet cell adenoma, *912
and 6-aminonicotinamide, *1198
anti-lipolytic action, *836
blood clearance
and alcoholism, *983
dosage
in UGDP study, 1037-1038
and forearm metabolism, *1206
and hyperglycemia
and arterial disease, *122-123
hyperresponsiveness to
and diazoxide pretreatment, *360
and hypophysectomized dogs, *378-379
-induced hypoglycemia
and hyperparathyroidism, *773
-induced insulin release, 989
and cytochalasin B., *327
and iodoacetate and antimycin A., *56
and propranolol, *122
in rat islets, *1205
and insulin immunoreactivity, *313
insulin response to
and diethylstilbestrol and growth hormone, *378
and insulin response to glucose, 684
and insulin secretion, *55, *370
and blood sugar, *1120
and hypoglycemia, *1123
and islet cell adenoma cyclic AMP content, *346-347
and labeling laws, 833, 1116-1117
and lipolysis and cyclic AMP in white fat cells, *835
and liver cirrhosis
and insulinemia, *121-122
and microangiopathy, *357
and pancreas islet cell electrical activity in response to, *345
pharmacodynamic aspects, *249, *249-250
and plasma glucagon, 216-223
plasma insulin response to
and diabetes, 1012
response
and diazoxide, *311
- UGDP study of, 976-978, 1036-1037
- TOLBUTAMIDE TEST**
and insulinoma, *250, *1206
- TOLINASE**
and lactic acid levels
and anoxia and exercise, *351
- TRANSPLANTATION**
of fetal rat pancreas into maternal hosts
and insulin content study, 193-201
kidney
and diabetes, *322
of pancreas
and diabetes, *355
- TRAUMA**
and liver metabolism, *315
- TRIGLYCERIDES**
long-chain
and insulin secretion, 923-928
synthesis
and ethanol, *769-770
and insulin, *351-352
and ketogenesis, *1203
- TRYPSIN**
and fat cell lipolysis, 423
-treated fat cells
and insulin degradation, 409
- TRYPTOPHAN**
-insulin complex
isolation of, *1045
- TUBERCULOSIS**
and diabetes, 634
- TUCO-TUCO**
diabetic syndrome in, *1205
- TUMORS**
adrenal
and Cushing's syndrome in infancy, *120
beta cell, 535
catecholamine-secreting
and glucose intolerance, *838
endocrine adenomatosis
and familial nesidioblastosis, *1122
fibrosarcoma
insulin-like activity in, *352-353
and glucose metabolism
and insulin secretion, *1200
and hypocholesteremic drugs in mice, *837
insulinoma
diagnosis, *1206
and glycolytic enzymes, *773

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

SUBJECT INDEX 1972

- islet cell
and blood proinsulin-like components, 665
and cyclic 3'5' AMP formation and degradation, *185
and hypoglycemia, *248
immunoreactive glucagon in, *333
and insulin and glucose patterns, *250
and plasma proinsulin, *1204
proinsulin content, 675-676
and proinsulin-like component of insulin, *313
and surgery, *185
islet cell adenomas
and adenylcyclase activation by glucagon and tolbutamide, *912
and effects of glucose, glucagon, tolbutamide and theophylline on cyclic AMP content of, *346-347
and surgical procedures, *185
in obese mice
and lipid mobilization and food uptake, *774
pancreatic
insulin-secreting, *1120
- TWINS**
and chemical diabetes study, 45
identical
and diabetic retinopathy, *321-322
- TYROSINE AMINO TRANSFERASE**
and cyclic AMP
and insulin, 439-445
- U**
- UMBILICAL CORD**
glucose
and infant hypoglycemia, *1202-1203
- UNIVERSITY GROUP DIABETES PROGRAM, *57**
evaluation of, 976-978, 1035-1039
and labeling laws for oral hypoglycemic drugs, 1116-1117
- UREMIA**
and carbohydrate tolerance, 1109-1114
and experimental diabetic ketosis, *121
and insulin release, *910-911
- UROGENESIS**
and cyclic AMP
and insulin, 442-443
- URIC ACID**
excretion
and nicotinic acid, *313
- URINE**
catecholamines
and ouabain, *913
epinephrine and norepinephrine
and idiopathic hypoglycemia, *1200
glycolate
and streptozotocin diabetes, *372
17-ketosteroid excretion
and diabetic impotence study, 24
sodium and potassium
and growth hormone, *1046
tests
and lipotrophic diabetes, 830
- UTERUS**
relaxants
and hyperglycemia, *1045
- V**
- VASCULAR DISEASE**
and blood glucose control, 976-978
and diabetes, 678-683
and blood coagulation, 108-112
and combined hyperlipoproteinemia, *376
and insulin, 633
and serum phospholipids, *123
and diabetes duration, *314
and oral hypoglycemic agents, *57
peripheral
and insulin response to glucose, *836-837
and insulin response studies, *836
- VASCULAR SYSTEM**
aorta
glycosaminoglycans, 1163-1166
clearance
and reticuloendothelial system in dogs, *312
and disseminated intravascular coagulation
and diabetes, 108-112
- VASOPRESSIN**
action
and cyclic AMP, *251
and antidiuretic action of chlorpropamide, *189
- VEIN**
reactivity
and diabetes, *909
- VENOPATHY, DIABETIC, *909**
- VINBLASTINE**
and insulin release, 989-991, 996-997
- VIRUSES**
and diabetes, 713-714
encephalomyocarditis
and mouse pancreas, *338-339
and insulinitis in late-onset diabetes, 766-767
- VITAMINS**
B
and hemoglobin synthesis, *311
K
and resistance to oral anticoagulant drugs, *183
- W**
- WEIGHT. See also Body, weight; Obesity**
gain
and high-fat diet, *182
loss
and calorie restriction in obese hyperglycemic mice, *835
and insulin sensitivity, 6-11
and low calorie diet with anorectic agent, *361
reduction
and adipose tissue lipolysis and cellularity, 754-760
and phenformin, *362
and serum glucose
in *Mystromys albicaudatus*, 718, 719, 720
- X**
- XANTHOMA**
and familial hypercholesterolemia, *1121
- X-IRRADIATION**
and mortality and longevity in mice, *914
- XYLITOL**
absorption
in healthy men, *350-351
and insulin release, 561, 565
and diabetes and obesity, *187-188
metabolism
in fasted and streptozotocin diabetic rat, *122
and pancreas metabolism, 562-564
- D-XYLOSE**
excretion
and metformin, *771
transport
and biguanides, *119
- Z**
- ZINC**
and insulin, 487-489, 497-498, 509, 570

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

In this index are the names of authors of articles that have appeared in **DIABETES** and those whose articles have been abstracted in the Journal during 1972. Entries marked with an asterisk (*) indicate authors of material that appeared in the **ABSTRACTS** only. The Subject Index appears on page 1.

A

Abe, Hiroshi, 203-208
 Abildgard, F., *769
 Abrams, M. E., *980, *1047
 Ackerman, Eugene, *775, *836
 Adams, Donald A., *349
 Adams, Yvonne L., *179
 Adelman, Neil, 1-5
 Adibi, Siamak A., *179
 Admitt, P. I., *187, *771
 Agot, H., *912
 Ahlborg, Gunvor, *776
 Ahrens, E. H., Jr., *1200-1201
 Ahrens, Richard A., *179
 Aiach, M., *776
 Akerblom, Hans K., *349-350
 Alavi, Ilfat, A., *54
 Alberti, K. G. M. M., *59, *350, *1117
 Alexander, James K., *980
 Alexander, Kenneth R., *1123
 Allen, Lindsay H., *1041
 Allen, Michael, *772
 Alpert, Joseph S., *769
 Alric, R., *912
 Alvarez, Enrique, *359
 Amherdt, Mylene, *326, *346, 1060-1071
 Ammon, H. P. T., 143-148, *350, *365, *1198, *1205
 Amsterdam, Daniel, *338-339
 Andersen, Dana K., *252
 Andersen, O., *769
 Anderson, James H., Jr., *311
 Anderson, James W., *188
 Anderson, P. A., *352
 Andersson, Arne, 546-554
 Andres, Reubin, *347
 Ansah, B., *1204
 Antoniadis, Harry N., 930-934, *1123
 Aoki, T., *323
 Aranda, J. V., *185
 Arieff, Allen, *774
 Arky, Ronald A., *54, *334, *772
 Arons, Daniel L., *54

Asano, T., *350-351
 Ashcroft, Stephen J. H., 538-545
 Ashkar, F. S., *351
 Ashmore, James, 426-427, 453, *982
 Assal, J.-Ph., *179, *323, *361-362, *366
 Assan, Roger, 843-855, *1120
 Assemany, Salma R., *1042
 Atkin, E., 149-156
 Atkins, T., *179
 Avruch, Joseph, *1042
 Avruskin, T. W., *381
 Azumi, Kazuo, *776

B

Bagdade, John D., 65-70
 Bagul, C. D., *351-352
 Baker, David H., *771
 Baker, Lester, *189
 Baker, Nome, *914
 Baker, R. W. R., 1173-1178
 Balasse, Edmond O., 280-288
 Baldwin, R. L., *315
 Ball, Michael F., *1118
 Balodimos, Marios C., *118, *769
 Barbezat, Gilbert O., *769
 Barbier, P., *123
 Baroja, Isabel M., 289-294, *837-838
 Barter, Philip J., *835
 Bassett, John M., 538-545
 Batalla, M. A., *118
 Batchelder, Timothy, *372
 Bates, Margaret W., *246
 Battaglia, Frederick C., *187
 Bauer, G. Eric, *58-59
 Bayley, T. J., *773
 Beall, Robert J., *983
 Beard, Alice, *179-180
 Beaser, S. B., *370
 Becker, Kenneth L., *328-329, *375-376
 Begin-Heick, Nicole, *912
 Behrens, Otto K., viii Supplement 2, 685
 Beisel, W. R., *316
 Beitch, Janis, 506-508
 Belfiore, Francesco, 1168-1172
 Bender, S. A., *1046
 Bengtsson, Calle, *180
 Bengtsson, Kristina, *1198
 Bennet, C. Vann, *1042
 Bennett, Peter H., *180, *365-366
 Benson, Bryant, 935-938
 Berenson, Gerald S., 733-743
 Bergan, J., *355
 Bergman, E. N., *118, *314
 Berkowitz, Stuart, *980
 Berman, Mones, *347
 Bernardis, Lee L., *771, *1043, *1204-1205
 Bernick, Sol, *248
 Bernstein-Hahn, L., 23-30
 Berridge, Michael J., *315
 Best, Charles H., 385-395
 Bewsher, Peter D., *186
 Beyer, J., *249, *249-250
 Beyer, W. R., *370
 Bhai, Idrees, *311
 Bhatia, S. K., *365
 Bhawanji, Jain, *359-360
 Bianchi, R., *376
 Bianchine, Joseph R., *1121
 Bianco, Jesus A., *118-119
 Bier, Dennis M., 280-288
 Bierman, Edwin L., 65-70, *342, *380
 Binkiewicz, A., *377
 Bitensky, Mark W., *80, *981, *1117-1118
 Bitsch, Vibeke, *186-187, *1045
 Bivens, C. H., *352
 Björntorp, Per, *54, *180, *312-313, *771, *909
 Black, W. L., *367
 Blackard, William G., *187, *188, 311, *360
 Blanks, M. C., *337-338
 Block, Marshall B., 661-672, 1013-1026
 Blohmé, Göran, *180

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Blondel, B., *346, *368
 Bloodworth, J. M. B., Jr., *321, *352
 Bloom, A., *120-121
 Bloom, Gail, *346-347
 Blum, André L., *54
 Blumenthal, Stanley A., *180-181, *1205
 Blundell, T. L., 492-505
 Boberg, J., *316
 Boder, George B., 535-537
 Bomboy, J. D., *332, *340-341
 Bommer, G., *911
 Bonar, J. R., *352-353
 Boquist, Lennart, 1051-1059
 Borchers, Raymond, *980-981
 Borek, Ernest, *253
 Borensztajn, J., *344
 Borin, Bruce M., *837
 Borner, E., *769
 Borowitz, J. L., *184
 Bortz, W., *375
 Boshell, B. R., *351-352, *371
 Breur Richard I., *1199
 Boucher, B., *1047
 Boulanger, M., *357
 Boulter, Philip R., *334
 Boveris, A., *184-185
 Bowen, V. R., *328-329
 Bowers, Mary, *325
 Bradley, R. F., *118
 Brancato, Paul, *338-339
 Brandenburg, Dietrich, 468-475
 Brange, J., 649-656
 Braun, Theodor, *60
 Bravo, Ivan R., *180
 Bray, George A., *838, *1206
 Bressler, Rubin, 713-715
 Breur, Richard I., *1199
 Bricaire, H., *775-776
 Brickman, Fred, 733-743
 Bridgeman, J. F., *769
 Birdgen, W. D., *120-121
 Brisson, Guy R., *119, *326-327, *1042
 Brock, Frances E., *58
 Bromer, William W., 485, 509
 Brooks, Mary R., *914
 Brophy, P. D., *1046
 Brown, Joseph D., *835, *1045
 Brunfeldt, K., *769
 Brunzell, John D., *342, *348
 Brush, James S., *122
 Bruylands, J., *59
 Bryant, Gilleen M., *910
 Buber, V., *1119
 Buchanan, Keith D., *1122, *1206
 Buckman, M., *1043
 Burch, Thomas A., *180
 Burgess, J. A., *248-249
 Burkle, P. A., *246

Burns, T. W., 89-100
 Burr, I. M., *246
 Burrill, Karen C., *982
 Buse, John, *911
 Buse, Maria G., *911
 Buselmeier, T. J., *322
 Bussey, Dietrich, *248
 Butcher, Fred R., *54
 Butt, J., *250-251
 Butterfield, W. J. H., *980
 Buzzi, Alfredo, *359
 Byrd, Gerald W., *311

C

Caccamo, Anna, *312
 Cahill, George F., Jr., 703-712
 Camanni, F., *122
 Camerini-Davalos, R. A., *321, *373
 Cameron, Donald P., 1060-1071
 Campbell, G. D., *250
 Camus, J., *59
 Canary, John J., *1118
 Canever, J. V., *120-121
 Canfield, Robert E., *835
 Canivet, J., *838
 Cantrell, Jerald W., 872-880
 Car, Joseph R., *358-359
 Caren, Raymond, *311-312
 Carlson, L. A., *316, *980
 Carmelutti, Margherita, *312
 Carrera Vescio, L., *253
 Carroll, Carthage J., *366-367
 Carroll, Kevin F., *835, 923-929
 Carter, Edward A., *769-770
 Carter, James R., Jr., *1042
 Caspary, W. F., *119
 Cassar, J., *1199
 Castillo, E. J., *184-185
 Castillo, L., *775
 Castleman, Benjamin, *1042
 Cavalli-Sforza, L. L., *1045-1046
 Cederquist, Dena, *983
 Celener, David, *359
 Celik, Ziya, *364
 Cerasi, Erol, 224-234, *312, *323-324, 685-694, *770
 Cerchio, Gerard, *982
 Cerletty, James M., *773
 Chabot, V., *1119
 Chance, Ronald E., 461-467, 657-660
 Chandler, Michael L., *353
 Chang, M. L. W., *770
 Chao, Ping-Yu, *353
 Chapal, J., *1045, *1120
 Chapman, Betty B., *837
 Charles, M. Arthur, *327
 Chase, G. R., 89-100
 Cheek, Donald B., *1201
 Chen, S., *344
 Chernick, Sidney S., 946-954
 Cherrington, A., *382-383
 Cherry, Thomas, *1204
 Chevalier, M., *835
 Chez, Ronald A., 39-44, *180
 Chick, William L., *1120
 Chisholm, D. J., *1118
 Chiumello, Giuseppe, *312
 Chlouverakis, C., *119, *353-354, *835
 Chochinov, Ronald H., *341-342, *1199
 Chow, Kye-Wing, *835-836
 Christacopoulos, P. D., *354
 Christensen, Halvor N., *55-56
 Christiansen, Aa. Hein, 649-656
 Christlieb, A. Richard, *354-355
 Christophe, J., *59, *119, *182
 Cibeira, Jose B., *359
 Clancy, Barbara A., *983
 Clark, Charles M., Jr., 946-954
 Clayton, Barbara E., *119-120
 Clements, Rex S., Jr., *180-181, *330
 Clifford, A. J., *184
 Clough, G., *913
 Cloutier, Mark D., *982-983
 Cochran, Alan, *982
 Coddling, J. C., *339, *1204
 Coffman, Jay D., *769
 Cohen, A. M., *770
 Cohn, Major L., 39-44
 Cole, Harold S., 16-22
 Colinas, Rodolfo, *359
 Colle, E., *185
 Collipp, Platon J., *366
 Colwell, A. R., Jr., 209-215
 Colwell, Arthur R., Sr., 839
 Colwell, John A., 13-15, 108-113, *355
 Colwill, James R., *187
 Conly, Patricia, 175-177
 Conn, Jerome W., *55-56, 216-223, *322, *324, *331-332, *837, *1204
 Constam, G. R., *120
 Conway, Martin, *1043
 Corbo, Lucille, *311-312
 Corkey, B. E., *344-345
 Cornblath, Marvin, *179-180, *181
 Cornell, Robert P., *312
 Corredor, D. G., *250
 Costrini, Nicholas V., *773
 Court, J. M., *1042-1043
 Cowan, Donald H., 906-907
 Cragan, Mary, *1200
 Craig, James W., *56
 Craig, L. S., *254
 Craighead, John E., *247
 Crawford, John S., *182

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Cremer, Guillermo M., *836
 Crespin, Stephen R., 1179-1184
 Creutzfeldt, W., *119
 Crofford, Oscar B., *332, *335, *340-341, 403-413
 Crowley, Leo, *773
 Cruz, Sidney R., 13-15, *355
 Cryer, Philip E., *181
 Cuatrecasas, Pedro, 396-402, *772, *1042
 Cummings, Nancy P., *355-356
 Cunningham, E. J., 89-100
 Curry, Donald L., *55
 Cutfield, J. F., 492-505
 Czech, Michael P., *336-337
 Czerwinski, C., *356, *360-361
 Czyzyk, Artur, *121-122, *909

D

Daggett, Willard M., *118-119
 Daikuhara, Yasuchi, *1122
 Dalferes, Edward R., 733-743
 D'Andrea, R. J., *314
 Daniel, P. M., *247
 Danowski, Thaddeus S., *250, *314, *1118
 Dashe, Alfred M., *349
 Davenport, Katherine, *378
 Davidoff, Frank, *367, *376-377
 Davidson, Mayer B., 6-12, *335-336
 Davis, Barbara H., *328-329, 1173-1178
 De Oya, Manuel, *55
 De Santis, R. A., *356, 360-361, *775
 Deconinck, J. F., *120
 Deisseroth, Albert, *376-377
 Del Greco, F., *355
 Del Guercio, M. José, *312
 Delcher, H. K., *336-337
 Demers, Laurence M., 1185-1191, *1199
 DePalma, Ralph G., 257-270
 Deren, Julius J., *249
 derKinderen, P. J., *1046
 Deschodt-Lanckman, M., *59
 Devetta, Mario, *312
 Devrim, Ahmet Sevim, *356
 Dhawar, V. P. S., *250
 DiGirolamo, Mario, *247, 1151-1161
 Diaz-Fierros, Maruxa, 289-294, *837-838
 Dilling, Louis A., *1119
 Dilman, V. M., *55
 Distefano, G., *316
 Ditzel, J., *1120
 Dixit, Padmakar K., *363-364
 Dobbie, J., *355
 Dodson, E. J., 492-505
 Dodson, G. G., 492-505

Dolger, Henry, *376
 Domanski, Robert, *247
 Donabedian, Richard, *312
 Dornhorst, Ann, *247-248
 Dorris, Susan, *57
 Doyle, Richard E., 715-721
 Drash, Allan L., 45-49, *60
 Dreizen, Samuel, *248
 Driscoll, John M., Jr., *837
 Drummey, Gladys D., *769-770
 Du Boistesselin, R., *357
 Duckworth, William C., *122, *355, *356, 935-938
 Dudl, R. James, *333-334, *357
 Duga, Judith, *369-370
 Duhault, J., *357
 Dunbar, J. C., *344
 Dunlop, Marjorie, *1042-1043
 Dupre, John, *374-375
 Dymock, I. W., *1199

E

Earley, L. E., *189
 Eaton, R. Phillip, *55, *357, 744-753, *1043
 Eckel, Robert E., *56
 Edelstein, Diane, *56
 Edwards, A. V., *770
 Edwards, Charles C., 1116-1117
 Edwards, J. C., *909
 Efendic, Suad, 224-234, *312, *770
 Egdaht, Richard H., *364, *775
 Ehrenreich, T., *373
 Ehrlich, Edward N., *57
 Eichner, Harvey L., *358
 Eisenstein, Albert B., *358
 Ekaraphanich, Sompol, *1122
 Ekholm, R., *120, *251-252
 El-Khodary, Ashraf Z., *1118
 Ellerman, Jeanette, *328, 555-569
 Ellis, Robert A., 506-508
 Elsas, Louis J., *248
 Empey, G., *1204
 Ensink, John W., *333-334, *357
 Epel, Rosa, 16-22
 Epple, August, *358-359
 Ericson, L. E., *120, *251-252
 Erlich, R. M., *248, *254
 Essner, Edward, *56
 Ettinger, Bruce, *189
 Etwiler, Donnell D., 967-971
 Evans, D. J., 114-116
 Evans, G. W., *1043
 Exton, J. H., *254, *339-340, 439-446
 Ezekiel, M., *775

F

Fabre, J., *1120-1121
 Fabre, L. F., Jr., *313
 Faerman, Isaac, 23-30, *359
 Fagerberg, S.-E., *981
 Fahlén, Martin, *312-313, *771, *909
 Fain, John N., 414-425, *836
 Fajans, Stefan S., *55-56, 216-223, *322, *324, *331-332, 678-684, *1204
 Falch, Dagfinn, 939-945
 Faloona, Gerald R., *58, *183, *912-913, *1198-1199
 Falorni, Adriano, *1199-1200
 Fariss, Bruce L., *1047
 Farmer, R. W., *313
 Farquhar, John W., *372, *380, *1121
 Fatourechi, Vahab, *1203
 Federlin, K., *246
 Fekete, M., *1120
 Felber, J.-P., *1119
 Feldman, Jerome M., *184, *248, *252, *315-316, *345, *352, *370-371, 779-788, *1200
 Felig, Philip, 308-310, *323-324, *770-771, *776, *1118, *1202
 Feller, D. D., *836
 Felts, James M., *188
 Felts, P. W., *332, *340-341
 Feng, Louise Y., *1201
 Fernbach, Donald J., *1119
 Fernstrom, J. D., *909
 Ferris, Deward O., *185
 Fertel, Richard, *359
 Fertig, John W., *247
 Field, James B., *346-347, *980
 Filer, L. J., Jr., *315
 Fineberg, S. Edwin, *342-343, *372, *774-775
 Fink, C. Joan, 987-998
 Fink, Gloria, *329, *359-360
 Fischer, Edward P., *1201
 Fischer, Lawrence J., 71-79
 Fischer, M., *913
 Fischer, U., *909, *911
 Fisher, Edwin R., *1118
 Flatt, J. P., 50-52
 Fleischman, D. E., *838
 Fleming, Gary A., *181
 Floyd, John C., Jr., *55-56, 216-223, *322, *324, *331-332, *1204
 Foà, P. P., *313, *344
 Foglia, V. G., *253
 Folling, I., 814-826
 Fono, Peter, *188
 Forfang, Kolbjorn, 939-945
 Forrest, E., *1205-1206
 Forrest, Jill M., *248-249

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Forsham, Peter H., *332-333, *358, *982, *1045
 Forster, Harald, 1102-1108
 Foster, Daniel W., *1203
 Foster, Richard O., 703-712
 Fox, Dora, 23-30, *359
 Fox, Orlando J., 157-162, *1044
 Fracassini, Francesco, *1199-1200
 Frank, B. H., 486-491
 Frayn, K. N., *771
 Fredholm, Bertil B., *836
 Fredrickson, Donald S., *1044-1045
 Freedlender, Arthur E., *183-184
 Freinkel, Norbert, *340
 Fremstad, Dag, 939-945
 French, Frank S., *1122
 Fresquez, Vidal, *982
 Frey, Harald M. M., 939-945
 Freychet, Pierre, *334-335, 673-677, *909-910, *1200
 Freytag, G., *911
 Friedmann, N., *254
 Fritsch, John M., 506-508
 Froesch, E. R., *122
 Frohman, Lawrence A., *771, *1043
 Frost, Philip, 794-796
 Fuchs, F. S., *913
 Fujimoto, Wilfred Y., *329, *345-346, *360
 Furnelle, J., *182
 Furner, R. L., *836
 Fussgänger, Rolf D., *313, 1072-1076

G

Gabbay, Kenneth H., 295-300, *327, *838
 Gabbe, Steven G., 1185-1191, *1199
 Gabbiani, Giulio, *314
 Gagliardino, J. J., *184
 Galloway, John A., 637-648, 657-660
 Gapp, D., *370
 Garaza Pereira, A. M., *184-185
 Garcia, Angel R., *360
 Garcia, Mariano J., *356, *360-361, *375
 Gardiner, Robert J., 946-954
 Gardner, Lytt I., *1042
 Garner, Ann M., *1204
 Garratt, C. J., *980
 Gary, A., *1046
 Gatewood, Lael C., *836
 Gattner, Hans-Gregor, 468-475
 Gaut, Z. N., *313
 Geever, Erving, *773-774
 Gentz, J., *179-180
 Genuth, Saul M., 1003-1012
 Georg, Ralph H., *56
 George, Jack M., *381-382, *771

Gepts, W., *120, *253-254
 Gerich, John E., *332-333
 Gerneth, J. A., *314
 Gerritsen, G. C., *337-338
 Gershberg, Herbert, *361
 Gerschenson, Lazaro E., *335-336
 Gertner, Melvin, *366
 Ghazarian, Hagop G., *980-981
 Chilchik, Margaret W., *836, *836-837
 Gibson, G. E., *184
 Gillette, Paul C., *1119
 Gingell, Robert L., *181
 Ginsberg-Fellner, Freda, *361, 754-761
 Giombetti, Robert, *120
 Gipstein, Robert M., *349
 Girgis, Medhat, *369-370
 Glasgow, Joseph L., *352
 Gleason, Ray E., *354, *361-362, *366, *373, *383, *1044-1045
 Glennon, Joseph A., *362
 Glick, Seymour M., 1-5
 Glocer, Leticia, *359
 Glueck, Charles J., *1043
 Goberna, Raimundo, *313
 Goeken, James A., *1043
 Goetz, F. C., *322, *350-351
 Gold, Ernest M., *378
 Goldberg, M. D., *250
 Goldberg, Paul, *364
 Goldfischer, Sidney, *56
 Goldman, Jack K., *1043, *1204-1205
 Goldman, Roger B., *771
 Goldstein, Jack, *1120
 Goldstein, Joseph L., *1121
 Gomez, F., *1119
 Gonzalez, Alejandro R., *250, *1118
 Goodall, McChesney, *1200
 Goodman, H. Maurice, *59-60
 Goodman, Michael N., *341, *343
 Goodner, Charles J., *362-363, *1200
 Gorden, Phillip, *313, 673-677, *909-910, *1043-1044
 Gordon, Edwin E., *369-370
 Gordon, Hymie, *771
 Gordon, Walter, *771
 Goren, Elihu N., *185
 Gorman, Ronnie E., *180, *981, *1117-1118
 Gossel, Thomas A., 80-83
 Gotlin, Ronald W., *250
 Gourgon, R., *838
 Graber, George, *771
 Graef, Irving, 178
 Grande, Francisco, *55
 Grasso, S., *316
 Grauel, Ludmila, *189
 Grayburn, J. A., *188

Grebin, Burton, *837
 Greene, Warner, 1109-1115
 Greengard, Paul, *773
 Greenwood, M. R. C., *316
 Greenwood, Ronald D., *249
 Greep, Roy O., *1199
 Greider, M., *355
 Grey, Neil, *249
 Greze, M., *776
 Gries, F. Arnold, *122, *911-912
 Griffiths, Anthony D., *910
 Grodsky, Gerold M., *327, 584-593, 856-862, *1045
 Groffman, H., *315
 Grossman, Morton I., *252, *769
 Gruber, Charles, *773-774
 Grundy, Scott M., *1200-1201
 Guder, Walter, *910
 Guglielmi, Hans, *1122-1123
 Gupta, Vicrum, *329-330
 Gürson, C. T., *313
 Gustafson, Anders, *771
 Guthrie, Richard, 45-49
 Gutman, Raul A., *329, *775
 Gutman, Samuel Wilkins, *359-360
 Guy, Matthew J., *249
 Guyton, Robert A., *118-119
 Gwinup, Grant, 722-732

H

Habbick, B. F., *56
 Haeckel, H., *910
 Haeckel, R., *910
 Haft, Jacob I., *376
 Hagen, Thad C., *1199
 Hager, Diana L., 594-604
 Hagstrom, Jack W. C., *120
 Hagura, Ryoko, 856-862, *1045
 Hahn, H. J., *914
 Haist, R. E., *339, *1204
 Hallund, O., 649-656
 Halpern, Alfredo, *363
 Hamilton, C. L., *1201
 Hamilton, M. A., *70
 Handschumacher, Robert E., *254
 Hann, Lucy, *362
 Hansky, J., *249
 Harano, Yutaka, 257-270
 Hardman, Joel G., *251
 Hare, John W., *340
 Harrill, Inez, *1202
 Harris, Alan, *772-773
 Harris, Grady W., 703-712
 Harrison, Lura A., *250
 Hashim, Sami A., 789-793
 Hashimoto, Tadashi, 476-484

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Haslbeck, Manfred, 1102-1108
Haugen, H. N., *123
Haupt, E., *249, *249-250
Havel, Richard J., 280-288
Haven, G. T., *1047
Haworth, James C., *179-180, *1119
Hayes, K. C., *1044
Hayles, Alvin B., *982-983
Hazelwood, Robert L., *59
Hazlett, Barbara, 906-907
Hazzard, William R., *348, *1121
Heath, H., *120-121
Hebbelinck, M., *119
Hechter, Oscar, *60
Heding, L. G., 649-656
Hedner, Pavo, *981
Hegre, Orion D., 193-202
Hegsted, D. M., *60, *1044
Heinemann, Martha, *122
Heird, William C., *837
Hellerström, Claes, 546-554, *909
Hellman, Bo, *58, *181, *771-772, *837, *910-911, *999-1002
Hemm, G., *246
Hendler, Rosa, *323-324, *1118-1119
Hengstenberg, Fay, *60
Henry, James E., Jr., *363
Herberg, L., *122
Herman, Clifford M., *181
Hernandez, Rodolfo E., *363
Herrera, M. G., *60
Herrold, Joyce, *381
Hertelendy, F., *313
Hetenyi, G., Jr., 797-804
Heuser, Gunnar, *349
Hiebert, John M., *364
Hill, Donald E., *1201
Hill, L. Leighton, *1119
Hillbom, Matti E., *181
Hime, J. M., *1205-1206
Hinderaker, Paul H., *187
Hingson, Robert A., 39-44
Hirsch, Allen H., *185
Hirsch, Jules, *316, *1201
Hirschel, Bernhard J., *314
Ho, Chen-Kung, 789-793
Hochman, H., *377
Hockaday, T. D. R., *350, *1119
Hodge, J. S., *1120
Hodgkin, Dorothy Crowfoot, 492-505, 1131-1150
Hoffman, Richard S., *772
Hohenegger, M., *121
Hohmann, T. C., *314
Holanders, Egils, 271-279
Hollander, Daniel, *1122
Hollinden, C. Stephen, 235-245

Holowach-Thurston, Jean, *359
Holzmann, H., *250
Hommel, H., *909, *911
Horiuchi, A., *773
Hornbrook, K. R., *1203
Hoshi, Mitsuru, 827-831
Howard, Charles F., Jr., 138-142
Howell, S. L., *328
Hsia, S. L., *189
Huber, V., *246
Hughes, J. R., *838
Hulse, Mildred, *361
Humbert, James R., *250
Hummeler, Klaus, *189
Hunt, C. E., *1044
Hunter, P. R., *120-121
Hutchins, G. M., *1201
Hutchinson, Donald L., *180
Huttunen, Jussi K., *314

I

Iber, Frank L., *362, *983
Idahl, Lars-Ake, 999-1002
Illiano, Gennaro, *772
Insel, Paul A., *347
Irving, William R., *185
Isenberg, Jon I., *769
Issekutz, Bela, Jr., *772
Isselbacher, Kurt J., *316, *769
Iversen, Johan, *314
Izumi, Kanji, 827-831
Izzo, Joseph L., *333
Izzo, Mary Jane, *333

J

Jackson, James A., *983
Jackson, Richard L., 235-245
Jackson, W. P. U., *250
Jacobi, H. P., *1047
Jacobson, Mitchell, *773
Jadzinsky, Mauricio N., *23-30, *359
Jaffé, Ernst, *773-774
James, Albert L., *121
Jansen, F. K., *121
Jarett, Leonard, *343, *772, *1119
Jaya Rao, Kamala S., *1119-1120
Jefferson, L. S., *341
Jenkins, David W., *56
Jequier, E., *1119
Johansen, Klaus, *911
Johnsen, Ch., *981
Johnson, D. G., *329
Johnson, Irving S., 535-537
Johnson, Leonard R., *250

Johnson, P. R., *316
Johnson, R. A., *335
Johnston, H. M., *774
Jones, Rayford S., *771
Jonsson, Anders, *180
Jordan, George L., Jr., *1201
Jordan, Scott W., *837
Jorfeldt, Lennart, *776
Jorgensen, K. H., 649-656
Joshua, Henry, *57
Juan, C., *381
Juliano, Joseph, *376
Jung, Y., *250, *314
Junker, K., *1120

K

Kabara, J. J., *837
Kachra, Zarin, *374-375
Kagan, Avir, 1-5
Kahan, Miles, *364
Kahn, Charles B., 31-37, *365
Kahn, Ronald, *334-335, 673-677, *1200
Kajinuma, Hiroshi, *332
Kalkhoff, Ronald K., *365, *773
Kallio, Anna-Kaarina, *349-350
Kalnins, A., *1204
Kamenetzky, Stephen A., *365-366
Kan, Dorinne, *773-774
Kanazawa, Yasunori, *121
Kansal, Prakash C., *911
Karabula, C., *182
Karam, John H., *332-333, *353, *982
Karasaki, Kenkichi, 203-208
Karjala, Robert G., 6-12
Karlberg, Bengt, *1198
Karlsso, Kirsten, *1201-1202
Kasperska, Teresa, *121-122
Kato, Mikio, *314
Kattamis, C., *182
Katsoyannis, Panayotis G., *772-773, *981
Katz, Adrian, *347
Kaufman, C. F., *314
Kaufmann, R. L., *361-362, *365, *366, *383
Kawamori, Ryuzo, 203-208, *382
Kaye, Gordon I., *835
Keamy, Donald G., *185
Kebabian, John W., *773
Keenan, William J., *1202-1203
Keller, U., *122
Kellum, Mike, *179-180
Kelsey, J., *120-121
Kemmler, Wolfgang, 572-581
Kendall, M. J., *773
Kenny, Frederick M., *60
Kerly, Margaret, *57

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320

Supplement 1, 321-384
Supplement 2, 385-714
June, 715-778
July, 779-842

August, 843-922
September, 923-986
October, 987-1050
November, 1051-1130
December, 1131-1210

AUTHOR INDEX 1972

Kerr, Sylvia J., *253
 Kershner, Ann K., *981
 Kessler, Irving I., *1044
 Khan, Farida, *348
 Khurana, Ramesh C., *250, *1118
 Kikkawa, Ryuichi, 827-831
 Kilo, Charles, *254, 881-905
 Kim, Hakjoong, *773
 Kim, Young Jin, *1118-1119, *1202
 Kim Young S., *771
 Kimmelstiel, Paul, *338
 Kimura, H., *773
 King, Katherine C., *250-251
 King, Ronald, *180
 Kipnis, David M., *249, 606-616, 744-753, *1119
 Kitabchi, Abbas E., *122, *355, *356, 935-938, 1027-1034, 1091-1101, *1122
 Kitamura, T., *773
 Kjellmer, Ingemar, *1201-1202
 Kjellstrand, C. M., *322
 Klachko, D. M., 89-100
 Klahr, Saulo, *57
 Klatt, D., *914
 Klayton, R., *250
 Kleeman, Charles R., *774
 Kleinman, Leonard I., *914
 Klimt, Christian R., *57, 1035-1040
 Klitgaard, Howard M., 271-279
 Klöppel, G., *911
 Knatterud, Genell L., *57, 1035-1040
 Knittle, Jerome L., *361, *366, 754-761
 Knochel, Gerald R., *1198-1199
 Knöfler, H., *911
 Knopf, Ralph F., 216-223, *322, *324
 Knopp, Robert H., *366-367
 Knospe, S., *182
 Knowles, Harvey C., Jr., *381
 Knusmann, R., *251
 Koberich, W., *249, *249-250
 Kogut, Maurice D., *981
 Kohler, William C., *355-356
 Komaroff, Anthony L., *367
 Konec, Lajos, *769
 Konsek, John P., *57
 Korman, M. G., *249
 Korp, W., *913
 Koschinsky, Theodor, *122, *911-912
 Kotler-Brajburg, Janina, *328, *359, 555-569
 Koutras, Phoebus, *1120
 Kovacevic, Nada, *188
 Kozak, G. P., *323
 Krah, M. E., 695-702
 Krall, L. P., *361-362
 Kranz, Paul, *376
 Kreisberg, Robert A., 157-162, *367, *1202

Kroes, J. F., *1044
 Krouse, H. A., *1200
 Krstic, M. K., *1046
 Kruck, F., *769
 Kryston, Leonard J., *367-368
 Kubli, F., *1045
 Kumar, Dinesh, *368
 Kuo, Peter T., *1201
 Kuroda, Kohei, *60
 Kurup, P. A., 1162-1167
 Kurwa, Aziz, *251
 Kutzner, R., *119
 Kwann, Hau C., 108-113
 Kyner, Joseph L., *1044-1045

L

Lacy, Paul E., *326, *328, 987-998
 Lacy, W. W., *332, *340-341
 Lafrance, Louise, *912
 Lake, Nareen, *1202
 Lambert, André E., *121, *368
 Lan, V. V., *356, *360-361
 Landau, Bernard R., *329-330
 Lande, Saul, *981
 Landey, Stephanie, *120, *1046
 Landgraf, R., *369, 555-569
 Landgraf-Leurs, M., *369
 Lang, C. Max, *338
 Langer, L., *981
 Langworthy, Alice, *324-325, *1203
 Larkins, R. G., *122, *1204
 Larner, Joseph, 428-438
 Larsson-Cohn, V., *316
 Laube, Heiner, 1072-1076
 Laube, Heinrich, *313
 Lauris, V., *70
 Lavine, Lawrence, 257-270
 Lavis, Victor, *336
 Laweck, January, *121-122
 Lazarow, Arnold, 193-202
 Lazarus, L., *1118
 Lazarus, Norman R., *328-329
 Lazarus, Sydney S., 129-137, *325-326
 Le Dune, Martha A., *181
 Leary, Peter M., *771
 LeBlanc, Jacques, *912
 Lebon, F., *357
 Lebovitz, Harold E., *184, *248, *315-316, *345, *352, 779-788, *1200
 Lecocq, Frank R., 101-107
 LeCompte, Philip M., *365-366, 762-768
 Lee, J. A., *770
 Lee, Thomas C., *378
 Leef, M. R., *254
 Lefebvre, Pierre J., *334, *369
 Lefler, Allan T., III, *181
 Lefrak, Edward A., *1201
 Legg, Merle A., 762-768
 Leitner, J. Wayne, *56
 Lemaire, F. R., *366
 Lemieux, Guy, *251
 Lemonnier, D., *182
 Leonard, Ingrid, *1042-1043
 Leonard, R. F., *1042-1043
 Leopold, Newman A., *374, *1121
 Lerner, Roger L., *348, *773
 Lernmark, Ake, *910
 Leslie, E., *1199
 Leveille, G. A., *835
 Levenson, Stanley M., *773-774
 Levey, Gerald S., *912
 Levin, Emanuel, *774
 Levin, Seymour R., *327, 856-862, *982, *1045
 Levine, Rachmiel, *314, *370, 396-402, 454-456
 Levitt, M. D., *350-351
 Lev-Ran, Arye, *57
 Levrat, R., *179
 Levy, Barnet M., *248
 Levy, Leonard J., *369-370
 Levy, Robert I., *1044-1045
 Lewis, A. A. G., *55
 Lewis, S. B., *332, *340-341, 439-446
 Liddle, Grant W., *251, *332
 Lie, T. H., 89-100
 Liebelt, A. G., *774
 Liebelt, R. A., *774
 Light, Irwin J., *914, *1202-1203
 Like, A., *326, *346, 511-534, *1120
 Liljenquist, J. E., *332, *340-341, *347
 Limburg, B., *321
 Lin, Boniface J., *188, *1204
 Lindgren, Soren, *1198
 Lindros, Kai O., *181
 Lindsay, D. B., *57-58
 Lindsey, Al, *331
 Lindsey, J. R., *1044
 Linscheer, G. William, *54
 Linzell, J. L., *57-58
 Lione, A. P., *775
 Lipman, Richard L., 101-107, 175-177
 Lippert, T. H., *1045
 Lipshitz-Wiesner, Rakoma, *253
 Little, Hunter L., *189
 Little, John R., *251
 Londono, J. H., *376
 Longnecker, Daniel S., 71-79
 Lorente, P., *838
 Loreti, L., *344
 Loubatières, A., *912, *1045, *1120
 Louis, Lawrence H., *837
 Love, E. R., *247

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Love, Tommy, 101-107
 Lovrien, Fred C., *1045
 Lowenstein, J. M., *1203
 Lucke, Christoph, 1-5
 Luft, Rolf, 224-234, *312, *323-324, 685-694, *770
 Lundquist, I., *120, *251-252
 Lussier, Yolande, *251
 Luton, J.-P., *775-776
 Luyckx, Alfred S., *334, *369
 Lynch, Vincent, *1118-1119
 Lyngsoe, Jens, *186-187, *1045
 Lynn, William S., *336-337

M

Macchi, I. A., *370
 McCormick, J. R., *775
 Mackay, Ian R., *914
 Mackay, J. S., *253
 Mackerer, C. R., *981
 Madison, Leonard L., *331
 Mahan, Clare M., *183-184
 Mahler, Richard J., *314-315, *370
 Majid, P. A., *913
 Majno, Guido, *314
 Mako, Mary E., 1013-1026
 Makowski, Edgar L., *187
 Makulu, David R., *58, *982
 Malaisse, Willy J., *119, *326-327, 594-604, *838, *982, *1042
 Malaisse-Lagae, Francine, *119, *982, *1042
 Malathy, K., 1162-1167
 Maler, Mario, *359
 Malherbe, Christian, *982
 Malins, J. M., *186
 Malone, John I., *315
 Manchester, Keith L., 447-452
 Mandel, Emanuel E., *364-365
 Mann, J. I., *58
 Mannheimer, Shoshana, *57
 Manzano, F., *323
 Marble, Alexander, 632-636
 Marco, Jose, *58, 289-294, *837-838
 Marecek, Raymond L., *370-371, *1200
 Maria, J., *838
 Mariani, M. M., *912, *1045, *1120
 Marine, N., *250
 Marinetti, G. V., *1121-1122
 Marliss, Errol B., *246, 308-310, *346, *368
 Marreiro Rocha, Dalva, *324
 Marshall, Garland R., 506-508
 Martin, David E., *774, *912
 Martin, Donald B., *57, *1042
 Martin, F. I. R., *182, *972-975, *1204

Martin, Pierre, *251
 Martin, R. J., *315
 Martino, Joseph A., *772
 Masazumi, Adachi, *364
 Mashiter, Keith, *346-347, *1047
 Massara, F., *122
 Massi-Benedetti, Ferdinando, *1199-1200
 Masson, Georges M. C., *253
 Matsaniotis, N., *182
 Matschinsky, Franz M., *328, *345, *359, 555-569
 Matty, A. J., *179
 Maturo, Joseph M., III, *1045
 Matute, M. L., *365
 Maughan, G. B., *316
 Maxfield, L. M., *1044
 Mayhew, D. A., *344-345
 McDaniel, H. G., *371
 McGarry, Denis J., *1203
 McGee, J. H., *376
 McGoodwin, Michael M., *1121
 McKeel, Daniel W., *772
 McMahon, Edward M., *252
 McMillan, Donald E., *371, 863-871
 McMurray, J., *352-353
 McNeely, Betty, *1042
 McNeish, A. S., *56
 Meade, Robert C., 271-279
 Mehlman, M. A., *981
 Mehnert, Hellmut, 1102-1108
 Meinert, Curtis L., *57, 1035-1040, 1197-1198
 Meissner, H. P., *769
 Melani, Franco, 661-672
 Mendlinger, Sheldon, *247, 1151-1161
 Meng, H. C., 149-156
 Mennear, Jon H., 80-83, *184
 Menser, Margaret A., *248-249
 Menzel, Ruth, *182
 Mercola, D. A., 492-505
 Merimee, Thomas J., *342-343, *372, *774-775, *1045-1046
 Merin, Saul, *182
 Merkel, F., *355
 Mertz, Walter, *1043
 Meschia, Giacomo, *187
 Messaritakis, J., *182
 Messina, A., *316
 Metz, Robert, *325
 Metzger, Boyd E., *340
 Metzger, Robert P., *372
 Meyer, James H., *252
 Meyer, Richard J., *772-773
 Meyer, Roland K., *774, *912
 Miale, A., Jr., *351
 Michael, Alfred F., 163-174
 Michael R., *182, *909
 Mickelsen, Olaf, *983

Miller, Leona V., *368, *1120
 Miller, Max, *180, 257-270
 Miller, R., *351
 Milliez, P., *776
 Million, Marcia, *361
 Mills, Lewis C., *367-368
 Milner, R. D. G., *182, *1120
 Mintz, Daniel H., 175-177, *180, *912
 Miya, T. S., *184
 Moffitt, Emerson A., *185
 Molinatti, G. M., *122
 Molnar, George D., *185, *324-325, *775, *836, *1203
 Molsted-Pedersen, Lars, *912, *1046
 Moore, Jack D., *182-183
 Moore, T. J., *775
 Moorhouse, John A., *341-342, *1199
 Moorhouse, S. R., *247
 Morgan, C. D., *254
 Morgan, Jean M., *1046
 Morganroth, Joel, *376-377
 Morita, K., *773
 Morris, A. S., *836
 Morrison, Anthony D., *180-181, *330
 Morrison, George R., *58
 Morsches, B., *250
 Moses, Hamilton, III, *1199
 Moss, Gerald S., *982
 Motte, G., *838
 Motulsky, Arno G., *1121
 Moxness, Karen E., *775, *836
 Mueller, Walter A., *183
 Mukherjee, N. R., 1192-1196
 Mullen, Donald C., *1206
 Muller, Walter A., *301-307, *324, *364, *912-913
 Munger, Bryce L., *338
 Murthy, V. K., *982
 Muzzo, Santiago, *1042
 Myers, R. D., *1046

N

Nabarro, J. D. N., *187, *188, *379
 Nafz, Mary Ann, *353
 Najarian, J. S., *322
 Nakao, Komei, *773-774
 Nankin, Howard, *909-910
 Napoli, Elena, 1168-1172
 Narrod, Stuart A., *247
 Nath, M. C., *311
 Nath, N., *311
 Needham, L. B., *337-338
 Nemerson, Yale, *312
 Nestel, Paul J., *835, 923-929
 Neubauer, B., *252
 Neufeld, Arthur H., *180, *1117-1118

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Neville, David M., Jr., *334-335, *1200
 Neville, E. D., *836
 New, Maria I., *120, *1046
 Newman, G. B., *188
 Newton, N. E., *1203
 Newton, R. H., *314
 Nielsen, Poul Ebbe, *186-187
 Nijjar, M. S., *183
 Nishikawa, Mitsuo, *60
 Nitzan, M., *315
 Nobis, H., *913
 Noda, Katuhiko, *183
 Noe, Bryan D., *58-59
 Nonaka, K., *313
 Norman, Nils, 814-826, 939-945
 Novak, J., *314
 Novak, Ladislav P., *982-983

O

Oakley, W. G., *321-322, *1199
 Ockner, Robert K., *121
 O'Dell, Boyd L., *59
 Odén, A., *312-313
 Ogilvie, James T., *362-363
 Ogilvie, R. I., *1206
 Ohira, S., *1204
 Ojl, N., *252
 Okada, Akira, 203-208
 Oldendorf, William H., *315
 Olefsky, Jerrold, *372, *380, *1121
 Olsen, Ward A., *252-253
 Olsson, A. G., *980
 Ono, Masayoshi, *1122
 Opperman, W., *321, *373
 Orci, Lelio, *121, *326, *346, *368, 511-534, 594-604, *838, 1060-1071
 O'Reilly, Robert A., *183
 Ornholt, Jorgen, *911
 Orö, L., *980
 Osborne, Robert K., *57
 Oschman, James L., *315
 Osterby, R., *913
 Ostheimer, Gerald W., *118-119
 Ostrowski, K., *909
 O'Sullivan, John B., *183-184
 Ouyang, Ann, *247-248
 Overack, Daniel E., *182-183
 Oweiss, Ibrahim M., *1118
 Owen, Charles A., Jr., *775
 Owen, O., *375
 Owen, W. Crawford, 157-162, *1202

P

Paasikivi, J., *122-123
 Pace, Caroline S., *345

Packer, James T., 715-721, *1043
 Palazzolo, M., *336
 Pallotta, Johanna, *367, *376-377
 Pallotta, M. G., *253
 Pandos, P., *775-776
 Pannbaker, R. G., *838
 Park, B. N., *373
 Park, C. R., *254, *335, 439-446
 Parker, Donal C., *913
 Parks, Gary A., *1046
 Parrilla, Roberto, *341
 Parrish, James E., *980
 Partridge, John W., *1204
 Passa, P., *838
 Passy, Victor, 722-732
 Patel, D., *373
 Patel, Tehmi N., *350, *1205
 Paul, P., *375
 Peabody, Robert R., *189
 Pearson, Donald, *184
 Pearson, Margaret J., *182, *1204
 Pek, Sumer, *55-56, 216-223, *324, *331-332, *1204
 Pekar, A. H., 486-491
 Pekarek, R. S., *316
 Pellizzari, E. D., *313
 Penhos, Juan C., *356, *360-361, *375, *775
 Perez Lloret, A., 23-30
 Perley, Michael J., *837
 Perry, W. F., *183
 Persson, Bengt, *179-180
 Pestana, Angel, *187
 Peterson, Daniel T., *339
 Peterson, James D., 572-581
 Peterson, Kirk L., *980
 Petersson, B., *909
 Petpierre, B., *1120-1121
 Pfeiffer, Ernst F., *313, *369, *913, 1072-1076
 Phillips, Gerald B., *184
 Pilkis, S. J., *335
 Pillay, Veerasamy, K. G., *54
 Pimstone, Bernard L., *58, *771
 Pingel, M., 805-813
 Pinto, J. E. B., *253
 Pirart, J., *123
 Pi-Sunyer, F. X., *373-374
 Pitkin, R. M., *315
 Pitot, Henry C., *187
 Pittman, Robert P., *59
 Plank, C. J., *315
 Plante, Gerald E., *251
 Plavidal, Ferdinand, 733-743
 Pocelinko, R., *313
 Podolsky, Stephen, *374, *1121
 Poffenbarger, Philip L., *1120

Pollock, J., *120-121
 Pond, Wilson G., *835-836
 Porch, James, *338
 Porte, Daniel, Jr., 65-70, *342, *348, *773, *1123
 Posner, Barry I., *374-375
 Potter, Van R., *54
 Potvliege, P. R., *120
 Powell, William John Jr., *118-119
 Pratt, O. E., *247
 Price, Steven, *345
 Prigge, William F., *55
 Prior, R. L., *184
 Proakis, A. G., *184
 Prout, Thaddeus E., 1035-1040
 Pruitt, Kenneth M., 872-880
 Pyke, D. A., *321-322, *1199

Q

Quibrera, Ricardo, *55-56
 Quickel, Kenneth E., Jr., *184, *315-316, 779-788, *1200

R

Rackley, C. E., *367
 Radhakrishnamurthy, B., 733-743
 Ragab, Abdelsalam H., 906-907
 Raghuramulu, N., *1119-1120
 Raheja, Krishan L., *1046
 Räihä, Niels, *250-251
 Raines, P. L., *775
 Raivio, K., *250-251
 Ramey, Estelle R., *375
 Rand, Robert W., *349
 Randle, Philip J., 538-545
 Rao, K. Visweswara, 1192-1196
 Rao, Kamal S. Jaya, 1192-1196
 Rappaport, A. M., *1204
 Raptis, S., *913
 Rasio, Eugenio A., *330
 Raskin, Philip, 101-107
 Rauls, Tyler J., *189
 Reaven, Eve P., *339
 Reaven, Gerald M., *84-88, *339, *372, 794-796, 1109-1115, *1121
 Recant, Lillian, *329, *359-360, *775
 Reddy, W. J., *351-352, *371
 Reddy, Bandaru S., *775
 Redetzki, H. M., *838
 Redetzki, J. E., *838
 Reed, D. W., *838
 Reed, Peter C., *982
 Regen, D. M., *775
 Reichard, G. A., Jr., *375

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

Reichle, Frederick A., *322-323
 Reiffen, Barney, *367
 Reinke, U., *1204
 Reitano, G., *316
 Renauld, A., *253
 Renner, Rolf, *1122-1123
 Renold, Albert E., *179, *246, *326,
 *368, 510, 619-631, 1060-1071
 Retzlaff, K., *911
 Reuter, Melanie, *772
 Reza, Michael J., *330
 Ribes, G., *912, *1120
 Ricketts, Henry T., 648, 660, 677, 684
 Riemann, J. F., *352
 Rifenberck, David, *247
 Rimoin, D. L., *1045-1046
 Rishi, Surendra, *375-376
 Rivarola, M. A., 23-30
 Rivera-Calimlim, Leonor, *1121
 Robb, Jean R., 967-971
 Robberecht, P., *59
 Roberts, Philip, *251
 Robertson, J. W., *341
 Robertson, R. Paul, *348
 Robitaille, Pierre, *251
 Robolledo, O. R., *184
 Rodman, Harvey M., *329-330
 Roe, Thomas F., *981
 Rogala, Henry K., *121-122
 Rogers, Lydia, *252-253
 Rogers, Marsha, *328
 Rogers, Nancy L., 403-413
 Roginski, E. E., *1043
 Roheim, Paul S., *56
 Roldan, A. G., *184-185
 Roncone, Angela, *333
 Root, Mary A., 637-648, 657-660
 Rose, Herbert G., *376
 Rose, Noel R., *253
 Rose, Shelby D., *1043
 Rosen, Ora M., *185
 Rosenberg, I. H., *983
 Rosenberg, Leon E., *248, 414-425
 Rosenbloom, Arlan L., 45-49, *355-356,
 376, *776
 Rosenfeld, Paul S., *378
 Rosenthal, Judith W., *836
 Rosevear, John W., *185, *775, *836
 Rosner, J. M., 23-30
 Ross, Iain S., *186
 Rossi, Livia, *312
 Rossman, Lawrence G., *913
 Rössner, S., *316, *980
 Roth, Jesse, *313, *334-335, 673-677,
 *1200
 Roth, Nathan H., *349
 Rottiers, R., *914

Rousseau, Suzanne, *912
 Roux, J., *250-251
 Rowe, John W., *376-377
 Rubenstein, Arthur H., *57, *344, *347,
 572-581, 661-662, 1013-1026
 Rubin, Emanuel, *838
 Rudas, B., *121
 Ruderman, Neil B., *341, *343
 Rudo, N. D., *983
 Ruegamer, W. R., *1047
 Ruiz, Harold, 733-743
 Russell, R. O., *367
 Russell, Wilson G., 403-413
 Russo, R. E., *361-362, *366
 Ruttgers, H., *1045
 Ryan, Graeme B., *314
 Ryan, Jerome R., *188

S

Saba, Thomas M., *312
 Sadeghi-Nejad, A., *377
 Safrit, Henry F., *184
 Saito, Tokuko, *1047
 Sakagami, Masanori, 476-484
 Sakai, Tsunesada, *336
 Sakura, Naoki, 476-484
 Salen, Gerald, *1200-1201
 Saliternik, R., *770
 Salvatierra, Cairo, *914
 Sandler, Richard, *185
 Saner, G., *313
 Santeusano, Fausto, *324
 Santti, Risto S., *185
 Saraceni, D., 23-30
 Sau, K., *381
 Saudek, Christopher D., *334
 Sauerherber, Richard D., *372
 Savory, J., *376
 Sax, Daniel S., *374, *1121
 Saxton, C., *913
 Sayers, George, *983
 Schanberg, Saul M., *252
 Schauder, Peter, *377-378
 Schedl, Harold P., *59, *983
 Scheid, C., *370
 Schein, P. S., *59
 Scheynius, A., *123
 Schiff, D., *185
 Schimmel, Richard J., *59-60
 Schlein, Edward M., *1198-1199
 Schlichtkrull, J., 649-656
 Schmidt, William M. I., *912
 Schnatz, J. David, *353-354, *1043
 Schneeloch, B., *187-188
 Schneider, Louis E., *983
 Schnelle, Norbert, *185

Schnure, Joel J., 101-107
 Schöffling, K., *249, *249-250
 Scholtz, Michael C., *914
 Schreiber, Paul H., *54, *1200-1201
 Schroder, Karl E., 1072-1076
 Schrott, Helmut G., *1121
 Schteingart, David E., *331-332
 Schullinger, John N., *837
 Schwartz, Ernst, *1046
 Schwartz, Robert, *60, *250-251
 Schwarz, F., *1046
 Schwarz, K., *369
 Scorpio, Ralph M., *247
 Scott, David F., *54
 Scow, Robert O., 946-954
 Scriba, P., *369
 Scully, Robert, *1042
 Seelig, Steven, *983
 Segal, Stanton, *315
 Sechlin, Jahove, *56, *181, *771-772
 *837, *910-911
 Seifter, Eli, *773-774
 Seiler, M. W., *60
 Selawry, Helena, *329, *359-360
 Seltzer, Holbrooke S., 955-966, 976-980
 Senior, B., *377
 Serafini, A. N., *351
 Service, F. John, *836
 Setchell, B. P., *57-58
 Sethi, S. S., *373-374
 Shah, Madhukar N., *983
 Shanahan, E. Anne, *118-119
 Shapiro, Stanley H., 129-137, *325-326
 Sharma, Bal K., *54
 Sharma, Opendra K., *253
 Shaw, Ralph A., *367-368
 Shaw, Walter N., viii Supplement 2
 Sheikholislam, Bagher M., *378
 Sheldon, W. H., *1201
 Sheridan, B., *253
 Sherman, Barry M., *313, *1043-1044,
 *1204
 Sherman, Herbert, *367
 Sherwin, Robert S., *347
 Shetty, Kaup R., *378
 Shichiri, Motoaki, 203-208
 Shier, Nathan William, *983
 Shigeta, Yukio, 203-208, 827-831
 Shih, Vivian, *316
 Shima, Kenji, *60
 Shimizu, Taeko, *1047
 Shishiba, Yoshimasa, *1047
 Shizume, Kazuo, *1047
 Shlatz, L., *1121-1122
 Shrader, Ruth E., *1047
 Shreeve, W. W., *252
 Shroyer, Lois A., *382

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210

AUTHOR INDEX 1972

- Shuangshoti, Samruay, *1122
 Shuman, Charles R., *322-323
 Sidbury, James, *1200
 Siegal, Alan M., 157-162, *1202
 Siegel, Donald C., *982
 Sieracki, J. C., *250
 Siltanen, Irmeli, *349-350
 Silver, Donald, *1206
 Silverman, David A., *253
 Simmons, R. L., *322
 Simon, James D., 930-934
 Simons, N., *770
 Simopoulos, Artemis, *1043-1044
 Sinclair-Smith, B. C., *332, *340-341
 Sirek, Ann M., *378-379
 Sirek, Anna, *378-379
 Sirek, O. V., *378-379
 Sjöström, Lars, *54, *180
 Skyler, J. S., *352
 Slack, Warner V., *367
 Slaunwhite, W. Roy, III, *1204-1205
 Slavinski, R. H., *252
 Slesinger, Marvin H., *771
 Sloan, J. M., *253
 Slusher, Norman, 843-855
 Smith, Desmond F., *327, 856-862, *1045
 Smith, Leslie F., 457-460
 Smith, Robert M., *343, *1119
 Snarr, J. F., *1123, *1206
 Snider, Joel J., 295-300
 Snodgrass, G. J. A. I., *1047
 Snook, Jean Twombly, *185-186
 Sobel, R. E., *376
 Sode, Jonas, *181
 Soeldner, J. Stuart, *354, *373, *383, 703-712, *769, *775, *1044-1045
 Soifer, David, *60
 Soler, N. G., *186
 Solomon, H. M., *313
 Solomon, Solomon S., *336, *363, 1027-1034
 Song, Sun K., *838
 Sonksen, Peter H., *379, *775
 Soveny, C., *249
 Spalding, J. F., *914
 Spargo, Benjamin H., *338
 Spark, Richard F., *334
 Spathis, G. S., *186
 Spergel, Gabriel, *348
 Sperling, Mark A., *60
 Spingola, Laurence J., *252
 Spitzer, John J., *251
 Sprague, Randall G., 632
 Spruyt, Joy E. L., *57
 Srinivasan, Sathanur R., 733-743
 Srivastava, M. C., *379
 Stacpoole, Peter W., *358
 Stadler, F., *769
 Stanley, A. W., *367
 Starling, Kenneth A., *1119
 Starman, Barbara, *377-378
 Starr, Jerome I., *347, 661-672
 Stauffacher, Werner, *179, *246, *326, 1060-1071
 Stearns, Frank, *247
 Steele, Ann A., *835, *1045
 Steele, Forest A., *835
 Stein, Janet M., *186
 Steinberg, Daniel, 1179-1184
 Steinberg, Terry, 722-732
 Steiner, Alton L., *1119
 Steiner, Donald F., *347, 572-581, 661-672, 1013-1026
 Steiner, George, *982
 Steinke, Jurgen, 143-148, *247, 350, *365, *379, *838, *1198, *1205
 Stenberg, J., *909
 Stephenson, J. B. P., *56
 Sterky, G., *980-981
 Stern, Judith, *316
 Stern, L., *185
 Stern, Michael P., *380
 Stiltz, John G., 235-245
 Stimmler, L., *1047
 Stoll, Ralph W., *1047, *1122
 Stone, Daniel B., *1045
 Stoppani, A. O. M., *184-185
 Storvick, Waldemar O., 235-245
 Stout, Clarke, *338
 Stout, Robert W., *186, *380
 Strack, I., *385
 Strandgaard, Svend, *186-187
 Strauch, G., *775-776
 Strickland, Alva L., *1122
 Stroeh, Lowell E., 235-245
 Stromberg, P., *329
 Strong, Leroy E., *382
 Stroud, Robert M., 872-880
 Strul, Anna, *348
 Strumia, E., *122
 Stuhlman, Robert A., 715-721, *1043
 Stukowski, Barbara, *910
 Stunkard, Albert J., *1205
 Sudilovsky, Oscar, *187
 Sulev, J. C., *254
 Sun, A. M., *339
 Sussman, Karl E., *56
 Sussman, Leonard, *336
 Sutherland, James M., *914, *1202-1203
 Suwanwala, Nibha, 108-113, *355
 Suzuki, Fujio, *1122
 Swenson, Donna E., *55
 Swenson, Robert S., 1109-1115
 Sverdlik, R. C., *253
 Sybulski, S., *316
 Szabo, Andrew J., *337, *380-381
 Szabo, Olga, *314-315, *337, *380-381
 Szulman, Aron E., 39-44
- ## T
- Tacus, Leonardo, *359
 Taft, P., 972-975
 Takeda, Yoshiro, *1122
 Talaric, K. S., *836
 Talbert, O. Rhett, *911
 Täljedal, Inge-Bert, *56, *123, *181, *771-772, *837, *910-911
 Tallman, Carter B., *185
 Tanaka, Kay, *316
 Tanner, J. M., *119-120
 Tarpley, H. L., *775
 Tarui, Seichiro, *60
 Tateishi, Hiroshi, *253
 Tattersall, R. B., *321-322
 Taylor, Andrew L., 175-177
 Taylor, Enid, *187
 Taylor, G. W., *187
 Taylor, J. Bradley, 1109-1115
 Taylor, K. W., *909
 Taylor, L. M., *187
 Taylor, S. H., *913
 Taylor, William F., *324-325, *775, *836, *1203
 Tcherdakoff, P., *776
 Teitelbaum, A., *770
 Tepperman, Jay, *1046
 Teramo, K., *250-251
 Thijssen, J. H. H., *1046
 Thomas, G. B., *313
 Thompson, Clara W., *1204
 Thuy, Le Phuc, *1047
 Tibblin, Elisabeth, *180
 Tibblin, Gösta, *180, *312-313
 Tildon, J. Tyson, *181
 Tobin, R. B., *981
 Toews, C. J., *341
 Tomita, Tatsuo, *326
 Tomkin, Gerald H., *381
 Tompkins, C. V., *379
 Torno, N., *381
 Toseland, P. A., *187
 Tragl, Karl H., 84-88
 Traisman, Howard S., *249
 Trap-Jensen, Jens, *1045
 Treasure, T., *187
 Triebwasser, John, 101-107
 Trimmer, Michael, 39-44
 Trout, David L., *179
 Truswell, A. S., *58
 Tsang, Reginald C., *914, *1043
 Tseng, Chiu H., *338
 Tsoulos, Nicholas G., *187

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 1, 321-384	August, 843-922
February, 65-128	Supplement 2, 385-714	September, 923-986
March, 129-192	June, 715-778	October, 987-1050
April, 193-256	July, 779-842	November, 1051-1130
May, 257-320		December, 1131-1210

AUTHOR INDEX 1972

Turner, Paul, *771
 Turner, R. C., *187-188
 Tweel, Harry K., *188
 Tyler, Jean M., *332
 Tyrrell, J. B., *188
 Tyson, R. Robert, *322-323
 Tzagournis, Manuel, *381-382
 Tze, Wah Jun, *327

U

Ullygot, G., *1199
 Underwood, Louis E., *776, *1122
 Unger, Roger H., *58, *60, *183, 301-307, *324, *912-913, *1198-1199

V

Valverde, Isabel, 289-294
 van Assche, F. A., *253-254
 Vance, James E., 570-571, 581-583, *1047, *1122
 Van Herle, Andre J., *335-336
 Van Itallie, T. B., *374
 Van Lan, Vo, *375
 van Marthens, Edith, *189
 vanRiet, H. G., *1046
 vanWayjen, R. G. A., *1046
 VanWoert, Maureen, *1119
 Van Wyk, Judson J., *1122
 Vanderlaan, Eileen F., *913
 Varandani, Partab T., *353, *382
 Vasil'eva, I. A., *55
 Vecchio, Luigi Lo, 1168-1172
 Veneziale, Carlo M., *330-331
 Vermeulen, A., *914
 Veros, A. J., 486-491
 Vilar, O., 23-30
 Villanueva, Maria L., 289-294, *837-838
 Villee, Claude A., *185, *1199
 Vinay, Patrick, *251
 Vince, F. P., *119-120
 Vining, Keats K., Jr., *382
 Visek, W. J., *184
 Vogler, Nancy J., *254, 881-905
 Voight, Karl H., *313
 Voigt, K. D., *1204
 Voina, Sandra J., *776, *1122
 Volk, Bruno W., *338-339
 Volund, Aa., 805-813
 Voyles, Nancy, *329
 Vranic, Mladen, *188, *382-383

W

Wade, Angel, *329
 Wahl, Georgia, *772

Wahlberg, F., *122-123
 Wahren, John, *323-324, *770-771, *776
 Wajchenberg, Bernardo L., *363
 Walaas, E., *123
 Walker, G., *379
 Walker, Mary M., 987-998
 Walter, Robert M., *333-334
 Wannemacher, R. W., Jr., *316
 Wapnir, Raul A., *181
 Ward, J. D., 1173-1178
 Ward, Walter F., *836
 Wasserman, R. C., *314
 Watkins, Dudley T., *983
 Waxler, S. H., *254
 Weber, B., *1205
 Weidemann, Eckehart, *1046
 Weinges, K., *769
 Weinstock, Murray, *376
 Weir, B. J., *1205-1206
 Weisinger, Jose, 1109-1115
 Weissman, Peter N., *324
 Weitzel, Gunther, *1122-1123
 Wellmann, Klaus F., *338-339
 Wells, Henry J., *315
 Wells, Lemen J., 193-202
 West, Kelly M., *338
 West, Susan B., *835
 Westall, Janet R., *372
 Westberg, N. Gunnar, 163-174
 Westfall, David N., *776
 Wexler, B. C., *1123
 Whayne, Thomas F., Jr., *188
 White, Priscilla, 31-37, *361-362, *366
 White, Raleigh R., *1120
 Whitehead, Richard, *251
 Whitfield, Margaret, *328
 Whittingham, Senga, *914
 Wichelow, M. J., *980
 Wick, Arne N., *372
 Wieland, Otto, *910
 Wiesner, Wolfgang, *910
 Wildenhoff, K. E., *1205
 Wilder, B. J., *355-356
 Wiley, J. H., *835
 Wilhelmsen, Lars, *180
 Wilke, W., *182
 Wilkinson, J. S., *352-353
 Wille, L., *123
 Williams, R., *1199
 Williams, Robert E., *183-184
 Williams, Robert H., *329, *360, *377, *378, *1047, *1122
 Williams, T. F., *254
 Williamson, D. H., *59
 Williamson, Joseph R., *254, 881-905
 Wilmshurst, E. G., *365, *366, *383
 Wilson, Helen D., *59

Wilson, John E., *1205
 Wilson, Penelope, *247
 Winand, J., *119, *182
 Winegrad, Albert I., *180-181, *330
 Winters, Robert W., *837
 Wise, P. H., *1205
 Wissler, R. W., *344
 Witters, Lee, *376-377
 Wittman, James S., III, *188-189
 Wold, John S., 71-79
 Wolf, Richard C., *774, *912
 Wolfe, Walter G., *1206
 Wolff, J. E., *118
 Wolff, M. Kirsch, *56
 Wolff, Peter H., *254
 Wollheim, C. B., *346
 Woods, James S., *254
 Woods, Stephen C., *1123
 Wrenshall, G. A., *382-383
 Wright, Peter H., *58, 605, 617-618
 Wright, R., *189
 Wurtman, R. J., *909

Y

Yakovac, William C., *189
 Yamaguchi, N., *775
 Yamaguchi, K., *250-251
 Yanaihara, Chizuko, 476-484
 Yanaihara, Noboru, 476-484
 Yeung, C. Y., *1123
 York, David A., *838, *1206
 Young, J. D., *1118
 Young, Margaret C., *120
 Younger, Donna, 31-37
 Yudilevich, David L., *180
 Yunis, Eduardo, *60

Z

Zahn, Helmut, 457, 468-475
 Zalut, Clyde, *772-773, *981
 Zamenof, Stephen, *189
 Zandomeneghi, R., *1206
 Zatzman, Marvin L., *182-183
 Zeman, Frances J., *1041, *1047
 Zetterström, Rolf, *179-180
 Ziboh Vincent A., *189
 Ziegler, M., *182, *909, *914
 Zingg, W., *254
 Zinman, B., *1206
 Zivin, J. A., *1123, *1206
 Zor, Uriel, *346-347
 Zucker, Louis M., *316, *1123
 Zuckerman, Leon, 209-215, *1199
 Zweig, S. M., *89
 Zweng, H. Christian, *189

DIABETES: VOLUME 21 (1972) PAGE NUMBERS BY ISSUE

January, 1-64
 February, 65-128
 March, 129-192
 April, 193-256
 May, 257-320

Supplement 1, 321-384
 Supplement 2, 385-714
 June, 715-778
 July, 779-842

August, 843-922
 September, 923-986
 October, 987-1050
 November, 1051-1130
 December, 1131-1210



American Diabetes Association, Inc.

18 East 48th Street

New York, N. Y. 10017
